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Small Interfering RNA Imaging Probes for Neurological Applications  
Abstract  
 Small interfering RNAs (siRNAs) have emerged as a potent new class of 
therapeutics that regulate gene expression through sequence-specific inhibition of mRNA 
translation. Clinical trials of siRNAs have highlighted the need for robust delivery and 
detection techniques that would enable the application of these therapeutics to 
increasingly complex diseases and organ systems.  Here we detail the generation and 
evaluation of siRNA-based optical and magnetic resonance imaging  (MRI) contrast 
agents for the treatment of neurological diseases, including ischemic stroke and 
glioblastoma multiforme brain cancer.   
 First, we designed and tested a fluorescent probe for neuroprotection in the setting 
of stroke that consists of siRNA complexed with myristoylated poly-arginine peptide 
(MPAP).  MPAP, a peptide shown to cross cell membranes and the blood brain barrier, 
promoted robust internalization of siRNA by neurons in vitro and in mouse brain after 
intracerebral injection. Cellular uptake of MPAP-siRNA probes directed against a protein 
implicated in stroke pathology, c-Src, led to statistically-significant reductions of 
endogenous mRNA expression.  The neuroprotective potential of probes was tested in a 
mouse model of ischemic stroke.   
 Second, superparamagnetic iron oxide nanoparticles were investigated as vectors 
for siRNA delivery to glioblastoma multiforme brain tumors. Nanoparticles were 
designed to enhance chemotherapeutic treatment of tumors through siRNA-mediated 
knockdown of O6-methylguanine–DNA methyltransferase (MGMT), a protein 
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implicated in glioblastoma chemotherapy resistance. The iron oxide core of nanoparticles 
rendered them detectable by MRI while fluorescent labeling was used for optical 
imaging.  Functionalizing nanoparticles with the peptide chlorotoxin enabled tumor 
targeting and cellular accumulation of probe.  Probe uptake was accompanied by 
reductions in MGMT activity and enhanced cellular responses to the chemotherapeutic 
temozolomide.  Nanoparticles were tested in an orthotopic glioblastoma mouse model, 
where intratumoral administration proved effective in suppressing MGMT expression 
and tumor volume. These studies serve as proof-of-principle that siRNA-based imaging 
agents can be used as therapeutic tools for diseases of the central nervous system.   
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1. In vivo Imaging of the Systemic Delivery of Small Interfering RNA 
1.1 Introduction 
 The discovery of small RNA molecules that regulate gene expression has had a 
transformative impact on the study of gene function and has led to the emergence of a 
new class of RNA-based therapeutics being investigated in human trials.  Double-
stranded small interfering RNAs (siRNAs) mediate gene silencing through 
complementary base-pairing, leading to potent, sequence-specific suppression of mRNA 
translation (Fire, Xu et al. 1998; Elbashir, Harborth et al. 2001).  This process, known as 
RNA interference (RNAi), can theoretically be harnessed to treat any pathology caused 
by aberrant protein.   Effective RNAi therapy requires that exogenous siRNAs be 
introduced into affected cells in quantities sufficient to inhibit target gene expression and 
improve clinical outcome.  This is complicated by several factors, including rapid 
nuclease degradation of siRNA molecules after exposure to blood and a negatively-
charged sugar phosphate backbone that impedes siRNA translocation across cellular and 
biological membranes.  The first clinical trials of siRNA therapeutics circumvented these 
delivery issues by focusing on organ systems that were amenable to simple topical or 
local drug administration, such as the eyes, respiratory system, and skin (Vaishnaw, 
Gollob et al. 2010).    However, for RNAi therapy to expand to additional disease targets, 
it is necessary that robust, site-specific delivery of siRNAs be perfected.  To this end, 
extensive research has focused on the development of vector systems that stabilize 
siRNA while promoting siRNA targeting, uptake and expression following systemic 
administration.  Chemical modifications of siRNA duplexes, novel injection techniques, 
and lipid-, polymer- and nanoparticle-based delivery vehicles have all proven effective in 
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improving the bioavailability of siRNAs in a variety of disease models.  In contrast, 
significantly less focus has been placed on developing methods to non-invasively image 
the delivery and actions of siRNAs in vivo, a process that will be important in a clinical 
setting where understanding the pharmocodynamics of drugs is crucial. 
 During the past decade, several studies have illustrated how the versatility of 
siRNA therapies expands once molecular imaging capabilities are incorporated.  The first 
demonstration of siRNA efficacy in mammalian cell culture employed bioluminescent 
reporter genes to assess silencing (Elbashir, Harborth et al. 2001). A year later, whole 
body bioluminescence imaging of adult mice following hydrodynamic co-injection of 
luciferase plasmid and siRNA enabled noninvasive monitoring and quantification of 
RNA interference (McCaffrey, Meuse et al. 2002).   Imaging of reporter gene expression 
has since been used to acquire organ-specific siRNA silencing profiles (Lewis, Hagstrom 
et al. 2002), to evaluate nuclease stabilization of siRNAs for in vivo applications (Layzer, 
McCaffrey et al. 2004; Bartlett and Davis 2007), and to elucidate biological pathways 
(Zhang, Safran et al. 2004).  More recently, the focus of the siRNA imaging field has 
shifted to include clinically-relevant imaging modalities.  Accordingly, siRNAs are 
increasingly being integrated into contrast agents for detection by radionuclide or 
magnetic resonance (MR) imaging.  This requires flexible siRNA delivery systems that 
stabilize siRNA molecules while acting as a platform for modification by targeting or 
imaging reporter groups for improved probe contrast and specificity.  In this chapter, we 
review the current status of siRNA imaging and therapy, with particular emphasis placed 
on the novel methods that have been developed to improve siRNA delivery and detection 
following administration in vivo.     
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1.2 Naked and Chemically-Modified siRNA Delivery 
 The earliest examples of siRNA imaging utilized reporter gene systems to 
evaluate the handling of synthetic naked siRNAs in mice (Lewis, Hagstrom et al. 2002; 
McCaffrey, Meuse et al. 2002).  These studies used an in vivo transfection strategy 
originally developed for plasmid DNA, hydrodynamic high-pressure tail vein injection 
(Liu, Song et al. 1999), to promote cellular delivery of naked siRNAs and luciferase-
expressing plasmids. The primary site of siRNA uptake following hydrodynamic 
injection was the liver, with suppression of luciferase gene expression of 80-90% (Lewis, 
Hagstrom et al. 2002; McCaffrey, Meuse et al. 2002).  Though these delivery and 
imaging methods are impractical in a clinical setting, they have been instrumental in the 
transition to in vivo siRNA therapies.  This was excellently demonstrated in a report that 
investigated luciferase knockdown efficiency as a function of siRNA dose, siRNA 
delivery method, and target cell division rate (Bartlett and Davis 2006).   By monitoring 
luminescence knockdown kinetics in vitro and in vivo in both nondividing hepatocytes 
(transfected by hydrodynamic injection) and rapidly dividing tumor cells (transfected 
using a targeted siRNA carrier), Bartlett et al. was able to show that the duration of gene 
silencing is dictated by cell division, not intracellular siRNA half-life.  These results 
formed the basis of a mathematical model that predicts siRNA efficacy and persistence as 
target protein half-life, target cell doubling time, and siRNA dosing parameters are 
varied, providing a valuable aid for the design of future experiments.  
 An alternative method of naked siRNA delivery that has been investigated by 
imaging is in vivo electroporation (Takabatake, Isaka et al. 2005; Golzio, Mazzolini et al. 
2007).  In rats, selective uptake of siRNA by kidney mesangial cells was promoted by 
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applying electrical pulses to the renal artery following co-injection of luciferase-
expressing plasmids and siRNA (Takabatake, Isaka et al. 2005).  Bioluminescence 
imaging confirmed significant luciferase reduction of 70%.  Similarly, fluorescence 
imaging has been used to investigate in vivo electroporation in tumors expressing an 
EGFP reporter gene (Golzio, Mazzolini et al. 2007).  Electrical pulses applied to tumors 
following direct microinjection of siRNAs mediated intracellular delivery and a modest 
degree of silencing in a mouse subcutaneous tumor model.  
 Chemical modification of naked siRNAs has proven effective in extending the 
half-life of siRNAs exposed to serum (Braasch, Jensen et al. 2003; Czauderna, Fechtner 
et al. 2003), helping them to persist in the blood following conventional systemic 
injection.  Additionally, several groups have chemically-modified siRNAs to include 
radioactive tracers to extend their application to clinically-relevant imaging modalities.  
Liu et al. created a tracer for single photon emission computed tomography (SPECT) 
imaging by conjugating chelator S-Acetyl N-hydroxysuccinimide (NHS) hydrazine 
nicotinamide (HYNIC) to naked siRNAs for labeling with 99mTc (Liu, Ding et al. 2007). 
Precise tissue distributions of 99mTc-siRNAs were acquired by analysis of whole body 
scintigraphic images of mice bearing human kidney cancer tumors. An alternative 
chelator, N-hydroxysuccinimide-mercaptoacetyltriglycine (NHS-MAG3), for 99mTc 
radiolabeling of siRNA has similarly been used to generate siRNA biodistributions in 
tumor-bearing mice (Kang, Wang et al. 2010).  Viel et al. performed a detailed 
investigation of the bioavailability and pharmacokinetics of siRNAs labeled with a 
positron emitter, fluorine-18, and subsequently assessed the in vivo effects of their probes 
(Viel, Boisgard et al. 2008).  Tissue distributions and blood persistence and stability of 
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siRNAs with different chemically-modified riboses were performed, and time-activity 
curves of siRNA in rat organs were generated from dynamic whole-body positron 
emission tomography (PET) scans.  In vivo RNA interference of the siRNAs was 
assessed using a luciferase-expressing xenograft nude mouse model, which resulted in 
very small, though significant, decreases in luciferase expression in tumors 48 hours after 
siRNA injection.  Results from these studies serve as an important proof-of-concept that 
siRNAs can be effectively adapted for nuclear imaging and provide valuable insight into 
the in vivo trafficking and stability of the resulting probes.  They also highlight the 
importance of incorporating a method of delivery assistance into siRNA probes to 
overcome limited cellular uptake following intravenous administration.   The sections 
below detail the different vector systems that have been investigated as integrated 
imaging and delivery platforms for improved delivery of siRNA to target tissues.   
1.3 Lipid-Based Delivery  
 Lipid-based vectors have been used as transfection agents for oligonucleotides for 
over two decades (Felgner, Gadek et al. 1987), preferred for their efficiency, low 
immunogenicity, and straightforward preparation.  Recent success of stable nucleic acid 
lipid particles (SNALPs) for siRNA delivery to the liver of non-human primates has set 
lipid-based siRNA carriers apart as promising candidates for clinical translation 
(Zimmermann, Lee et al. 2006; Frank-Kamenetsky, Grefhorst et al. 2008).  Most lipid 
carriers are cationic liposomes that electrostatically complex with siRNAs, spontaneously 
associate with negatively-charged cell membranes and become endocytosed by cells.  
Upon cell entry, liposomes are believed to destabilize endosomal membranes, enabling 
delivery of siRNAs to the cytoplasm where they are processed by RNAi machinery (Xu 
 6 
and Szoka 1996).  Liposome size, stability, and circulation half-life can readily be varied 
by changing lipid content and by adding surface modifications.  Therefore, lipid 
nanoparticles are particularly valuable from a molecular imaging perspective because 
functional groups can be complexed or covalently grafted to form targeted or labeled 
probes. 
 The simplest lipid-based imaging probes consist of fluorescently-tagged siRNAs 
that have been either encapsulated by or complexed with liposomes.  Though the utility 
of this approach is generally limited to ex vivo microscopic examinations of excised 
tissues, studies that have used it have clarified aspects of siRNA delivery including 
siRNA organ distributions, cellular handling, clearance and dosing (Sioud and Sorensen 
2003; Landen, Chavez-Reyes et al. 2005; Morrissey, Lockridge et al. 2005; Santel, Aleku 
et al. 2006). The addition of targeting groups to fluorescently-labeled liposomes has been 
shown to increase the bioavailability of siRNA duplexes in even the most inaccessible 
tissues, as was demonstrated recently when cationic liposomes complexed with siRNA 
and peptide derived from rabies virus glycoprotein were delivered across the mouse 
blood-brain barrier, resulting in 25% suppression of cellular prion protein in the brain 
(Pulford, Reim et al. 2010).  
 In vivo imaging of siRNA delivery using lipids has routinely been investigated 
with fluorochromes in the near infrared (NIR) range and luciferase reporter genes. One 
approach incorporated NIR fluorochrome-labeled siRNA into nanoparticles through 
electrostatic interaction with lipidoids, a class of lipid-like molecules formed by the 
coupling of aliphatic side chains to an amine backbone (Goldberg, Xing et al. 2011).  
Intraperitoneal injection of the lipidoid-siRNA formulation resulted in significant tumor 
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uptake of nanoparticles in a murine ovarian cancer model as assessed by whole body 
optical imaging.  Additionally, dual siRNA treatment promoted the induction of tumor 
apoptosis and ultimately increased animal survival.   Whole body optical imaging was 
also used to investigate a siRNA ‘wraposome’ consisting of a cationic liposome and Cy5-
labeled siRNA complex surrounded by a PEGylated, neutral lipid bilayer envelope that 
prolongs the systemic half-life of siRNA and reduces toxicity (Yagi, Manabe et al. 2009).  
In mice bearing a human prostate carcinoma tumor, NIR imaging revealed retention of 
wraposomes in the tumor 11 days after administration by tail vein injection.   Wraposome 
siRNA mediated mRNA and protein knockdown of transcription factor Klf5 in tumors, 
leading to reductions in both angiogenesis and tumor growth.  Another group developed a 
mouse model with liver-specific expression of a luciferase reporter to non-invasively 
screen a library of lipid nanoparticles for siRNA delivery (Tao, Davide et al. 2010).  
Lipid nanoparticles composed of different cationic lipid, polyethylene glycol (PEG) and 
cholesterol contents were evaluated for their efficiency in carrying siRNA to hepatocytes 
following systemic injection.  Whole body bioluminescence imaging was used to select 
the optimized delivery vehicle, capable of up to 90% silencing of luciferase-specific 
siRNA for 10 days.  A combination of bioluminescence and optical imaging was used in 
a study that targeted cationic liposomes to the liver using apolipoprotein A-I (Kim, Shin 
et al. 2007).   Biodistribution of the liposomes was evaluated using two methods, 
including whole body optical imaging of near infrared dye-labeled liposomes and gamma 
camera evaluation of 131I-labeled liposomes. In addition to these methods, 
bioluminescence imaging was used to demonstrate 70% gene silencing by liposomes 
when loaded with luciferase-specific siRNA.   
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 Liposomes have also been adapted for clinical imaging modalities.   The 
biodistribution of systemically-administered cationic liposome/siRNA complexes has 
been acquired through radiolabeling of the siRNA component with positron emitter 
18F[SFB] and subsequent PET imaging (Hatanaka, Asai et al. 2010). Other groups have 
taken advantage of the functionalization and encapsulation properties of liposomes to 
incorporate multiple imaging moieties into probes. Mikhaylova et al. developed a 
multimodal imaging probe by incorporating fluorescently-labeled siRNA into liposomes 
(Mikhaylova, Stasinopoulos et al. 2009).   Liposomes were subsequently loaded with 
gadolinium and iron oxide MRI contrast agents.  Iron oxide lipoplexes reduced 
endogenous COX-2 protein expression when tested in cultured cells. Although siRNA 
efficacy was not evaluated, the authors demonstrated that the lipoplexes formed effective 
imaging probes in vivo, first, by monitoring the biodistribution of liposomes with optical 
imaging and second, by evaluating delivery to tumor cells in a breast cancer xenograft 
model with MRI. Another multimodal imaging approach used gadolinium- and 
rhodamine-labeled lipids as constituents during liposome preparation to form MR-
sensitive, fluorescent delivery probes (Kenny, Kamaly et al. 2011).  Therapeutic probes 
were created when siRNA directed against survivin, a member of the inhibitor of 
apoptosis family and potent antitumoral target, were added to the liposomes.  The 
resulting probes, termed liposome-entrapped siRNA (LEsiRNA) nanoparticles, were 
administered to tumor-bearing mice, leading to signal enhancement in MR images of 
xenografts.  Delivery to tumor was also confirmed by visualization of the nanoparticle 
rhodamine label with fluorescence microscopy and by reductions in survivin protein 
expression detected using western blot analysis.   Furthermore, survivin LEsiRNA 
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nanoparticles retarded tumor growth relative to nontargeted control siRNA nanoparticles, 
confirming that LEsiRNA nanoparticles are effective theranostic agents.  These 
numerous studies provide strong evidence of the versatility of lipid-based strategies for 
siRNA delivery, particularly in the setting of cancer.   
1.4 Peptide- and Polymer-Based Delivery 
 One of the most diverse and flexible approaches for siRNA delivery involves the 
use of peptide, protein, or polymeric carriers (Puebla, Esseghir et al. 2003; Simeoni, 
Morris et al. 2003; Kumar, Wu et al. 2007; Peer, Zhu et al. 2007).   As with lipid-based 
methods, siRNA cargoes become incorporated into the delivery vehicle, often through 
electrostatic interactions, where they are protected from degradation.  Polymer-based 
delivery similarly allows for siRNA escape from endosomal compartments once 
internalized, presumably through the promotion of lysosomal rupture, or the proton 
sponge effect (Boussif, Lezoualc'h et al. 1995).  Also, polymer-based probes can be 
interrogated using a variety of imaging modalities due to the ease with which they are 
functionalized.   
 One of the first protein siRNA carriers investigated with imaging was 
atelocollagen, a pepsin-treated form of collagen protein (Minakuchi, Takeshita et al. 
2004; Takeshita, Minakuchi et al. 2005).  Atelocollagen complexes with siRNA 
molecules to form 100-300 nm nanoparticles.   Nanoparticles were tested in vivo with 
bioluminescence imaging in a luciferase xenograft tumor model, where they were found 
to enhance luciferase silencing relative to cationic liposome-mediated delivery and to 
inhibit tumor growth (Minakuchi, Takeshita et al. 2004).  Atelocollagen siRNA 
complexes have also been evaluated in a bone metastasis model with optical imaging 
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(Takeshita, Minakuchi et al. 2005).  Their therapeutic potential was confirmed by 
significant gene silencing of endogenous genes in metastatic lesions accompanied by 
tumor regression.   
 Several synthetic cationic polymers have been used as efficient transfection 
agents for siRNA and can easily be modified to facilitate imaging.  Polyethylenimine 
(PEI), one of the best characterized polycations, was complexed with siRNA that had 
been radiolabeled with indium through a DTPA chelate (Merkel, Librizzi et al. 2009). 
The siRNA-PEI polyplexes were monitored with SPECT imaging to investigate their 
biodistribution and pharmacokinetics relative to free, radiolabeled siRNAs.  In another 
study, pH-sensitive siRNA carriers composed of polycations were designed to enhance 
siRNA escape from acidified endosomal compartments following endocytosis (Ofek, 
Fischer et al. 2010). Cationic polyplexes consisted of a dendritic core and 
polyglycerolamine shell that formed complexes with luciferase siRNA.  The polyplexes 
displayed low toxicity and efficient in vivo silencing in a mouse tumor model as 
confirmed by bioluminescence imaging.   
 Triblock copolymer PDMAEMA was selected as the basis of a group of micelle 
siRNA carriers (Gary, Lee et al. 2011).   PDMAEMA complexed with siRNA, with 
multiple siRNA molecules adsorbing to the surface of micelles to form micelleplexes.  In 
vitro testing revealed a small but significant effect of siRNA carriers on mRNA 
expression.   Further modification of micelles with folate was shown to improve uptake 
by cancer cells, though this improved uptake was not accompanied by a significant 
increase in silencing relative to unmodified micelles.  PET/CT imaging of tumor-bearing 
mice following systemic administration of I124 radiolabeled micelleplexes demonstrated 
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their accumulation and retention in tumor tissue.   Another group of polymeric micelles 
were recently investigated as vehicles for co-delivery of the chemotherapeutic agent 
doxorubicin (DOX) and siRNA (Xiong and Lavasanifar 2011).  The target of siRNA was 
drug transporter protein, p-glycoprotein, selected to improve the efficacy of DOX.  
Polymeric micelles composed of poly(ethylene oxide) (PEO) and poly(ε-caprolactone) 
(PCL) copolymers (PEO-b-PCL) were attached to targeting moieties RGD and TAT to 
form shell-functionalized micelles following assembly.  RGD was selected for cancer 
targeting through its affinity to αvβ3 integrins while the cell-penetrating peptide TAT 
was selected to promote cellular internalization.  Therapeutics were localized to the 
micelle core when copolymers conjugated to DOX or complexed with siRNA were added 
to the micellar formulations.   Spermine was incorporated into the micelles to promote 
nanocarrier release from endosomes.  In addition, the carrier and its component siRNA 
were differentially tagged with near infrared dyes for imaging. RGD/TAT functionalized 
nanocarriers showed enhanced cellular uptake relative to controls, and following 
internalization, a pH-dependent release of micelle contents from endosomes was evident.  
In formulations where siRNA and DOX were co-delivered, DOX localized to the 
nucleus, leading to sensitization of multi-drug resistant cancer cells to DOX.   
Preliminary in vivo studies were then performed showing accumulation of nanocarriers in 
αvβ3-positive tumors following systemic administration.  
 Polymer-based delivery has also been used to create imaging probes that can be 
detected by MRI.  Imaging of the temporal and spatial distribution of siRNA was used to 
direct and refine therapy in a study investigating siRNA/prodrug enzyme conjugates (Li, 
Penet et al. 2010).  Prodrug enzyme therapy for cancer refers to the process in which an 
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inactive drug becomes converted to a cytotoxic one by an enzyme present in a tumor.  
The prodrug enzyme, bacterial cytosine deaminase (bCD), was delivered to tumors 
intravenously as a component of a fluorescently-labeled PEG/PEI siRNA conjugate that 
also contained a multimodal image reporter platform.  The latter consisted of Cy5.5-
labeled Gd3+-DOTA for multimodal imaging.  After injection of the nanoplex into tumor-
bearing mice, the biodistributions of its components were acquired by in vivo optical 
imaging.  Proenzyme concentration was monitored over time to identify the point at 
which concentration in normal tissues was negligible relative to the levels in the tumor, 
corresponding to the time of optimal prodrug administration. The presence of nanoplexes 
in the tumor was also evident as MR signal enhancement in MR images. The conversion 
of the prodrug, 5-fluorocytosine, to cytotoxic 5-fluorouracil by bCD in the tumor was 
confirmed by noninvasive 19F MRS, while siRNA-mediated silencing of antitumoral 
target, Chk-α, was monitored by 1H MR spectroscopic imaging.  Dual treatment of 
tumors with bCD and siRNA led to a significant delay in tumor growth and increases in 
necrosis without damage to nonmalignant tissues. 
 One of the most successful polymer-based delivery modules for siRNAs is 
cyclodextrin-containing polycations, a group of polymeric, cyclic oligosaccharides that 
self-assemble with siRNA molecules to form a stable delivery vehicle (Hu-Lieskovan, 
Heidel et al. 2005; Bartlett and Davis 2006).  In one study, cyclodextrin-containing 
polycations were modified with targeting ligand, transferrin, to increase their affinity for 
cancer cells that express the transferrin receptor (Hu-Lieskovan, Heidel et al. 2005).  The 
polycations were tested in a murine metastatic cancer model that expressed firefly 
luciferase.  In vivo, whole-body imaging of bioluminescence confirmed delivery of 
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siRNA targeting luciferase to tumors.  In another study, cyclodextrin-containing 
polycation nanoparticles were loaded with luciferase-specific siRNA that had been 
radiolabeled with 64Cu-DOTA to form multimodality imaging probes (Bartlett, Su et al. 
2007).  The biodistribution of nanoparticles was monitored by micro-PET/CT, while 
siRNA knockdown was simultaneously evaluated by bioluminescence imaging.  Direct 
imaging of siRNA silencing proved crucial, since it provided a way to distinguish 
between nanoparticles that had passively accumulated in the tumor due to the enhanced 
permeability and retention effect and those that had been internalized by cancer cells and 
were bioactive.  Consequently, the improved functionality of nanoparticles modified with 
targeting ligand transferrin relative to nontargeting nanoparticles was confirmed with this 
method.  These studies have paved the way for the first clinical trial to use a targeted, 
systemically-administered siRNA formulation, in which cyclodextrin-based siRNA 
carriers are being tested against solid tumors in humans (Davis, Zuckerman et al. 2010).   
1.5 Nanoparticle-Based Delivery 
 Magnetic nanoparticles were the first siRNA delivery modules designed for in 
vivo visualization by magnetic resonance imaging (Medarova, Pham et al. 2007).  
Superparamagnetic iron oxide nanoparticles are contrast agents that decrease T2 
relaxation of surrounding tissues and lead to corresponding negative contrast, or image 
darkening, in magnetic resonance images.  Dextran-coated magnetic nanoparticles (MN) 
were modified with three distinct functional groups that included near-infrared 
fluorochrome Cy5.5 (NIRF) for optical imaging, siRNA molecules targeting GFP 
(siGFP), and a membrane translocation peptide (MPAP) to promote cellular 
internalization.  Mice bearing bilateral 9L-GFP and red fluorescent protein (9L-RFP) 
 14 
tumors were used to evaluate the efficacy of these MN-NIRF-siGFP probes after 
systemic administration.  Probe accumulation in cancer cells was reflected by signal loss 
in MR images and distinct NIRF signal in optical images at the site of the tumors (Figure 
1.1).  Furthermore, probe siRNA led to significant and specific reduction in fluorescence 
of 9L-GFP tumors, with no effect on 9L-RFP cells (Figure 1.2).  The therapeutic 
potential of probes was tested by designing nanoparticles bearing siRNA targeting the 
Birc5, a gene that encodes the protein survivin.  Survivin is expressed in most tumor cells 
and has antiapoptotic functions.  MN-NIRF-siSurvivin probes were tested in mice 
bearing human colorectal carcinoma tumors and were detected using MRI and optical 
imaging. MN-NIRF-siSurvivin probe accumulation was associated with decreased 
survivin expression and increased apoptosis and necrosis in tumors relative to those 
treated with scrambled control siRNA probes.  These effects were obtained without any 
detectable interferon or inflammatory response.  Further implementation of this approach 
involved adding tumor targeting functional groups to nanoparticles to reduce non-specific 
uptake (Kumar, Yigit et al. 2010).  Probes were conjugated with EPPT peptide, the target 
for tumor-specific antigen uMUC-1, siRNA directed against survivin, and Cy5.5 dye.  
MN-NIRF-siSurvivin nanoparticles were tested in mice bearing human breast 
adenocarcinoma tumors.  Tumoral uptake of probes was demonstrated by MRI (Figure 
1.3a) and optical imaging and confirmed with follow-up fluorescent microscopy of 
excised tumor sections.  Treatment with experimental probes induced significant tumor 
apoptosis and necrosis relative to control siRNA probes, as well as a two-fold reduction 
in tumor growth (Figure 1.3b-c).  
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Figure 1.1.  Multimodality imaging of NIR-labeled iron oxide nanoparticle (MN-
NIRF-siGFP) delivery to tumors.  Accumulation of MN-NIRF-siGFP in 9L-GFP and 
9L-RFP bilateral tumors was confirmed by both magnetic resonance and optical imaging. 
MN-NIRF-siGFP delivery was reflected by decreased T2 relaxation in MR images (a) 
and by the emergence of high intensity NIR signal in whole body optical images (b) 
twenty-four hours after probe administration. Reprinted with permission from Macmillan 
Publishers Ltd.: Medarova et al., Nature Medicine, 13, 372-77 (2007).   
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Figure 1.2.  Efficacy of siGFP delivered with iron oxide nanoparticles.  (a) MN-
NIRF-siGFP delivery resulted in reduction of 9L-GFP tumor fluorescence 48 hours after 
probe administration.  No reduction of 9L-RFP fluorescence was observed, indicating 
that silencing by MN-NIRF-siGFP was gene specific.  (b) Suppression of GFP expression 
by MN-NIRF-siGFP was confirmed by quantitative RT-PCR analysis of RNA extracted 
from 9L-GFP tumors.  Treatment reduced gfp mRNA levels by 85% and 97% relative to 
saline-treated and mismatch scrambled control siRNA probes, respectively (P < 0.001). 
Reprinted with permission from Macmillan Publishers Ltd.: Medarova et al., Nature 
Medicine, 13, 372-77 (2007). 
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Figure 1.3. Tumor-targeted siRNA delivery with iron oxide nanoparticles (MN-
EPPT-siBIRC5).  (a) T2 MR images and T2 maps of mice bearing human breast 
adenocarcinoma tumors showed decreased signal intensity and T2 shortening in tumors 
following intravenous injection of MN-EPPT-siBIRC5, indicating accumulation of probe.  
(b) MN-EPPT-siBIRC5 accumulation was associated with a five-fold increase in 
apoptosis induction relative to scrambled control siRNA (MN-EPPT-siSCR) probes 
(P=0.003).  (c) MN-EPPT-siBIRC5 also led to a 2-fold reduction in tumor growth rate 
relative to controls eight days after treatment (P < 0.01). Reprinted with permission from 
AACR: Kumar et al., Cancer Research, 70:7553-7561 (2010). 
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 Magnetic nanoparticle-based modules designated ‘dendriworms’ are another 
platform investigated for siRNA delivery (Agrawal, Min et al. 2009). Elongated magnetic 
nanoparticle chains were surface modified with near infrared fluorochromes for imaging, 
siRNAs for target therapy, and polyamidoamine dendrimer cationic polymers to promote 
endosomal escape of the dendriworms.  Following convection-enhanced diffusion of 
dendriworms into brain tumors in mice, reduction in the expression of the siRNA target, 
EGFR, was observed.  Though MR imaging was not a component of the study, the iron 
oxide nanoparticles comprising dendriworms could potentially be evaluated with this 
modality to extend their versatility.  Another group investigated nanocarriers composed 
of iron oxide nanoparticles that form a stable cluster structure when combined with 
alkylated PEI and luciferase siRNA.  These complexes had high T2 relaxivity in MRI 
phantom studies, signifying their potential as MRI contrast agents (Liu, Xie et al. 2011).  
In vivo investigation focused on bioluminescence imaging, where significant siRNA 
knockdown in luciferase-expressing tumors was observed. 
 Recently a form of inducible RNAi using siRNA-conjugated hollow gold 
nanospheres was investigated (Lu, Zhang et al. 2010).  When irradiated with near infrared 
light, gold nanospheres undergo a structural change that causes the release of siRNA 
molecules from the nanosphere surface in a process termed photothermal transfection.  
Nanoparticles conjugated to siRNA molecules were further modified with a targeting 
ligand, folic acid, to give them an affinity for cancer cells.  In culture, NIR irradiation led 
to rupture of endolysosomal membranes, escape from endocytic vesicles to the 
cytoplasm, release of siRNA from nanospheres, and downregulation of the siRNA target, 
NF-κB p65 subunit.  Positron emission tomography imaging of in vivo delivery was 
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enabled by conjugating 64Cu-labeled DOTA-LA chelating ligands to the nanoparticles.  
Micro-PET/CT imaging revealed accumulation of folate receptor-targeted nanoparticles 
in subcutaneous tumors and photothermal transfection resulted in significant decreases in 
p65 expression in tumor tissue.  Notably, irradiated tumors that received a combination 
treatment of targeted siRNA nanospheres and chemotherapeutic irinotecan had enhanced 
tumor apoptosis and growth reduction relative to non-irradiated targeted nanospheres or 
irinotecan treatment alone. 
 Several nanoparticle carrier systems have shown promise in preliminary in vitro 
studies.  Superparamagnetic nanoparticles have been designed with a variety of 
functional groups to improve stability and promote receptor-mediated uptake for cancer 
treatment and imaging (Mok, Veiseh et al. 2010; Veiseh, Kievit et al. 2010).  Iron oxide 
nanoparticles functionalized with PEI, siRNA, and tumor-targeting chlorotoxin have been 
designed for selective enhanced cellular uptake and gene silencing in the low-pH 
conditions of tumor microenvironments (Mok, Veiseh et al. 2010).  Multi-functional 
hollow manganese oxide nanoparticles have been developed as T1 contrast agents for 
siRNA delivery to cancer cells (Bae, Lee et al. 2011).  Nanoparticles that had been 
surface modified with PEI, Herceptin for targeting of cancer cells with the HER2 
receptor, and siRNA directed against VEGF were internalized by cancer cells.  This 
process was detectable by in vitro T1-weighted MRI and was associated with reduction in 
VEGF release from human breast adenocarcinoma cancer cells that overexpressed HER2.  
In addition, PEI-modified large pore hollow silica nanocapsules loaded with siRNA have 
been shown to efficiently transfect cells and downregulate target protein by 64% (Chen, 
Chu et al. 2011).  Their imaging potential was confirmed when nanocapsules loaded with 
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iron oxide nanoparticles exhibited reduced T2 relaxation.   These different nanoparticle-
based approaches to siRNA delivery provide strong evidence that properly modified 
siRNAs can be monitored in a clinical setting.   
1.6 Conclusion 
 The preceding has been an overview of the imaging methods that have developed 
in parallel with siRNA delivery systems to promote tissue targeting and gene silencing 
efficiency.  Monitoring delivery provides vital information about the in vivo handling and 
efficacy of siRNA molecules as they are applied to increasingly complex disease models.  
As RNAi-based therapeutics progress to clinical trials, image-guided methods can only 
serve to improve siRNA delivery and patient care.    
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2. Small Interfering RNA Fluorescent Probes for Ischemic Stroke 
Therapy  
2.1 Introduction 
 In the United States, stroke is the fourth leading cause of death in the general 
population and the main source of long term disability among the elderly (2001; Thom, 
Haase et al. 2006; National Center for Health 2012).  Stroke is a general term that denotes 
cerebral cell death due to the disruption of the circulation.  The most common source of 
disruption is an intravascular blood clot or embolus that interferes with the delivery of 
nutrients and oxygen to cells (Rosamond, Folsom et al. 1999).  Restricted blood flow, 
known as ischemia, induces a cascade of pathological cell signaling events, culminating 
in widespread cell death (Lipton 1999).  Within minutes of an ischemic insult, 
impairment of energy-dependent processes occurs in neurons.  ATP-driven ion channels 
fail to maintain ionic gradients, leading to membrane depolarization and the release of the 
excitatory neurotransmitter glutamate in large quantities (Martin, Lloyd et al. 1994; 
Danbolt 2001).  Excitotoxic overstimulation of glutamate receptors leads to the spread of 
ion imbalance and deleterious elevations in intracellular calcium levels (Danbolt 2001).   
Calcium, in turn, activates degradative enzymes and promotes the production of reactive 
oxygen species by mitochondria (Choi 1995; Brouns and De Deyn 2009).  The resulting 
enzymatic and oxidative damage to the brain parenchyma contributes to tissue death, or 
infarction, within minutes to hours of blood stoppage (Doyle, Simon et al. 2008).  In 
addition, oxidative stress to vascular structures causes blood-brain barrier dysfunction 
and recruitment of inflammatory cells that contribute to tissue damage over a period of 
days (Doyle, Simon et al. 2008; Brouns and De Deyn 2009).    
 22 
 The main strategy for limiting the severity of ischemic stroke damage is the 
restoration of blood flow, or reperfusion, to provide resources for the repair of injured 
cells (1995; Hacke, Donnan et al. 2004). This approach employs recombinant human 
tissue plasminogen activator (t-PA), a thrombolytic agent that improves neurologic 
outcome and increases long-term patient survival when administered intravenously 
within hours of stroke onset (1995).  Although reperfusion by t-PA is essential for 
minimizing damage, it can also aggravate conditions by placing marginally-injured cells 
into contact with blood while their regulatory abilities are impaired (Hamann, Okada et 
al. 1995; Hamann, Okada et al. 1996; Wang, Tsirka et al. 1998; Wu, Tamaki et al. 1998). 
This is particularly critical in the cells surrounding the core of the infarct, collectively 
known as the ischemic penumbra, which have the potential to progress to apoptosis but 
can be rescued under certain conditions.  Reducing the deterioration of cells in the 
penumbra has been the goal of numerous studies investigating neuroprotective agents for 
the treatment of stroke.  Pharmaceuticals that inhibit cellular mediators of excitotoxicity 
(Lyden, Jacoby et al. 2001; Diener, AlKhedr et al. 2002), inflammation (2001), and 
reactive oxygen species (Shuaib, Lees et al. 2007) or that promote neuroregeneration 
(Bogousslavsky, Victor et al. 2002) have been investigated clinically.  None have led to a 
successful FDA-approved therapy, partly due to the failure of drugs to reach their 
therapeutic targets.   
2.1.1 RNA Interference and Cell Penetrating Peptide (CPP) Delivery 
 RNA interference (RNAi) technology is a potentially valuable approach to stroke 
therapy because it can easily be adapted to target any gene that minimizes cell damage 
after ischemia, provided that the gene sequence is known.  In the past decade, RNAi has 
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been rapidly integrated into basic biomedical research, emerging as a premier method for 
regulating gene expression in a variety of model systems.  As RNAi-based therapies 
progress to clinical trials and are applied to increasingly complex human diseases, the 
need for improved small interference RNA (siRNA) delivery methods and monitoring 
becomes critical (Castanotto and Rossi 2009).  These considerations are particularly 
relevant in neurological pathologies, in which an intact blood-brain barrier (BBB) may 
limit direct contact between diseased cells and most systemically administered agents.   
 One approach for overcoming biological membranes exploits naturally-occurring 
membrane translocation sequences that are known in the literature as cell penetrating 
peptides (CPPs), protein transduction domains (PTDs) or Trojan peptides (Derossi, Joliot 
et al. 1994; Vives, Brodin et al. 1997).  CPPs were originally derived from membrane 
permeable cationic viral protein transduction domains, transcription factors, or cell 
adhesion proteins and range in size from 10-30 amino acids (Langel 2007).  CPPs have 
been modified to accommodate and promote the intracellular delivery of diverse 
molecular cargoes, including proteins (Schwarze, Ho et al. 1999), liposomes (Torchilin, 
Levchenko et al. 2003), and nanoparticles (Lewin, Carlesso et al. 2000).  While the 
precise mechanism of CPP internalization remains controversial, most studies suggest 
that peptide entry is mediated by energy-dependent endocytic pathways, though there is 
evidence that direct translocation across membranes occurs, particularly by CPPs with an 
amphipathic nature.  A summary of the best-characterized CPPs is presented in Table 2.1.   
 Recently it was demonstrated that intravenously injected siRNA, when used in 
conjunction with a peptide sequence from rabies virus glycoprotein, was delivered to the 
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Table 2.1.  Cell Penetrating Peptides.  
Peptide/ Amino acid 
Sequence 
Source Internalization Mechanism Cargo Molecules Delivered 
HIV-Tat/ 
GRKKRRQRRRPPQ 
Peptides 48-60 of the Tat protein 
of human immunodeficiency virus 
type 1 (HIV-1)(Vives, Brodin et al. 
1997). 
Clathrin-dependent and caveolin-
independent endocytosis (Richard, 
Melikov et al. 2005), lipid raft-
dependent endocytosis (Wadia, Stan et 
al. 2004), temperature-dependent 
caveolar endocytosis (Fittipaldi, Ferrari 
et al. 2003).  
• Fusion peptides (Schwarze, Ho et al. 
1999). 
• Liposomes (Torchilin, Rammohan et 
al. 2001). 
• Iron nanoparticles (Lewin, Carlesso 
et al. 2000). 
• Oligonucleotides (Astriab-Fisher, 
Sergueev et al. 2002). 
Penetratin/ 
RQIKIWFQNRRMKWK
K 
 
Peptides 43-58 of the 
Antennapedia (Antp) 
homeodomain third helix (Derossi, 
Joliot et al. 1994). 
Direct translocation (Derossi, Chassaing 
et al. 1998; Letoha, Gaal et al. 2003), 
adsorptive-mediated endocytosis with 
endosomal acidification (Fischer, 
Kohler et al. 2004). 
• Oligonucleotides (Troy, Derossi et 
al. 1996). 
• Peptides (Perez, Lledo et al. 1994; 
Theodore, Derossi et al. 1995; Troy, 
Stefanis et al. 1996). 
 
Oligoarginine/ RRR…R 
[6-15 R’s] 
Designed (Futaki, Suzuki et al. 
2001). 
Endocytosis (Fuchs and Raines 2004), 
macropinocytosis (Nakase, Niwa et al. 
2004), energy-independent entry 
(Thoren, Persson et al. 2003). 
• Nucleic acids and peptides (Kim, 
Christensen et al. 2006; Kumar, Wu 
et al. 2007). 
Transportan/ 
GWTLNSAGYLLGKIN
LKALAALAKKIL 
 
Chimeric protein formed by the 
fusion of the neuropeptide galanin 
and wasp venom toxin mastoparan 
(Pooga, Hallbrink et al. 1998). 
 
Clathrin dependent and independent 
endocytosis (Saalik, Elmquist et al. 
2004; Padari, Saalik et al. 2005). 
• Gold nanoparticles (Saalik, Elmquist 
et al. 2004). 
pVEC/ 
LLIILRRRIRKQAHAHS
K 
Peptides 615-632 of murine 
vascular endothelial cadherin 
(Elmquist, Lindgren et al. 2001). 
Clathrin-dependent endocytosis 
(Elmquist, Hansen et al. 2006). 
 
• Peptide nucleic acids (Elmquist, 
Lindgren et al. 2001). 
• Streptavidin-FITC (Elmquist, 
Lindgren et al. 2001). 
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Table 2.1. (Continued).  
Pep-1/ 
KETWWETWWTEWSQ
PKKKRKV 
 
Designed, chimeric CPP with 
tyrosine-rich hydrophobic region 
and a nuclear localization sequence 
derived from simian virus 40 large 
T antigen (Morris, Depollier et al. 
2001).   
Direct membrane translocation 
(Deshayes, Morris et al. 2005; 
Henriques, Quintas et al. 2007). 
• Peptides (Morris, Depollier et al. 
2001). 
• Proteins [e.g., -galactosidase] 
(Henriques, Costa et al. 2005). 
MPG/ 
GALFLGFLGAAGSTM
GAWSQPKSKRKV 
N-terminal residues derived from 
HIV gp41 transmembrane protein 
(Morris, Vidal et al. 1997). 
 
Direct translocation (Morris, Vidal et al. 
1997; Simeoni, Morris et al. 2003; 
Deshayes, Morris et al. 2005). 
• DNA (Morris, Vidal et al. 1997). 
VP22/ 
DAATATRGRSAASRPT
ERPRAPARSASRPRRP
VD 
 
Herpes simplex virus type 1 (HSV-
1) tegument protein (Elliott and 
O'Hare 1997). 
Macropinocytosis (Normand, van 
Leeuwen et al. 2001). 
• Fusion proteins (e.g., p53 (Phelan, 
Elliott et al. 1998) and thymidine 
kinase (Dilber, Phelan et al. 1999)). 
• Oligonucleotides (Normand, van 
Leeuwen et al. 2001). 
KALA/ 
WEAKLAKALAKALAK
HLAKALAKALKACEA 
 
Designed (Wyman, Nicol et al. 
1997), amphipathic molecule with 
a hydrophobic leucine-rich region 
for DNA binding (Mascotti and 
Lohman 1993) and a hydrophilic 
lysine-rich region for cell 
membrane penetration  (Subbarao, 
Parente et al. 1987) 
Pore formation (Wyman, Nicol et al. 
1997) 
• Oligonucleotides and plasmid DNA 
(Wyman, Nicol et al. 1997). 
Model Amphipathic 
Peptide (MAP)/ 
KLALKLALKALKAAL
KLA 
 
Designed (Oehlke, Scheller et al. 
1998) 
Endocytotic and non-endocytotic entry 
(Oehlke, Scheller et al. 1998). 
• Peptide nucleic acids (Oehlke, 
Wallukat et al. 2004). 
25
 !
 
Table 2.1. (Continued).  
VPR/ 
DTWPGVEALIRILQQL
LFIHFRIGCQH 
From the 96 amino acid protein of 
human immunodeficiency virus 1 
(HIV-1) (Taguchi, Shimura et al. 
2004).  
Clathryn-mediated endocytosis 
(Coeytaux, Coulaud et al. 2003). 
Direct translocation via membrane 
permeabilization (Coeytaux, Coulaud et 
al. 2003). 
• Protein (e.g., GFP (Taguchi, Shimura 
et al. 2004) and -galactosidase 
(Taguchi, Shimura et al. 2004)). 
• Plasmid DNA (Coeytaux, Coulaud et 
al. 2003). 
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brain and retained its gene silencing capabilities (Kumar, Wu et al. 2007; Pulford, Reim 
et al. 2010).   In our laboratory, we have investigated a cationic arginine-based CPP 
modified with myristic acid that has a high affinity for lipid bilayer membranes, which 
promotes enhanced entry into cells relative to well-established Tat and oligoarginine 
CPPs (Pham, Kircher et al. 2004).  Hydrophobic moieties in CPPs, like myristic acid, are 
important because they improve CPP escape from endosomal vesicles to the cytoplasm 
(Takayama, Hirose et al. 2012).  We have used our myristoylated poly-arginine peptide, 
or MPAP, to promote cellular delivery of nanoparticle imaging agents to solid tumors 
after intravenous injection (Medarova, Pham et al. 2007; Kumar, Medarova et al. 2010).  
Furthermore, MPAP has demonstrated BBB permeability in vivo, where it was shown to 
localize to neurons, astrocytes and endothelial cells after intravascular administration 
(Pham, Zhao et al. 2005). These properties make MPAP ideally suited for use with 
siRNA to form a dual optical imaging and therapeutic probe for neurological 
applications, provided that a method of complexation is developed that does not inhibit 
the bioactivity of siRNA molecules.   
2.1.2 MPAP-siRNA Stroke Therapeutics  
 This chapter details our investigation of fluorescently labeled MPAP, comprising 
a poly-arginine peptide modified with a 14-carbon myristic acid moiety, for siRNA 
delivery.  We describe the generation and testing of an MPAP and siRNA (MPAP-
siRNA) imaging probe complex for the treatment of ischemic stroke.   We hypothesized 
that if siRNA directed against genes implicated in stroke pathology were effectively 
delivered to primary neurons and astrocytes to intercede in this process, neuroprotection 
could be elicited. With this in mind, we developed dual MPAP-siRNA optical imaging 
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probes directed against c-Src (Src), a protein tyrosine kinase with activity that becomes 
upregulated after stroke and is associated with increased tissue damage in cerebral 
ischemia models (Korematsu, Goto et al. 1994; Paul, Zhang et al. 2001).  Src is involved 
in numerous cellular roles ranging from proliferation and adhesion to cell survival 
(Collett, Brugge et al. 1978; Oppermann, Levinson et al. 1979; Thomas and Brugge 
1997).   In vitro hypoxia studies have demonstrated an increase in Src activation within 
minutes of hypoxic stimulus that is at least partially mediated by reactive oxygen species 
(Sato, Sato et al. 2005).  Src expression increases in ischemic stroke soon after the 
induction of reperfusion (Korematsu, Goto et al. 1994).  Src knockout mice are protected 
from ischemic damage, with an approximately 50% decrease in infarct size relative to 
wild-type controls (Paul, Zhang et al. 2001).  Protection from ischemia extends to wild-
type mice when treated with a Src-inhibitor within six hours of stroke induction, probably 
through reduction of VEGF-induced cerebral edema and inflammation.  Src may also 
contribute to excitotoxicity-related stroke damage through phosphorylation of proteins 
associated with NMDA (N-methyl-D-aspartate) receptors and increases in pathological 
calcium currents (Liu, Zhang et al. 2001; Liu, Hou et al. 2003; Du, Gao et al. 2009).  The 
conclusions drawn from these studies regarding the role of Src in stroke pathology and 
the effectiveness of Src-inhibitors after stroke induction made Src a strong potential 
target for stroke therapy in the proposed work. 
 Src-directed probes were assembled by utilizing the natural affinity of cationic 
peptides for oligonucleotides, a process that was optimized to ensure maximum siRNA 
incorporation.  MPAP complexes with Src siRNA (MPAP-Src) were tested for stability.  
Their internalization in primary central nervous system cells and an endothelial cell line 
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was monitored by flow cytometry and confocal microscopy.  The probes were also 
evaluated for cytotoxicity and siRNA silencing efficiency.  In vitro studies confirmed that 
MPAP-Src complexes become internalized by cells and cause statistically-significant 
reductions in endogenous Src levels without significantly affecting cell viability.  Next 
we transitioned to testing MPAP-Src complexes in experimental mouse models of stroke.  
Intravenous administration of MPAP-Src before or after transient middle cerebral artery 
occlusion resulted in marked accumulations of probe that were evident by ex vivo optical 
imaging.  However, neither treatment paradigm mitigated stroke damage to a statistically 
significant degree.  Direct intracerebral injection of probes resulted in significant 
reductions in Src mRNA expression, demonstrating that MPAP-Src can modulate gene 
expression in the brain.   Despite the observation that Src reduction was not 
neuroprotective, our results indicate that MPAP is a viable platform for siRNA delivery 
that may prove effective against alternative stroke targets.             
2.2 Experimental Procedures 
2.2.1 MPAP Probe Synthesis  
 Myristoylated polyarginine peptide (MPAP), C14-βAla-(Arg)7-Cys(SH)-NH2, 
was synthesized and purified as described previously (Pham, Zhao et al. 2005) and 
conjugated to Cy5.5 fluorescent dye (Amersham, Piscataway, NJ) to form MPAP-Cy5.5.  
Conjugation of the fluorescent dye, Cy5.5 mono maleimide (0.87 mmol), to purified 
MPAP (1.5 mmol) was carried out in 1:1 acetonitrile/50 mM NaOAc (pH 7.4) buffer at 
room temperature overnight with constant agitation.   The MPAP-Cy5.5 product was 
purified by reversed-phase HPLC.  The mass of MPAP-Cy5.5 determined by MALDI 
mass spectroscopy was 2536.42 (calculated 2537.04).  Scrambled siRNA and siRNA 
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directed against mouse Src, both labeled on the 5’ sense strand with fluorescent tag 
Dy547 (absorbance/emission max: 548/562nm), were designed and synthesized by 
Dharmacon (Chicago, IL).  To promote probe complex formation, MPAP-Cy5.5 was 
dissolved in water, combined with siRNA-Dy547 solution, and mixed through gentle 
aspiration.  The resulting probe mixture was incubated for 20 minutes at room 
temperature to induce complete complexation of the two components.    
2.2.2 Gel Mobility Shift Assay and Zeta Potential Characterization  
 To optimize stoichiometry of MPAP-Cy5.5 and siRNA complexes, we performed 
polyacrylamide gel electrophoresis.  For this, various dilutions of MPAP-Cy5.5 solution 
were added to siRNA (20 pmol) to obtain 1:10, 1:5, 1:2.5, 1:1, 2.5:1, 5:1 and 10:1 
siRNA-to-peptide molar ratios.  Samples were incubated for 20 minutes at room 
temperature to allow complexation, and loaded onto 20% polyacrylamide-TBE gels 
(Novex, Invitrogen, Carlsbad, CA) along with reference siRNA solutions (20, 10, 5, and 
1 pmol).  The gel was subjected to electrophoresis at 200 V for 30 minutes.  In each 
sample solution, free siRNA that had failed to associate with MPAP traveled through the 
gel, while complexes remained stationary in the gel’s loading well.  The gel was stained 
with ethidium bromide and visualized by UV-illumination.  The amount of free siRNA in 
each sample was quantified using ImageJ software (NIH) to analyze the density of each 
siRNA band relative to reference siRNA solutions.  The molar ratio for which complete 
incorporation of siRNA was demonstrated (i.e., 1:5 siRNA:MPAP ratio) was selected for 
further study.  The zeta potentials of MPAP-Src complexes were measured with a 
Malvern Zetasizer Nano Series ZS instrument.   
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2.2.3 Serum Stability 
 Solutions of free siRNA or MPAP-Cy5.5 complexed with siRNA (MPAP-Src) 
were incubated in mouse serum to evaluate the protective effect of MPAP-Cy5.5 against 
nuclease digestion of siRNA.  MPAP-Cy5.5 and c-Src siRNA were combined at a 1:5 
siRNA-to-peptide molar ratio and incubated for 20 minutes at room temperature.  The 
complexes were then incubated at 37°C in 75% fresh mouse serum.  Aliquots were 
removed at 0, 0.5, 1, 2, 4, and 8 hour time points, placed in 1 mg/ml proteinase K 
(Invitrogen, Carlsbad, CA) to remove any associated protein, and frozen in preparation 
for subsequent gel electrophoresis.  MPAP-Src samples were subjected to gel 
eletrophoresis in 20% polyacrylamide-TBE gels alongside samples of free siRNA that 
had been digested in serum.  The gels were visualized by SYBR Gold (Molecular Probes, 
Invitrogen, Eugene OR) staining.  For each sample, the amount of siRNA spared from 
nuclease digestion was quantified using ImageJ software (NIH) and normalized by 
undigested free siRNA or undigested siRNA complexed with MPAP-Cy5.5 to obtain the 
percentage of intact siRNA over time.  Results are a compilation of four separate 
experiments. 
2.2.4 Cell Culture and MPAP-Mediated siRNA Delivery 
Primary Mouse Cortical Neurons and Astrocytes   
 Cortical neuron cultures were generated from embryonic day 18 C57BL/6 mouse 
fetuses following the procedures outlined in (1998) with modifications.   After brain 
removal, cortices were dissected and separated from meningeal tissues.  Cortices were 
finely chopped, washed with HBSS, and suspended in Papain enzyme solution 
(Worthington Biochemical Corporation, Lakewood, NJ).  Following 15 minutes of 
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incubation in enzyme solution at 37°C, cortices were washed with Neurobasal medium 
(Gibco, Invitrogen, Grand Island, NY) and triturated through a small-bore pipet tip to 
form a single cell suspension.  The cells were passed through a 70-micron cell strainer, 
pelleted by centrifugation, and resuspended in Neurobasal medium containing 10% fetal 
bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin (pen-strep).  
Neurons were plated in 12-well plates coated with poly-D-lysine and laminin (Sigma, St. 
Louis, MO) at a density of 1×105 cells per well and incubated at 37°C for 1 hour.  Media 
was replaced with Neurobasal medium containing Glutamax and B-27 supplements 
(Gibco, Invitrogen, Grand Island, NY) and pen-strep.  Neurons intended for confocal 
microscopy were plated on glass coverslips coated with poly-D-lysine and laminin and 
maintained in 12-well plates.  The cells were treated with mitotic inhibitor cytosine-b-D-
arabinofuranoside (Sigma, St. Louis, MO) 24 and 48 hours after initial plating to inhibit 
glial cell growth.  Experiments were initiated 5-7 days after plating.   
 Cell culture of cortical astrocytes was performed using a slight modification of the 
procedure for neurons.  Cortices were dissected from C57BL/6 mouse pups, postnatal day 
1-2.  Following enzymatic digestion, cells were washed with DMEM containing 10% 
FBS and pen-strep, triturated, filtered, pelleted, and resuspended in DMEM media.  Cells 
were grown in culture flasks with media changes three times per week.  When confluent, 
the cells were placed on an orbital shaker at 250 rpm for four hours to promote removal 
of non-astrocytes.  Media was removed and astrocytes were dissociated with 0.05% 
Trypsin/0.53 mM EDTA and subcultured in DMEM/FBS solution in 12-well plates at 
1×105 cells per well.  Cells intended for confocal microscopy were plated on glass 
coverslips contained in 12-well plates.  All experiments were performed one day after 
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plating.  Media was changed to serum-free DMEM containing pen-strep prior to 
experiments.   
bEnd.3 Cell Culture   
 An endothelial cell line, bEnd.3, was obtained from American Type Culture 
Collection (Manassas, VA).   Cells were grown in DMEM containing 10% FBS and pen-
strep.  Cells were plated in 12-well plates at a density of 5×104 cells per well for all 
experiments except for confocal microscopy, for which cells were plated on glass 
coverslips.   Experiments were performed one day after plating on cells in serum-free 
DMEM containing pen-strep.    
In vitro MPAP-siRNA Delivery   
 Cy5.5-labeled MPAP (500 pmoles, 20 pmol/µl) was added to 100 pmoles (200 
pmol/µl) of Dy547-labeled scrambled or c-Src specific siRNA (Dharmacon, Chicago, 
IL).  The solution was incubated for 20 minutes at room temperature and added to 
primary astrocytes, primary neurons, or bEnd.3 cells plated in serum-free media in 12-
well plates.  Total siRNA and MPAP concentrations during incubation were 100 nM and 
500 nM, respectively.  Cells were incubated with the probe for 48 hours, unless otherwise 
stated.   
2.2.5 Cytotoxicity Assays 
 Cells were obtained according to the procedures described above, plated in 96-
well plates and grown to 80% confluency.  MPAP-Src was added to the cells in 
concentrations scaled down to accommodate 96-well conditions.  Experiments were 
performed at probe concentrations of 100 nM siRNA and 500 nM MPAP, with 
approximately 8 pmol:40 pmol siRNA:MPAP added per well.  Following 48 hours of 
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incubation with MPAP-Src or media only, cells were processed for 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) or caspase-3 analysis.  For MTT 
assays, cells were incubated in 0.5 mg/ml MTT (Sigma, St. Louis, MO) for 4 hours, after 
which the solution was replaced with dimethyl sulfoxide (DMSO).  The absorbance 
values of the resulting solutions were acquired by microplate reader at 570 nm with 630 
nm used as reference.  Cells incubated in 1 µg/ml staurosporine for 24 hours were used as 
positive controls.  Caspase-3 assays were performed using the CASP-3-C caspase-3 assay 
kit according to the manufacturer’s protocol (Sigma, St. Louis, MO).  All cytotoxicity 
measurements were performed in triplicate and normalized by total protein content (BCA 
(bicinchoninic acid) assay, Pierce, Rockford, IL).  Statistical analysis of differences 
between treatment groups was performed using Student’s t-testing, in which a value of p 
< 0.05 was considered statistically significant. 
2.2.6 Fluorescence-Activated Cell Sorting (FACS) 
 The extent of probe internalization by astrocytes, neurons and bEnd.3 cells was 
investigated using FACS analysis.  Cells incubated with MPAP-Src or MPAP associated 
with scrambled control siRNA (MPAP-Ctrl, designed by Dharmacon) for 24 hours were 
washed with HBSS, dissociated with trypsin, fixed with 2% paraformaldehyde and stored 
at 4°C until analysis.   Untreated cells served as a negative control.  Measurements of 
Dy547-labeled siRNA (FL-2) and Cy5.5-labeled MPAP (FL-4) fluorescence were 
performed using a FACS Caliber flow cytometer (Becton Dickinson Biosciences, San 
Jose, CA).   
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2.2.7 Fluorescence Confocal Microscopy of MPAP-siRNA Delivery 
 Confocal microscopy was used to visualize the intracellular distribution of 
MPAP-Src complexes.  Following 24 hour incubation with probe at 37°C, cells were 
washed with PBS and fixed in 4% paraformaldehyde.  Neurons and astrocytes were 
permeabilized in 0.1% Triton-X, blocked with bovine serum albumin, and incubated with 
rabbit antibody to mouse beta III tubulin specific for neurons or rabbit antibody to mouse 
glial fibrillary acidic protein specific for astrocytes (Abcam, Cambridge, MA).  This was 
followed by incubation with goat anti-rabbit secondary antibody labeled with Alexa Fluor 
488 (Molecular Probes, Invitrogen, Eugene OR).  Endothelial bEnd.3 cells were stained 
with a CD31 antibody that was labeled with a FITC conjugate (Invitrogen, Camarillo, 
CA).    The precise intracellular localization of probes was investigated using Lysosensor 
Green DND-153 (Molecular Probes, Invitrogen, Eugene, OR).  In preparation for live-
cell confocal microscopy, cells were incubated in 62 nM LysoSensor Green DND-153 in 
DMEM for 30 minutes.  Cells were washed with HBSS and imaged immediately.   
Imaging was performed with an Axiovert 200M inverted microscope (Carl Zeiss Inc., 
Oberkochen, Germany) that included the Zeiss LSM Pascal Vario RGB Laser Module 
(Arg 458/488/514 nm, HeNe 543 nm, HeNe 633 nm).  Cells were imaged in the Cy5.5 
channel to detect MPAP, the Cy3 channel to detect siRNA, and the FITC channel to 
detect LysoSensor Green and cell-specific stains.   
2.2.8 Real-Time Quantitative RT-PCR 
 For in vitro studies, astrocytes, neurons and bEnd.3 cells were incubated for 24 or 
48 hours with MPAP-Src (n=7) or MPAP-Ctrl (n=7) probes.   Total RNA was purified 
from cells using the RNeasy Mini kit (Qiagen, Valencia, CA).   For in vivo studies, fresh 
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brain tissue was disrupted on ice in lysis buffer (RP1 buffer, Clontech) and β-
mercaptoethanol using a rotor-stator homogenizer.  Total RNA was isolated from the 
lysate using the Nucleospin Total RNA and Protein Isolation kit (Clontech).   
 The RNA was subjected to real-time quantitative RT-PCR (TaqMan) to determine 
relative levels of c-src mRNA.  The sequences of primers and probe used for 
amplification are as listed: forward primer, 5’-AGCGGCGGTTTCTACATCAC -3’ (c-
src isoform 1 nucleotides 1033-1052); reverse primer, 5’-
GTAAGCCACGAGCTGCTGC-3’ (nucleotides 1077-1095); TaqMan probe, 5’-
TCCCGCACCCAGTTCAACAGCC-3’ (nucleotides 1054-1075).  Statistical analysis 
of RT-PCR results was performed using Student’s t-tests in which a value of p < 0.05 
was considered statistically significant.    
2.2.9 Middle Cerebral Artery Occlusion (MCAo) Surgery 
 All animal experiments were approved by the Subcommittee on Research Animal 
Care at Massachusetts General Hospital and carried out according to institutional 
guidelines.  Adult male C57BL/6N mice of 10-12 weeks of age, weighing between 25-31 
grams, were purchased from Charles River Laboratories.  Animals were housed in a 
facility with ambient temperature and humidity control and 12-hour light/dark cycles.  
Transient cerebral ischemia through middle cerebral artery occlusion (MCAo) was 
induced using a modification of the procedure developed for rats by Longa et al. (Longa, 
Weinstein et al. 1989) and later adapted to mice (Belayev, Busto et al. 1999).  General 
anesthesia was induced with inhalational anesthetic isoflurane (Forane, Baxter) applied at 
a dose of 2-2.5% in a mixture of 30% oxygen and 70% nitrous oxide using a precision 
vaporizer (Ohmeda Isotec).  Surgical depth of anesthesia was confirmed by reduction in 
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respiratory rate and the loss of pedal withdrawal reflexes (Flecknell 1996).  During the 
surgical procedure, anesthesia was applied via facemask with a vacuum scavenging 
system and maintained at 1.0-1.5% isoflurane in oxygen/nitrous oxide gas at a total flow 
rate of 2.0 L/min.  Mice were placed on a cleaned and sanitized surgical table, equipped 
with a heat pad with adjustable temperature control for maintenance of body temperature 
within normal physiological limits (37±0.5°C).  Temperature was monitored with a T-
type thermocouple temperature probe (AD Instruments) that was advanced 15 mm into 
the rectum and kept in place through the entirety of the experiment.  Surgeries were 
carried out using modified aseptic techniques with protective clothing, sterile supplies, 
sterile surgical field, and disinfection of animal skin surfaces with the iodophor Betadine.  
All surgical instruments were decontaminated using the Germinator dry bead sterilizer 
(Roboz) prior to use.  For analgesia, 2% lidocaine hydrochloride (10 ul, Hospira), was 
injected locally at the incision site pre-operatively, while postoperative buprenorphine 
(0.05 mg/kg subcutaneous, Bedford Labs) was administered every 12 hours or as needed.   
Fluid supplementation during surgery was performed through subcutaneous injections of 
0.9% NaCl (Flecknell 1993).    
 In preparation for the MCAo procedure, a laser doppler fine needle probe unit 
(AD Instruments) was implanted over the middle cerebral artery brain territory.  For this, 
the anesthetized mouse was placed in prone position.  A 5-mm midline incision was 
made through the scalp to reveal bregma, the anatomical marker of the skull where the 
sagittal and coronal sutures meet (Figure 2.1a).  To keep the doppler probe stationary 
during the experiment, a doppler probe holder was fashioned from PE-50 polyethylene 
catheter tubing modified on one end with a rubberband (Figure 2.1b).  The holder was   
 38 
Figure 2.1.  Middle cerebral artery occlusion (MCAo) surgery with cerebral blood 
flow monitoring.  Cerebral blood flow for MCAo was recorded by positioning a laser 
doppler flow unit on the skull overlying MCA territory as measured relative to (a) 
bregma (arrow).  The unit was held in place by (b) a doppler probe holder fashioned from 
PE-50 catheter tubing and attached to the skull surface before insertion of (c) a fine 
needle doppler probe (arrow).  For MCAo, (d) a midline incision was made in the ventral 
neck of the mouse, revealing the submandibular gland (sub).  Blunt dissection of the 
gland revealed the underlying (e) trachea (tr), right digastric muscle (dm), and 
sternocleidomastoid muscle (scm).  Coursing parallel to tr is the (f) common carotid 
artery (CCA), that was loosely tied with 6-0 silk suture thread caudal to its bifurcation 
into (g) internal carotid artery (ICA) and external carotid artery (ECA) branches (arrows).  
(h) Four additional sutures (1-4) were tied along the ECA.  Just medial to ECA sutures 1-
3 lies (i) a nerve (arrow) that was separated from dm to reveal j) the pterygopalatine 
artery (PPA) branch of the ICA (arrows). (k-l) The PPA (arrow) was permanently ligated, 
as were ECA sutures 1 and 2.  (m) An occluding monofilament (occ) was (n) introduced 
into external carotid artery between ECA sutures 2 and 3 and (o)  advanced  to the carotid  
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Figure 2.1 (Continued).   
bifurcation.  The ECA was cut between sutures 1 and 2, and (p) the occluding 
monofilament rotated such that it entered the ICA (arrow).  (q) The monofilament was 
advanced through the ICA (arrow) to the branchpoint of the MCA, where it induces 
ischemia.  (r) A schematic of the final monofilament placement relative to the ICA, ECA, 
the posterior cerebral artery (PCA) and anterior cerebral artery (ACA) is shown with 
ligatures marked by ‘X’ and collar sutures around the monofilament denoted by ‘\’.    
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attached to the skull surface 3.5 mm lateral and 1.5 mm posterior to bregma using a 
combination of cyanoacrylate glue and cyanoacrylate accelerator solution (ZAP). This 
site was selected because it overlies the central core of ischemic territory in the MCAo 
model (Shimizu-Sasamata, Bosque-Hamilton et al. 1998).  The doppler probe was 
introduced into the probe holder lumen and held in full contact with the skull using a 
hands-free clamp (Figure 2.1c).  The outputs of the doppler and rectal temperature probes 
were collected using the Powerlab Data Acquisition System (AD Instruments).  Real-time 
cerebral blood flow and temperature readings were recorded and displayed with LabChart 
5 software (AD Instruments) throughout the experiment.  
 MCAo surgery was carried out with the mouse in the supine position.  A 1-cm 
midline incision was made in the neck to reveal the submandibular gland (Figure 2.1d).  
The gland was bluntly dissected away and retracted to reveal the triangular junction of 
trachea, right digastric muscle, and right sternocleidomastoid muscle (Figure 2.1e).  
Superficial vessels in this junction were cauterized with a fine-tipped cautery pen, and the 
right carotid sheath, containing the common carotid artery (CCA) and vagus nerve, 
identified along its course running parallel to the trachea.  The CCA was dissected away 
from the surrounding structures without making contact with the vagus nerve, and size 6-
0 silk suture thread (Ethilon) loosely tied around the artery where it emerged from 
beneath the sternocleidomastoid muscle (Figure 2.1f).   The CCA bifurcates just rostral to 
this point into the internal carotid artery (ICA) and external carotid artery (ECA).  
Another suture was tied along the ECA (Figure 2.1g).  The suture was used to pull the 
ECA laterally to aid in the identification and cauterization of small branches of the ECA, 
including the occipital and superior thyroid arteries.  Three additional sutures were tied 
 41 
along the ECA for a total of four (Figure 2.1h).  Rostral and lateral to the tied sutures lies 
a nerve that runs along the digastric muscle (Figure 2.1i).  Figure 2.1j shows the nerve 
after it has been separated from the digastric muscle and bluntly dissected medially to 
reveal the ICA and its branch, the pterygopalatine artery (PPA).  A ligature was 
permanently tied around the PPA (Figure 2.1k-l) to prevent any collateral circulation to 
the brain that could influence the MCAo model in this strain (Chen, Ito et al. 2008).  In 
preparation for the introduction of the occluding monofilament into the ECA, the suture 
loosely-tied around the CCA and ECA suture 4 was temporarily ligated, and ECA sutures 
1 and 2 were permanently ligated to prevent any back-flow of blood.  A pair of micro-
dissecting spring scissors were used to cut a small hole between ECA sutures 2 and 3.  A 
20-mm long silicon rubber-coated 6-0 size occluding monofilament with coating 
diameter of 0.23±0.02mm (Figure 2.1m, Doccol Corporation) was introduced into the 
hole and advanced past suture 3, where it was tied in place by ECA suture 3 (Figure 
2.1n).  Suture 4 was loosened, the monofilament was advanced to the common carotid 
bifurcation and suture 4 tightened around it (Figure 2.1o).  The ECA was sectioned 
between sutures 1 and 2, and suture 2 was lifted caudally to maneuver the tip of the 
occluding monofilament from the bifurcation into the ICA (Figure 2.1p).  ECA sutures 3 
and 4 were loosened slightly and the monofilament was advanced in the ICA past the 
PPA to the branch point of the MCA, approximately 9-11 mm from the bifurcation of the 
CCA (Figure 2.1q).  A schematic of the final occluding monofilament placement during 
the ischemic phase of MCAo is shown in Figure 2.1r.  Occlusion of the MCA was 
characterized by a sharp reduction in cerebral blood flow to less than 25% of baseline 
levels.  In preliminary experiments, stroke volume was assessed as a function of 
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occlusion time (i.e., 15, 30, 60 min or permanent occlusion) to identify a duration that 
resulted in the most stereotyped infarcts.  Transient cerebral ischemia of 60 minutes was 
selected for all experiments unless otherwise stated.  After the designated occlusion time 
elapsed, the occluding monofilament was removed and blood flow restored in the 
ischemic right hemisphere.  Upon removal of the monofilament, ECA sutures 3 and 4 
were permanently ligated, and the CCA ligature was removed for full reperfusion.  The 
fine needle doppler probe, probe holder, and rectal temperature probe were removed, and 
all incisions sutured closed with 5-0 silk suture thread (Ethilon).  Following surgery, mice 
were allowed to recover from anesthesia on a heating pad attached to a circulating water 
heating system (Gaymar).         
2.2.10 Evans Blue Dye Evaluation of Blood-Brain Barrier Permeability    
 The permeability of the blood-brain barrier after cerebral ischemia was evaluated 
using the Evans Blue dye extravasation method (Vakili, Kataoka et al. 2005).   Mice were 
intravenously injected with 2% Evans blue dye (Sigma) in 0.9% saline at a dose of 3 
ml/kg immediately after reperfusion of MCAo.  Twenty-four hours later, transcardial 
perfusion was performed using a modification of the procedure described by Hockfield et 
al. (Hockfield, Carlson et al. 1993). Mice were anesthetized deeply with isoflurane in 
oxygen and transferred to a perfusion tray.  A midline incision was made along the 
sternum to expose the heart.  A 25-gauge winged infusion needle attached to a peristaltic 
pump (Econo-Pump, BioRad) for the circulation of heparinized normal saline was 
inserted in the left apex of the heart and advanced into the left ventricle.  An incision was 
made in the right atrium as the peristaltic pump flow rate was initialized to 0.5 ml/min.  
Mice were perfused with saline for ten minutes, or until perfusate was clear and the liver 
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became pale in color.  Following perfusion, the brain was excised and ex vivo imaging of 
Evans blue dye in whole brain or brain slices was performed using the IVIS Spectrum 
optical imaging system (IVIS Spectrum, Caliper Life Sciences) with excitation and 
emission wavelengths of 605 nm and 680 nm, respectively.  Data analysis was performed 
using LivingImage® 4.2 software.  Evans blue dyed brain slices were digitized using a 
Dell 810 flatbed scanner. 
2.2.11 Therapeutic Treatment with MPAP-Src: Systemic Administration 
 The effect of systemically-administered MPAP-Src on Src gene expression was 
investigated using two treatment regimens (pre-stroke injections and post-stroke 
injections).  Experiments were carried out using Dy547-labeled siSTABLE siRNA 
specific for c-src purchased from Dharmacon. The siRNA was dissolved in 1X siRNA 
buffer (Dharmacon) and separated into 50 mg aliquots (3.7 nmol Src siRNA).  Twenty 
minutes prior to injection, a siRNA aliquot was mixed in a 1:5 ratio with Cy5.5-labeled 
MPAP (18.5 nmol) in 5% dextrose (Hospira) solution in a total volume of 200 µl.   
 Intravenous pre-stroke tail vein injections of MPAP-Src 48 and 24 hours prior to 
60-minute MCAo ischemia were tested in a cohort of mice (n=5), followed 24 hours later 
by behavioral testing, and ex vivo imaging and sacrifice.  Stroke volume assessment and 
quantitative real time RT-PCR analysis of brains was then performed.  MPAP complexes 
with scrambled non-targeting siRNA (MPAP-Ctrl, n=5) were selected as a negative 
control.   Src kinase inhibitor, PP1, shown previously effective in limiting damage in 
stroke mice (Paul, Zhang et al. 2001), was selected as a positive control.  For this, PP1 (1 
mg, Enzo Life Sciences) was dissolved in sterile DMSO and further diluted in sterile 1X 
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PBS to a final concentration of 0.15 mg/ml.  PP1 was administered by intraperitoneal 
injection (n=5) at a dosage of 1.5 mg/kg.  
 Intravenous post-stroke injection of MPAP-Src complexes (n=3, 18.5 nmol 
MPAP : 3.7 nmol siRNA) was also investigated.  Fifteen minutes after 60-minute MCAo 
and reperfusion, MPAP-Src was injected by tail vein.  Mice were sacrificed 72 hours 
after reperfusion and brains were stained with TTC (described in section 2.2.14) and 
processed for quantitative real time RT-PCR to evaluate the effect on stroke volume and 
Src expression.  MPAP-Ctrl treatment served as a negative control (n=3).    
2.2.12 Therapeutic Treatment with MPAP-Src:  Intracerebral Injection 
 Intracerebral administration of MPAP-Src was investigated for its effects on Src 
gene expression.  MPAP was dissolved in 5% dextrose (Hospira) in concentrations of 500 
pmol/µl.  Twenty minutes prior to injection, the MPAP solutions were mixed with an 
equal volume of c-Src siRNA (siSTABLE, Dharmacon) in a 5:1 molar ratio (500 pmol/µl 
MPAP:100 pmol/ul siRNA) to form MPAP-Src complexes.  MPAP-siRNA mixtures 
formed using scrambled control siRNA (MPAP-Ctrl) were used as negative controls.   
 Ten male, 10-12-week-old C57BL/6 mice were anesthetized in 2.0-2.5% 
isoflurane in 30%/70% oxygen/nitrous oxide gas vehicle, and anesthesia was maintained 
at 1.0-1.5% isoflurane during surgery.  Mice were transferred and secured to a small 
animal stereotactic instrument (Kopf) with a Quintessential Stereotactic Injector 
(Stoelting Company) for controlled microinjection.  A 5-mm incision was made in the 
scalp, and the skull surface was wiped clean of loose tissues until the landmark bregma 
was clearly visible.  A hole was drilled through the skull over the right hemisphere, 2.5-
mm lateral and 0.8-mm posterior to bregma, using a high speed micro drill with 0.7-mm 
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steel burrs (Fine Science Tools).  In five mice, a total of 2 µl of MPAP-Src solution (i.e., 
100 pmol siRNA per injection) was injected through the hole at a depth of 2.5 mm from 
the skull surface using a 701RN 10-µl syringe with a 26-gauge needle attachment 
(Hamilton Company).  This injection location was selected because it was the most 
common site of infarction identified in our preliminary middle cerebral artery occlusion 
studies.  An identical procedure was repeated for the remaining five mice with the same 
volume of MPAP-Ctrl complexes.   Injection occurred at a rate of 0.25 µl/minute.  After 
injection was complete, the hole was patched with bone wax (Fine Science Tools) and the 
skin incision closed with 5-0 silk suture thread (Ethilon).  Postoperative buprenorphine 
(0.05 mg/kg subcutaneous, Bedford Labs) was administered every 12 hours or as needed.  
Mice were sacrificed 24-hours after injection and their brains processed for quantitative 
real time RT-PCR.  Ten additional mice were treated as described and subjected to 60-
minute MCAo 24-hours after injection to determine the influence of Src expression 
knockdown on infarct volume after stroke.   
2.2.13 Concentration Dependence of Intracerebrally-Injected MPAP-Src 
 MPAP-Src concentration effects were evaluated in male C57BL/6 mice injected 
in the right and left cerebral hemispheres with MPAP-Src and MPAP-Ctrl, respectively. 
MPAP was dissolved in 5% dextrose (Hospira) in concentrations of 125, 500 and 2000 
pmol/µl.  Twenty minutes prior to injection, the MPAP solutions were mixed with an 
equal volume of c-Src siRNA in a 5:1 molar ratio (i.e., 25, 100 or 400 pmol/ul siRNA, 
respectively) to form MPAP-Src complexes.  Mice were anesthetized with isofluorane 
and mounted on the stereotactic frame.  Holes were drilled through the skull over the left 
and right hemispheres, 2.5-mm lateral and 0.8-mm posterior to bregma.  MPAP-Src was 
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injected at a depth of 2.5 mm relative to the skull surface through the right hole, while 
MPAP-Ctrl complexes of the same concentration were injected at the same depth through 
the left.  Seventy-two hours after injection, mice were sacrificed and their brain 
hemispheres evaluated by western blot analysis. 
2.2.14 Stroke Volume Assessment by Triphenyltetrazolium Chloride (TTC) Staining 
 Quantification of cerebral infarct volume following transient MCAo by 
triphenyltetrazolium chloride staining was performed according to the protocol described 
by Joshi et al (Joshi, Jain et al. 2004).  Mice were anesthetized with isoflurane and 
sacrificed by decapitation.  The brain was removed from the skull and placed in an 
acrylic adjustable brain matrix (Braintree Scientific) for sectioning.  The brain matrix was 
submerged in phosphate-buffered saline (PBS, pH 7.4) and the brain sliced into 2-mm 
coronal sections using a razor blade.  Brain slices were transferred to 0.05% (w/v) TTC in 
PBS, and incubated at 37°C for 20 minutes.  Upon staining, viable brain tissue acquires a 
deep red color, while infarcted stroke tissue remains white. Slices were placed on a glass 
coverslip, caudal side down, and digitized using a Dell 810 flatbed scanner. When tissues 
were needed for RT-PCR or western blot analysis, the third slice of the series was snap 
frozen, and the rostral portion of TTC-stained slice 4 was used to approximate the infarct 
volume of the caudal portion of slice 3 (Joshi, Jain et al. 2004).  Image analysis was 
performed using Adobe Photoshop CS4 software.  For this, the infarcted area of each 
slice was measured by an observer who was blinded to the type of treatment received by 
the mice.  Infarct volume was estimated by multiplying the area by slice thickness.  The 
total percentage of infarct volume was calculated according to the Swanson method that 
corrects for edematous swelling of stroke tissues (Swanson, Morton et al. 1990).  The 
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Swanson corrected volume was calculated using the equation, 100x[(contralateral 
hemisphere volume)−(non-lesioned ipsilateral hemisphere volume)]/(contralateral 
hemisphere volume), where ipsilateral refers to the infarcted brain hemisphere (i.e., right 
hemisphere) and contralateral to the unaffected (left) hemisphere. Results were analyzed 
with one-way ANOVA and Bonferroni T-test for pairwise comparisons.  Brain edema, as 
quantified by ipsilateral hemispheric enlargement (Manley, Fujimura et al. 2000), was 
also calculated to evaluate the effect of probe treatment on vascular permeability. 
2.2.15 Behavioral Testing 
 Mice were subjected to behavioral tests 24-hours after ischemia according to the 
following procedure to determine if probe treatment had any effect on functional 
outcome. 
 Neurological Score.  Evaluation of neurological deficits was performed.  Mice 
were scored using the following scoring system to assess the functional consequences of 
stroke:  0 – no behavioral abnormality detected;  1 – bending of the torso to the ipsilateral 
side when held by tail; 2 – spontaneous turning behavior;  3 – spontaneous circling 
behavior, 4 - barrel rolling; 5 – no motor activity (Hara, Huang et al. 1996; Zhang, Chopp 
et al. 1997; Hunter, Hatcher et al. 2000).  Statistical analysis of scores was using Kruskal 
–Wallis one-way ANOVA. 
 Rotarod Testing. To test the effect of stroke on coordination, mice were evaluated 
using a rotarod apparatus that consists of a 3-cm diameter drum that rotates at 8 
revolutions per minute.  Prior to surgery, mice were habituated to walking on the rotarod 
until they could routinely demonstrate the ability to remain on the drum for 2 minutes.   
Twenty-four hours after surgery the mice were tested on the rotarod and the latency 
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before falling was recorded.  Two trials were performed, and the longest latency was 
selected for analysis (Hayakawa, Nakano et al. 2010). 
2.2.16 Western Blot Analysis 
 Protein samples from mouse brains were isolated either with the Nucleospin Total 
RNA and Protein Isolation kit (Clontech), or by disruption with a rotor-stator 
homogenizer in RIPA buffer supplemented with the Halt Protease Inhibitor Cocktail 
(Thermo Scientific).  Samples were quantified by Pierce BCA assay (Thermo Scientific).  
A total of 40 µg protein per sample was prepared for sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) by mixing with 2X Laemmli Buffer 
(BioRad) containing β-mercaptoethanol and denaturing at 95°C for five minutes.  The 
samples were loaded onto Novex 4-20% Tris-Glycine Mini Gels (Invitrogen) and 
separated at 125 V for 90 minutes.  The protein was transferred from gel to 0.2 µm 
nitrocellulose membrane for 90 minutes at 20 V.  The membrane was blocked in 5% non-
fat dry milk in Tris Buffer Saline (TBS, BioRad) for one hour at 4°C.  The membrane 
was then incubated in primary antibody for Src (ab47405 rabbit anti-mouse polyclonal, 
Abcam) diluted 1:500 in TBS containing 0.1% Tween 20 (TBST) for 2.5 hours at room 
temperature or overnight at 4°C.  This was followed by TBST washes and incubation in 
goat anti-rabbit secondary antibody conjugated to horseradish peroxidase (1:2000, 
ab6721, Abcam) for 1 hour at room temperature.  The membrane was washed and 
incubated in SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) for 
five minutes before being exposed to film or visualized by imaging system.  Src protein 
was quantified relative to beta actin standard (primary antibody 1:2000, ab8227, abcam) 
using ImageJ (NIH) or Living Image 4.2 software (Caliper).   
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2.2.17 Fluorescence Optical Imaging  
 In vivo and ex vivo near-infrared optical imaging was performed using a whole-
body optical imaging system (IVIS Spectrum, Caliper Life Sciences) for visualization of 
Cy5.5-labeled probe accumulations.  Anesthetized mice or excised brain tissue samples 
were imaged at excitation and emission wavelengths 675 nm and 720 nm, respectively.  
2.3 Results  
2.3.1 Characterization of MPAP-Src Probes 
 MPAP has proven effective as a membrane translocation moiety when covalently 
linked to optical probes and iron oxide nanoparticles (Pham, Zhao et al. 2005; Medarova, 
Pham et al. 2007; Kumar, Medarova et al. 2010).  In this work we wished to extend the 
use of optically labeled MPAP further by taking advantage of the potential for its poly-
arginine residues to electrostatically interact with negatively-charged siRNA molecules.  
To promote the formation of siRNA dual optical imaging probes, c-Src siRNA-Dy547 
and MPAP-Cy5.5 were mixed in several molar ratios.   The efficiency of MPAP binding 
to siRNA was determined by gel electrophoresis on the resulting MPAP-Src solutions to 
assess the proportion of free siRNA in each mixture.  MPAP-Src complexes remained in 
the loading well during gel electrophoresis, while uncomplexed siRNA readily entered 
the gel and stained with ethidium bromide (Figure 2.2a).  In solutions containing a 1:5 
siRNA-to-MPAP molar ratio or higher peptide content, the vast majority of siRNA was 
associated with MPAP.  Full incorporation of siRNA into probes was deemed important 
to maximize siRNA internalization and silencing potential.  Thus, the siRNA-to-peptide 
ratio at which no discernible siRNA remained unassociated with MPAP-Cy5.5, 1:5, was 
used for subsequent experiments.  Ultimate utility of MPAP-Src in vivo requires  
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Figure 2.2. Gel mobility shift assay and serum stability.  (a) MPAP-Cy5.5 was 
incubated with c-Src siRNA at several molar ratios to form MPAP-Src probes.  At the 0.4 
siRNA-to-MPAP ratio, most siRNA was incorporated into complexes.   Complexes 
composed of 1 siRNA molecule for each 5 molecules of MPAP were used for all further 
analysis. (b) Stability of MPAP-Src (open squares) in serum relative to Dy547-labeled c-
src siRNA alone (closed squares) was investigated by incubating probes in 75% mouse 
serum for 0-8 hours.  MPAP complexation to siRNA confers partial protection from 
serum nucleases, yielding a higher percentage of intact siRNA after incubation in serum 
than siRNA alone (mean±s.d.) relative to undigested controls (Pre).  Statistical analysis 
indicated significant siRNA protection by MPAP at all incubation durations (*p<0.01, 
**p<0.001). 
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protection of siRNA from nucleases in the bloodstream.  Generally, siRNAs are 
chemically modified to extend their serum half-life relative to naked siRNA, which 
becomes degraded and inactivated within minutes of blood exposure (Braasch, Jensen et 
al. 2003; Soutschek, Akinc et al. 2004).   To investigate the stability of the siRNA 
incorporated into MPAP-Src, siRNA complexes and naked siRNA-Dy547 were exposed 
to serum for up to 8 hours.  Following removal of serum proteins and MPAP with 
proteinase K (1 mg/ml), intact siRNA was analyzed by gel electrophoresis and quantified 
(Figure 2.2b).  It was observed that the optical label Dy547 conjugated to c-Src siRNA 
partially protects it from degradation by nucleases, with just over 25% of the total siRNA 
retained after 8 hours.  The presence of MPAP appears to confer an additional measure of 
protection, such that the amount of free siRNA after 8 hours of MPAP-Src incubation in 
serum was close to 55%.   These results indicate that MPAP complexation has a 
stabilizing effect on c-Src siRNA.   
2.3.2 In Vitro Testing of MPAP-Src Probes 
 Internalization of MPAP-Src probes was evaluated in vitro in a variety of cell 
types implicated in ischemic stroke pathology, including primary cortical neurons, 
astrocytes and the bEnd.3 brain endothelial cell line.  Cells incubated for 24 hours with 
MPAP-Src or MPAP associated with scrambled control siRNA (MPAP-Ctrl) were 
subjected to flow cytometry and monitored for Cy5.5 and Dy547 fluorescence.  Figure 
2.3 shows significant signal from both siRNA and MPAP relative to untreated controls in 
all cell types.   Internalization of MPAP-Src and MPAP-Ctrl occurred in similar patterns, 
indicating that MPAP association with Src siRNA is not sequence dependent.  
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Figure 2.3. Flow cytometry.  Astrocytes, neurons and bEnd.3 cells were incubated with 
MPAP-Src or MPAP-Ctrl for 24 hours and then analyzed with flow cytometry.  All cell 
types were positive for the presence of both MPAP-Cy5.5 and siRNA-Dy547. 
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 To confirm that MPAP-Src probe was internalized by cells, and not passively 
associated with the cell membrane, confocal microscopy was performed.  Neurons, 
astrocytes and bEnd.3 cells stained with cell-specific antibodies (Figure 2.4a-c) were 
positive for the presence of both MPAP (Figure 2.4d-f) and Src siRNA (Figure 2.4g-i).  
In general, Src siRNA colocalized with MPAP (Figure 2.4j-l), though, for neurons in 
particular, there was evidence that MPAP and siRNA became dissociated to some degree 
when taken up by cells (Figure 2.4k).   The presence of MPAP was crucial for 
internalization, as evident by the complete absence of Src siRNA uptake relative to 
MPAP-Src when cells were incubated with equivalent quantities of siRNA alone (Figure 
2.4m-o).   
 It has been reported that fixation can induce artifacts in cell-penetrating peptides 
studies, causing abnormal localization of peptides in the nucleus of target cells.  To 
provide more precise evidence of MPAP-Src delivery, we performed live cell imaging on 
unfixed, treated astrocytes, bEnd.3 cells and neurons.  In these studies the mechanism of 
cellular internalization was also investigated using Lysosensor Green staining, which is 
specific for endosomal vesicles (Figure 2.5a-c).  As in fixed cells, MPAP-Src 
substantially entered cells (Figure 2.5d-i).  MPAP and Src signal was present in punctate 
form and often colocalized with Lysosensor Green staining in each of the cell types, 
suggesting that one mechanism of MPAP uptake is endocytosis (Figure 2.5j-l).   
However, diffuse probe signal was also present throughout the cytoplasm and in 
occasional Lysosensor negative spots, indicating that some portion of material escapes 
endosomal compartmentalization.  Generally, MPAP and siRNA signals colocalized in 
cells, prompting us to wonder whether siRNA would be able access RNAi machinery to  
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Figure 2.4.  Cellular uptake of MPAP-Src probes.  Confocal microscopy of astrocytes, 
neurons and bEnd.3 stained with GFAP (a), beta-III tubulin (b), and CD31 (c), 
respectively.  Following incubation with MPAP-Src probe for 24 hours and cell-specific 
staining, cells were visualized by confocal microscopy.   MPAP (d-f) and Src siRNA (g-i) 
were taken up by cells following MPAP-Src incubation, whereas incubation with Src 
siRNA alone resulted in no detectable siRNA accumulations (m-o).  Scale bar = 10 µm. 
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Figure 2.5. Uptake mechanism of MPAP-Src. Cells were visualized using confocal 
microscopy following Lysosensor Green staining of unfixed astrocytes, bEnd.3 cells and 
neurons (a-c) to determine the mechanism of cellular uptake of MPAP-Src.  MPAP (d-f) 
and c-Src siRNA (g-i) generally co-localize with endosomal vesicles (j-l).  Scale bar = 10 
µm. 
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achieve successful Src silencing.  To address this, expression levels of endogenous Src 
mRNA were evaluated by RT-PCR following MPAP-Src uptake.  Total Src expression 
after MPAP-Src treatment was compared to expression after treatment with MPAP-Ctrl, a 
control used to differentiate siRNA-induced Src inhibition from off-target effects 
potentially caused by the MPAP method of siRNA delivery.  Endogenous Src levels were 
reduced to a statistically significant degree in all cell types subjected to MPAP-Src 
treatment for 48 hours relative to controls (Figure 2.6).  For astrocytes and bEnd.3 cells, 
Src expression decreased to approximately 66% of controls, while in neurons the 
decrease was to 75%.  Similar reductions in Src levels were achieved following 24-hour 
MPAP-Src treatment in astrocytes and bEnd.3 cells (data not shown).  Thus, despite the 
observation that MPAP-Src appears to traffic to some extent in endosomal vesicles, the 
endosomal escape of siRNA and its separation from MPAP is sufficient to mediate a 
significant degree of endogenous gene inhibition.   
 To determine if MPAP-Src mediated siRNA delivery was cytotoxic, MTT assays 
were performed.  MPAP-Src treatment resulted in no discernable increase in cytotoxicity 
in neurons, astrocytes or bEnd.3 cells relative to untreated controls (Figure 2.7).  These 
data were confirmed by an additional test of cytotoxicity, the caspase-3 apoptosis assay, 
which likewise revealed no significant toxicity of MPAP-Src treatment.  These data 
indicate that MPAP-Src treatment induced partial endogenous gene silencing without the 
degree of cytotoxicity that is often observed in other peptide-based delivery systems 
(Saar, Lindgren et al. 2005).   
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Figure 2.6.  Bioactivity of MPAP-Src probes.  Quantitative RT-PCR analysis of 
endogenous Src mRNA expression levels in astrocytes, neurons and bEnd.3 cells after 
MPAP-Ctrl (black bars) or MPAP-Src (white bars) treatment was performed. After 
administration of MPAP-Src, there was a significant reduction in c-src levels in all cell 
types tested (n=7, *p<0.05, **p<0.01).  
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Figure 2.7.  Cytotoxicity Assays. The percent survival (mean±s.d.) of cells treated with 
MPAP-Src or staurosporine (white and gray bars, respectively) relative to untreated 
controls (black bars) was obtained by MTT analysis.  MPAP-Src treatment resulted in no 
significant increase in cytotoxicity in any of the cell types. 
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2.3.3 MPAP Delivery in Experimental Stroke 
 After demonstrating that MPAP facilitates the delivery of functional siRNA to 
cells of the central nervous system in an in vitro setting, we transitioned to testing of 
MPAP-Src in experimental stroke.  Previous studies in our laboratory showed that MPAP 
bearing fluorescent cargoes was detected in the brain within six hours of intravenous 
administration, with increasing accumulations in neurons, astrocytes and endothelial cells 
detected at 24 and 48 hours in healthy mice (Pham, Zhao et al. 2005).  During our 
characterization of MPAP probes, it was observed that complexation with siRNA leads to 
a slight depression of probe zeta potential (MPAP: 56.4 to MPAP-siRNA: 42.3 ± 6.55 in 
H2O, pH 5.4).  This denotes the general stability of both probes, with an increased 
tendency for MPAP-Src to self-associate relative to MPAP alone.  In cell studies, these 
differences did not have a detrimental effect on MPAP-Src’s ability to enter cells and 
downregulate endogenous Src levels.  However, in an in vivo environment it is 
reasonable to assume that modification of MPAP with siRNA cargoes may change the 
trafficking of MPAP probes and ultimately their brain penetrating capabilities in normal 
animals.  Although penetration of an intact blood-brain barrier would be an essential 
characteristic of therapeutics for many CNS diseases, it is not a crucial issue in the setting 
of stroke, where blood-brain barrier dysfunction leads to compromise of the vasculature 
and leakage in ischemic tissue. We hypothesized that this breakdown would provide an 
avenue for MPAP-Src delivery and enable probe accumulations beyond those observed in 
normal mice.  This was a critical factor we considered while selecting an experimental 
animal model of stroke for the evaluation of MPAP-Src probes.   
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 The middle cerebral artery is the most common site of blockage found in ischemic 
stroke in humans, leading to focal infarction and impairment in movement and cognition 
(Paciaroni, Silvestrelli et al. 2003; Ng, Stein et al. 2007).  Experimental stroke models 
that employ middle cerebral artery occlusion (MCAo) have been developed in mice and 
rats (Longa, Weinstein et al. 1989; Belayev, Busto et al. 1999). These simulate the human 
condition through artificial restriction of blood flow to the MCA territory via occluding 
suture, embolus, or cautery (Zhang, Chopp et al. 1997; Belayev, Busto et al. 1999; 
Furuya, Kawahara et al. 2004).  For our experiments, we selected the C57BL/6 mouse 
strain and investigated the intraluminal suture method of MCAo at a variety of occlusion 
durations (i.e., 15, 30, 60 and permanent).  This enabled us to select the conditions that 
resulted in the most stereotyped infarcts and lowest animal mortality.  Infarct volume was 
assessed by TTC staining, which causes viable brain tissue to turn a deep red color and 
infarcted tissue to remain white.   Representative brain slices for each occlusion duration 
are shown in Figure 2.8.  Brief 15-minute occlusion of the mouse MCA rarely led to 
detectable tissue death or neurological deficits.  In contrast, mice subjected to 30-minute 
occlusion had highly variable stroke volume and territory, with an average infarct volume 
of 12.6±7.2 mm3.   Occlusion of 90 minutes or more was associated with animal 
morbidities that prevented long-term monitoring or behavioral evaluation.  For mice 
subjected to 60-minute MCAo, average stroke volumes (27.0±4.7 mm3) were within the 
range of those published in the literature (Chen, Ito et al. 2008). Additionally, 60-minute 
occlusion was associated with blood-brain barrier breakdown that was grossly evident in 
serial tissue sections (Figure 2.8, arrows).  Breakdown was confirmed by extravasation of 
Evans blue dye, which associates with serum albumin and is normally excluded from  
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Figure 2.8.  The effect of occlusion duration on infarct volume.  Mice subjected to 15 
min, 30 min, 60 min, or permanent intraluminal MCAo were sacrificed 24-hours after 
reperfusion.  Excised brains were TTC stained to identify white infarcted regions, which 
can be differentiated from red viable tissues after staining. Representative coronal brain 
slices (+0.4 to -0.8 mm rostral to bregma) are shown.  Arrows denote regions of vascular 
breakdown observed in the infarcted tissues of mice subjected to 60-min occlusions.  
Infarct volumes (mean±s.d.) were calculated according to the procedure described by 
Swanson et. al (1990). 
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the central nervous system unless the blood-brain barrier is compromised (Wolman, 
Klatzo et al. 1981).  Figure 2.9 shows ex vivo imaging of Evans blue dye extravasation 
into the ischemic hemisphere of the whole mouse brain (Figure 2.9a) and in coronal brain 
slices (Figure 2.9b).  Vascular leakage of Evans blue dye was also apparent in fresh brain 
tissue sections (Figure 2.9c).   
 In addition, we found that the blood-brain barrier permeability detected in our 
experimental stroke model enhances the delivery of MPAP-Src to ischemic tissues.  We 
used fluorescence imaging to evaluate the localization patterns of MPAP probes in the 
brain 48 hours after intravenous injection (Figure 2.10).  MPAP (Figure 2.10b) and 
MPAP-Src (Figure 2.10c) exhibited a similar degree of brain accumulation above 
background levels (Figure 2.10a).  Delivery was markedly increased in the ischemic 
hemisphere when MPAP-Src was administered after the induction of stroke (2.10d).  
Improved delivery was also observed in mice pretreated with MPAP-Src before ischemia 
(see Section 2.3.4).   These results prompted us to evaluate the therapeutic potential of 
MPAP-Src probes for ischemic stroke.   
2.3.4 The Efficacy of MPAP-Src Pretreatment in Experimental Stroke 
 MPAP-Src probes were first evaluated in a pretreatment stroke model in which 
male, 10-12 week old C57BL/6 mice were subjected to 60-minute occlusion after 
receiving two doses of MPAP-Src or control probes.  Probe administration (18.5 nmol 
MPAP: 3.7 nmol siRNA in 200 µl of 5% dextrose) was performed 48 and 24 hours prior 
to stroke induction.  This dosing schedule was informed first, by our in vitro experiments 
in which knockdown of Src was first detected at 24 hours after treatment and second, by 
our observations of the timing of in vivo trafficking of MPAP, and by extension, MPAP- 
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Figure 2.9. Ex vivo detection of Evans blue dye extravasation.  Mice subjected to 60-
minute MCAo were intravenously injected with Evans blue dye at the time of 
reperfusion, and sacrificed 24 hours later.  Fluorescence imaging of Evans blue dye 
(excitation 605 nm, emission 680 nm) using the IVIS optical imaging system revealed 
blood-brain barrier compromise in the ischemic hemisphere of perfused whole brain (a) 
and in sequential coronal brain slices (b).  The presence of Evans blue dye was also 
grossly evident in fresh tissue slices (c).  Radiant efficiency: [emission light 
(photons/sec/cm2/str)]/[excitation light (mW/cm2)].   
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Figure 2.10.  Fluorescence imaging of MPAP-Src probe delivery.  Excised brains 
from mice intravenously injected with (a) vehicle (5% dextrose), (b) MPAP (18.5 nmol in 
5% dextrose) or (c) MPAP-Src (18.5 nmol MPAP:3.7 nmol c-src siRNA in 5% dextrose) 
and perfused with heparinized saline (2 units/ml in 0.9% saline) 48 hours later are shown.  
 65 
Figure 2.10 (Continued).  When MPAP-Src is administered after ischemia at the time of 
reperfusion (d), delivery is enhanced beyond that observed in MPAP and MPAP-Src 
treated mice. Radiant efficiency: [emission light (photons/sec/cm2/str)]/[excitation light 
(mW/cm2)].   
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Src probes. MPAP complexed to scrambled non-targeting siRNA (MPAP-Ctrl) served as 
a negative control.   Positive control treatment entailed the administration of PP1, which 
has been shown to mitigate stroke damage when administered 15 minutes after 
reperfusion (Paul, Zhang et al. 2001).  Twenty-four hours after reperfusion mice were 
sacrificed and their brains subjected to ex vivo imaging using the IVIS Spectrum optical 
imaging system (Figure 2.11).  Imaging revealed significant accumulations of MPAP 
probes (Figure 2.11a, b), particularly in the ipsilateral, or stroke hemisphere. 
Quantification of probe fluorescence showed that these accumulations were significant, 
demonstrating that the blood-brain barrier breakdown associated with stroke improves the 
delivery of probes (Figure 2.11c) even when they are administered prior to stroke 
induction.  To determine if these probe accumulations had an effect on Src expression, 
we performed RT-PCR analysis of Src mRNA expression in a cohort of animals (n=5 per 
treatment type).  These studies showed a 36% increase in Src expression in the ipsilateral 
hemispheres of MPAP-Src treated mice compared with MPAP-Ctrl treated mice.  Closer 
examination led us to conclude that these results are likely artifactual.  In these brains, 
mRNA extraction was performed according to a published procedure, which claimed that 
reliable mRNA and protein expression can be obtained from experimental stroke animals 
after TTC-staining (Kramer, Dang et al. 2010).  However, when we compared mRNA 
expression from these brains to that obtained from fresh, unstained tissues, it was 
apparent that TTC processing had led to a skewing of the results that is probably due to 
degradation of the damaged tissues. Consequently, in all ensuing studies we used only 
fresh, snap-frozen tissues for RT-PCR processing. When only the results from fresh 
tissues were considered, c-src expression in MPAP-Src treated mice was 22%  
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Figure 2.11.  Fluorescence imaging of MPAP probe pre-stroke treatment.   MPAP-
Src (or MPAP-Ctrl) probes were administered 48 and 24 hours prior to 60-minute stroke 
induction.  Imaging of brains excised 24 hours after reperfusion reveals high fluorescence 
in brains treated with MPAP probes (b) relative to vehicle-treated controls (a).  
Quantification of fluorescence was performed to compare the differences between MPAP 
probe uptake in the ipsilateral (ipsi), stroke hemisphere and the contralateral (contra) side 
(c). MPAP probes localized predominantly in the infarcted territory, with significantly 
more accumulation evident in the ipslateral than in the contralateral hemisphere (c, n=8, 
*p=0.036). Fluorescence was calculated using region-of-interest analysis of each brain 
hemisphere.  Results are presented normalized, with the average background fluorescence 
from vehicle-treated mice for each hemisphere subtracted out. Radiant efficiency: 
[emission light (photons/sec/cm2/str)]/[excitation light (mW/cm2)].  Error bars denote 
standard deviations.  
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lower in the ischemic hemisphere than in MPAP-Ctrl treated mice.  These data suggested 
that MPAP-Src probes may be capable of modulating Src expression when administered 
before stroke induction.  To clarify the effect of MPAP-Src probes, we investigated their 
effect on several metrics of stroke outcome, including behavioral testing, infarct volume, 
and edema.   
 To evaluate whether MPAP-Src pretreatment has any effect on functional 
outcome after stroke, mice were subjected to behavioral tests 24-hours after ischemia.  
These tests included an evaluation of neurological score, in which mice were assessed 
according to the following scale of neurological symptoms: 0 – no behavioral 
abnormality detected; 1 – bending of the torso to the ipsilateral side when held by tail; 2 – 
spontaneous turning behavior;  3 – spontaneous circling behavior, 4 - barrel rolling; 5 – 
no motor activity (Hara, Huang et al. 1996; Zhang, Chopp et al. 1997; Hunter, Hatcher et 
al. 2000).  In these tests, MPAP-Src treated mice appeared the least impaired of all the 
treatment groups, with an average neurological score of 1.4 ± 1.9.   This score was 
influenced most by a high number of MPAP-Src mice (60%) with little or no discernible 
behavioral abnormalities (neurological score ≤ 1).  MPAP-Ctrl mice had the worst 
neurological scores (3.6±0.9), with no mouse having a score better than 3 in the testing.  
An intermediate score was obtained for PP1-treated mice (3.0±0.7).  The relatively high 
neurological score for these mice was surprising given that improvement in neurological 
symptoms was a key observation in the publication that serves as the motivation for this 
work (Paul, Zhang et al. 2001).  However, statistical analysis failed to show significant 
differences in neurological score (p > 0.05).  An assessment of mouse coordination after 
stroke was also performed using rotarod testing.  Mice habituated to walking on a 
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rotating drum prior to surgery were tested 24 hours after ischemia.  On average, all 
treatment groups averaged an approximately 60 second latency on the drum, with wide 
variations that failed to meet statistical significance.  Functionally, MPAP-Src treatment 
did not lead to any improvement in stroke outcome relative to other treatments.   
 We next evaluated the effect of MPAP-Src and control treatments on the 
formation of an ischemic infarct.  For this, excised mouse brains were sectioned in 2-mm 
slices and subjected to TTC staining.  Infarct volumes were extracted from TTC-stained 
slices by an observer who was blinded to the treatment type to avoid bias. Infarct 
volumes for MPAP-Src, MPAP-Ctrl and PP1 treated mice are shown in Figure 2.12.  
Infarct volume was the smallest in mice treated with the Src inhibitor PP1, the positive 
control with known neuroprotective properties.  Infarcts in these mice were 37.6% 
smaller than those of mice treated with non-targeting MPAP-Ctrl probes.  MPAP-Src 
treated mice also had reduced infarct volumes compared to MPAP-Ctrl treated mice, 
averaging 81.1% of infarct volume for control mice.  These results show a tendency 
towards reduction in infarct size for mice treated with MPAP-Src, though these 
reductions were not statistically significant.   One mechanism for Src-related tissue 
damage is its tendency to increase vascular permeability and consequently, brain edema 
(Paul, Zhang et al. 2001).  We calculated cerebral edema, as measured by hemispheric 
enlargement, in our treated mice and found that PP1-treated mice have the lowest edema 
values (17.0±9.0%), followed by MPAP-Src (23.7±8.0%) and MPAP-Ctrl (27.9±10.2%) 
treated mice (Figure 2.12).  Though not significant, these data suggest that Src inhibition, 
whether by PP1 or siRNA treatment, tends to reduce the consequences of Src 
upregulation after stroke.    
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Figure 2.12.  Infarct volumes and cerebral edema.   TTC-staining of stroke brains 
revealed reductions in infarct volume in mice treated with Src inhibitor PP1 (n=5) 
relative to MPAP-Ctrl (Ctrl, n=5) treated mice.  MPAP-Src (Src) probe treatment showed 
less pronounced reductions in infarct volume.  The same trend was observed in 
measurements of cerebral edema, which is known to worsen with increasing Src 
expression. 
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2.3.5 The Therapeutic Potential of MPAP-Src Administered Post-Stroke 
 To this point, administration of MPAP-Src probes had been associated with a 
small, though insignificant, modulation in stroke outcome as measured by infarct volume, 
hemispheric edema, and behavioral outcome. It was known from our probe delivery 
studies (see Figure 2.10d) that injection of MPAP-Src at the time of reperfusion resulted 
in high accumulations of probe in the ischemic hemisphere.  To determine if this 
alternative probe administration schedule would demonstrate improved probe efficacy in 
stroke treatment, we tested the effect of MPAP-Src probes when intravenously injected 
after reperfusion in the 60-minute occlusion mouse model.   Mice slated for either 
MPAP-Src or MPAP-Ctrl treatment were subjected to stroke and injected with probe 15 
minutes after reperfusion.  Mice were sacrificed 72-hours after reperfusion, and their 
brains processed for RT-PCR analysis and TTC staining.  The results of this analysis are 
shown in Figure 2.13.  As observed with MPAP-Src pretreatment, administration of 
experimental probe at the time of reperfusion was associated with a minor reduction in 
infarct volume and a negligible effect on hemispheric edema relative to scrambled 
controls (Figure 2.13a).  Both measures failed to achieve statistical significance.  Most 
notably, expression of mRNA in the ischemic hemisphere remained unaffected by the 
experimental probe (Figure 2.13b).  These results suggest that although MPAP-Src 
delivery to the site of ischemia appears to be robust under post-stroke treatment 
conditions, probe fails to access cells susceptible to infarct damage in time to influence 
Src expression in this model. 
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Figure 2.13.  MPAP-src post-stroke treatment effects.  Mice subjected to 60-minute 
occlusion were treated with MPAP-Src (Src) or MPAP-Ctrl (Ctrl) at the time of 
reperfusion.  TTC-staining revealed slight, though insignificant reductions in (a) infarct 
volume and cerebral edema in MPAP-Src treated mice relative to controls.  (b) 
Expression of c-src mRNA was unaffected by experimental probe treatment, suggesting 
that post-stroke treatment has negligible effects on the damaged brain.   
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2.3.6 The Efficacy of MPAP-Src Intracerebral Injection in Experimental Stroke 
 After determining that our intravenous administration models of stroke therapy 
had limited efficacy regardless whether probe is applied before stroke induction or after 
reperfusion, we turned to evaluate more direct injection modes.  In particular, we 
analyzed the effects of intracerebral injection of MPAP-Src probe.  Intracerebral injection 
involves performing a craniotomy in anesthetized mice followed by stereotactic injection 
of a small volume of prepared material in the stroke territory.  We began by testing 
whether injection of MPAP-Src (n=5) in the right cerebral cortex of healthy animals has 
an effect on Src production relative to MPAP-Ctrl (n=5) treatment.  Figure 2.14a 
compares Src mRNA expression in the right hemispheres of experimental and control 
mice.  We found that MPAP-Src treatment leads to a significant 18.6% reduction in Src 
expression (p = 0.027) in treated mice 24 hours after injection. A similar trend was 
observed when comparing the right and left hemispheres of MPAP-Src treated mice, such 
that the hemisphere receiving probe displayed a 24.5% reduction in c-src expression (p = 
0.012) relative to the untreated side.  In contrast, no significant differences between the 
right and left hemispheres of MPAP-Ctrl treated brains were observed.  It is notable that 
these effects on Src expression were elicited using less than 3% of the siRNA (100 pmol) 
used per injection in intravenous injection models (3.7 nmol).   
 We next tested whether this downregulation of Src would lead to improved 
outcome in our stroke model.  Mice pretreated with intracerebrally injected MPAP-Src 
were subjected to 60-minute occlusion, and their brains were evaluated by TTC staining.  
Despite the significant reductions in Src observed previously with intracerebral MPAP-  
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Figure 2.14.  Intracerebral MPAP-Src treatment effects.  MPAP-Src (100 pmol 
siRNA: 500 pmol MPAP) was directly injected into the stroke territory of healthy mice.  
(a) Analysis by rt-PCR revealed significant reductions in c-src mRNA expression 
approaching 20% (*p = 0.027) in mice treated with MPAP-Src (Src, n=5) compared to 
MPAP-Ctrl controls (Ctrl, n=5).  Additional mice were pre-injected with MPAP-Src or 
MPAP-Ctrl and subjected to 60-minute occlusion.   (b) MPAP-Src pretreatment did not 
confer protection against stroke damage. 
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Src treatment, total infarct volume was not reduced in mice treated with our experimental 
probe (Figure 2.14b).  We must conclude from these results that ~20% reduction in Src 
expression is not sufficient to mitigate stroke damage in our model.  We hypothesized 
that additional knockdown could be elicited if the quantity of injected siRNA were 
increased.  Accordingly, we investigated the concentration dependence of MPAP-Src 
treatment by injecting healthy mice with different quantities (25, 100 or 400 pmol) of 
MPAP-Src (right hemisphere) and MPAP-Ctrl (contralateral hemisphere).  Figure 2.15 
shows ex vivo imaging of the injected brain hemispheres (Figure 2.15a) and fluorescence 
microscopy of Cy5.5-labeled MPAP-Src probe uptake by cells in the brain (Figure 
2.15b). We used western blotting to quantify Src protein expression in brain tissues 72-
hours after injection (Figure 2.15c-d).  In brain hemispheres treated with small quantities 
of MPAP-Src (i.e., 25 or 100 pmol), protein expression was reduced by only 10% relative 
to MPAP-Ctrl treated hemispheres (Figure 2.15d).  At higher siRNA contents (i.e., 400 
pmol) we had difficulty creating a stable suspension of MPAP-siRNA complexes in the 
low injection volumes mandated by intracerebral injection.  This high probe 
concentration was associated with aggregation of material and precipitation out of 
solution, rendering it ineffective.  
 In all, these in vivo results demonstrate that we have developed a siRNA delivery 
platform capable of reducing endogenous mRNA expression in one of the most 
intractable organs of the body for drug delivery.   Intracerebrally injected MPAP-siRNA 
experimental probes had a significant effect on gene expression, though this effect did not 
extend to protection against stroke damage when Src was used as a target.  However,  
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Figure 2.15.  Concentration dependence of intracerebral MPAP-Src treatment.  (a) 
Mice were intracerebrally injected in the right and left hemispheres with MPAP-Src or 
MPAP-Ctrl probes, respectively.  Probes consisted of 25, 100, or 400 pmoles of siRNA 
complexed with a 5-fold excess of MPAP.  (b) Cellular uptake of MPAP probes, 
identified as Cy5.5 signal in frozen tissue sections, was confirmed by histology (Scale bar 
= 50µm).  Representative western blots of Src protein expression (with actin loading 
control) in each injected hemisphere are shown in (c).  Reductions of Src expression 
approaching 10% were observed in mice receiving low concentrations of MPAP probes 
(d).  High concentration probes (i.e., 400 pmol siRNA) were generally unstable and 
induced no effect in treated mice.  Src expression was quantified by normalizing each Src 
band by the actin loading control.  Results are expressed as the average percentage of Src 
expression in MPAP-Src treated hemispheres relative to expression in MPAP-Ctrl treated 
hemispheres. 
 77 
results provide promising evidence that our probes could be therapeutically effective if 
directed against alternative stroke targets.   
2.4 Discussion  
 In this work we have detailed the characterization, in vitro and in vivo testing of a 
fluorescent siRNA imaging probe for application to ischemic stroke.  MPAP, an 
amphipathic membrane translocation peptide derivative capable of crossing the blood-
brain barrier, formed probes with siRNA molecules and promoted protection from serum 
degradation.  MPAP differs from traditional cationic cell penetrating peptides in that it 
contains a 14-carbon saturated fatty acid, or myristoyl lipid chain.  Myristoylation is a 
common modification of proteins in cells that serves as a necessary, though insufficient, 
part of membrane binding (Resh 1999).  Myristoylation promotes weak interactions with 
the cell membrane, a process that becomes enhanced when associated peptides include 
basic amino acid residues that can interact with the acidic constitituents of the 
phopsholipid bilayer and membrane-associated proteoglycans (Murray, Ben-Tal et al. 
1997; Pham, Kircher et al. 2004; Nakase, Hirose et al. 2009).  Thus, myristoyl-peptide 
conjugates demonstrate higher affinities for cells than is observed for either component 
alone (Pham, Kircher et al. 2004).   
 In our studies, after confirming that complexation of MPAP and siRNA occurs 
stably and reproducibly, we investigated whether the resulting probes would be an 
effective platform for shuttling siRNA into cells.  Indeed, we found robust uptake of 
MPAP-Src complexes by primary cells of the central nervous system, most notably 
neurons and astrocytes.  Live cell imaging indicated that a subset of MPAP-Src 
complexes was associated with vesicular compartments, suggesting that they had become 
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internalized via an endocytic pathway.  A key consideration is the extent to which the 
internalized siRNA is able to access molecular mediators of RNA interference.   Two 
steps would be required: first, navigation of siRNA from endosomes to the cytoplasm and 
second, decoupling of siRNA from MPAP carriers.  Live cell imaging showed that while 
some siRNA signal was associated with endosomal vesicles, diffuse cytoplasmic MPAP-
Src signal was also observed, indicating endosomal escape.  Several approaches to 
improve the endosomal escape of molecules have been investigated, most notably the 
incorporation of fusogenic peptides into the delivery module that change conformation 
upon endosomal acidification (Wadia, Stan et al. 2004; Kobayashi, Nakase et al. 2009).   
It is believed that hydrophobic additions to poly-arginine peptides also promote cytosolic 
translocation through high affinity interactions with and destabilization of vesicular 
membranes (Takayama, Hirose et al. 2012).  The cytoplasmic presence of hydrophobic 
MPAP that we observed in our studies may be due to this mechanism.   
 The separation of siRNA from MPAP carriers was less evident by microscopy 
and therefore was mainly determined through gene expression analysis. Bioactivity of the 
internalized siRNA was seen in downregulation of endogenous Src mRNA, providing 
evidence of efficient cytoplasmic delivery of siRNA with our probe.  Effects were 
observed as early as 24 hours after probe exposure in cell types that are notoriously 
difficult to transfect (Washbourne and McAllister 2002). This indicates that a fraction of 
siRNA has been freed from MPAP binding, presumably through MPAP degradation.   
Clearance of the myristoyl acids that comprise MPAP would be routine given their 
ubiquity in cells, and several studies have reported that polyarginine peptides of six 
residues or more are cleaved by intracellular serine endoproteases (Cameron, Appel et al. 
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2000; Kibler, Miyazato et al. 2004). While mRNA knockdown in our studies was not as 
high as is often observed in immortalized cell lines treated with commercial transfection 
agents, the levels were not atypical for neurons (Omi, Tokunaga et al. 2004) and were not 
associated with high toxicity.   The query that dominated the remainder of our 
experiments was whether this degree of knockdown could be achieved in an experimental 
stroke model and be therapeutically relevant. 
 Although MPAP delivery to brain tissues within hours of intravenous 
administration has been established, it was unclear if accumulations of MPAP-siRNA 
probes were sufficient to modify gene expression in a living system (Pham, Zhao et al. 
2005).  By selecting a disease model with blood-brain barrier breakdown, we enhanced 
the delivery of the probe in the MCA territory, the region of the brain in need of 
neuroprotection after ischemic stroke. Our intravenous stroke models enabled us to test 
the influence of these probes on brain tissues damaged by ischemia and on normal tissues 
(represented by the hemisphere contralateral to the ischemic infarct).  Our analysis shows 
that MPAP delivery to brain regions with an intact blood brain barrier has a negligible 
effect on gene expression. Quantitative RT-PCR analysis of Src mRNA expression in 
contralateral hemispheres revealed no difference between experimental and control 
intravenous probe treatment.  This shows that any material delivered to the ipsilateral 
hemisphere during the interval before stroke induction is therapeutically inconsequential.  
Instead, the amount of probe available for delivery at the time of ischemia becomes 
crucial.  Fluorescent analysis of blood sampled from MPAP-Src injected mice showed 
that a significant portion of material (i.e., 77.9%) was excreted within six hours of 
injection, with an additional 31.9% lost by the time of the reperfusion period.  Thus, at 
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the time of reperfusion there is at best 15% of the original injected dose available in the 
blood for delivery across an impaired blood brain barrier in the pretreatment model.  This 
probe is presumably the source of the ipsilateral hemisphere accumulations observed by 
imaging in this model.   In the 60-minute occlusion model, blood-brain barrier 
breakdown is estimated to occur within one to three hours after reperfusion (Fujimura, 
Gasche et al. 1999; Ishikawa, Vowinkel et al. 2005; Chen, Chen et al. 2006).  Since Src 
inhibition has a long therapeutic window after ischemia of six hours (Paul, Zhang et al. 
2001), MPAP-Src probes must induce Src protein downregulation over a period of 
approximately five hours to be therapeutically effective.  Mathematical modeling of the 
kinetics of siRNA delivery indicates that inducing knockdown in this short window is 
feasible (Bartlett and Davis 2006), particularly since the target cells are non-dividing (i.e., 
neurons that are not subject to doubling-induced dilution of probe) and the target protein 
has a short half-life (Harris, Shoji et al. 1999; Bartlett and Davis 2006).  In support of 
this, MPAP-Src probes showed an increased tendency to limit infarct damage in mice in 
our pretreatment model.  This neuroprotection cannot be attributed to a passive effect of 
the delivery vehicle, since control probes differed from experimental only in the target 
strand siRNA sequence.  However, since the RT-PCR analysis of the ipsilateral 
hemisphere in this model was inconclusive, it was unclear whether the neuroprotective 
trends we observed were mediated by siRNA-induced mRNA knockdown.  This 
prompted us to shift to the post-stroke treatment model, in which the interval between 
blood-brain barrier breakdown and probe injection is minimized.  Improved probe 
delivery was evident by ex vivo imaging in this model relative to the pretreatment model, 
providing further support for the contention that much of the probe washes out of the 
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blood by the time of blood-brain barrier breakdown in the latter case.  Again we observed 
a tendency for MPAP-Src to benefit stroke mice.  However, this was not accompanied by 
a notable change in Src mRNA expression.  The lack of mRNA knockdown cannot be 
due to transiency of siRNA’s effects, which are predicted to persist for several days in 
non-dividing cells (Bartlett and Davis 2006).  We concluded from this data that 
intravenously-administered MPAP-Src probe accumulations in the ischemic hemispheres 
were unable to modulate Src expression rapidly enough to be therapeutically relevant.  
 We turned to an alternative means of evaluating Src as a target for stroke 
protection.   Stereotactic injection of MPAP-Src probes directly into the cerebral 
hemisphere was first evaluated in healthy mice with an intact blood brain barrier.  Direct 
injection led to significant knockdown of Src mRNA approaching 20%. This effect was 
present both when comparing MPAP-Src treated hemispheres to their contralateral 
counterparts and when comparing the ipsilateral hemispheres of MPAP-Src and MPAP-
Ctrl treated mice. Note that the knockdown we detected was obtained by evaluating a 
fairly large tissue sample (i.e., 2-mm coronal slice of hemisphere), so one can assume 
even higher gene downregulation in regions in the immediate vicinity of the injection 
site.  Such a concentration gradient of MPAP-Src probe was evident in ex vivo optical 
images.   
 The effective knockdown of stereotactically-injected probes has important 
implications.  First, it provides proof-of-principle that the MPAP-based siRNA platform 
we have developed is capable of delivering cargoes in the absence of disease or defect.  
Consequently, the value of our probes extends beyond the treatment of stroke to any 
pathology associated with a focal abnormality, particularly since exchanging the targeting 
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siRNA in MPAP complexes is trivial. In addition, since testing of probe knockdown is 
performed in healthy mice, the evaluations are not subject to degradation-related errors 
that may be associated with analysis of infarcted tissues.  Finally, our direct injection 
technique employed nearly two orders of magnitude less material than intravenous 
injection.  Low effective dose of material is particularly important for siRNA drugs, 
which at present are often prohibitively expensive.  Once knockdown was established, we 
could evaluate whether Src is an effective target for stroke protection.  We found that the 
Src knockdown achieved by our probes had no effect on final stroke volume in a group of 
mice subjected to 60-minute occlusion.  Assuming that higher knockdown might be 
achievable with more probe, we expanded our study to evaluate increasing concentrations 
of siRNA.  Here we found that higher concentrations of MPAP-Src were associated with 
aggregation of probe complexes such that they precipitated out of solution.  Here we 
were limited by the practicalities of stereotactic injection, which unlike intravenous 
injection, requires that the injection volume be constrained to a few microliters to prevent 
adverse effects to the mouse.  Therefore, protein Src expression reductions of no more 
than 10% were achievable when siRNA concentration was varied.  These results prompt 
us to consider whether our inability to achieve significant neuroprotection with our 
probes is a result of the choice of Src as a stroke target or insufficient Src 
downregulation. 
 Our motivation for selecting protein tyrosine kinase c-Src as a stroke target 
emerged from an extensive study of Src knockout mice (Paul, Zhang et al. 2001).  It was 
shown that mice without Src expression were protected from cerebral damage after 
ischemic stroke and retained a higher degree of neurological function than wild-type 
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mice.  It is believed that the detrimental effects of Src in stroke are mainly related to its 
activation by vascular endothelial growth factor (VEGF).  VEGF is a known mediator of 
vascular permeability, and in the setting of stroke, leads to increases in cerebral edema 
and tissue damage (van Bruggen, Thibodeaux et al. 1999; Marti, Bernaudin et al. 2000).   
While inhibition of VEGF has been effective in ameliorating ischemic damage, the 
benefits of VEGF-induced angiogenesis during the recovery phase of stroke make direct 
manipulation of VEGF levels undesirable in the long term (Zhang, Zhang et al. 2000).        
It has been shown that by inhibiting Src, a downstream mediator of VEGF-induced 
vascular permeability, the damaging effects of ischemia are prevented and presumably, 
the favorable aspects of VEGF signaling are preserved (Paul, Zhang et al. 2001).  
Importantly, the chemical inhibitor of Src, PP1, was beneficial when administered up to 
six hours after reperfusion, a therapeutic window that rivals that of t-PA drugs (1995).    
Src family tyrosine kinase activation has also been implicated in excitotoxic, reactive 
oxidative and inflammatory damage after stroke (Nakamura, Hori et al. 1993; Mocsai, 
Jakus et al. 2000; Liu, Zhang et al. 2001).  These studies provide strong evidence that Src 
is a potent drug target for ischemic stroke and were what first prompted us to evaluate Src 
with MPAP-based probes. 
 During the course of our experiments we routinely used Src-inhibitor PP1 as a 
positive control, administering it 15 minutes after reperfusion at concentrations reported 
in the literature to reduce infarct volume by nearly 70% (Paul, Zhang et al. 2001).  In our 
experience, PP1 was associated with only small decreases in infarct volume that did not 
exceed 35% and never achieved statistical significance.  Similar modest, though 
significant, reductions in infarct volume were achieved in a transient ischemia study in 
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rats using PP2, a Src inhibitor that is structurally-related to PP1 (Lennmyr, Ericsson et al. 
2004).  The reductions in stroke damage were not accompanied by significant reductions 
in vascular permeability that have been reported elsewhere (Paul, Zhang et al. 2001).  In a 
study of transient ischemia in hyperglycemic rats, Src inhibition had no protective effect 
against stroke (Farrokhnia, Roos et al. 2005).  Considered together with previous reports, 
these results provide conflicting evidence of the value of Src as a therapeutic target for 
stroke protection.  Thus, the difficulty we experienced in achieving improvement after 
stroke, even using potent chemical means, may explain why the reductions in Src 
expression achieved by direct injection of MPAP-Src probe had little effect.   
 The difference in the therapeutic potential of chemical Src inhibitors and MPAP-
Src probes grows larger when one considers that PP1 and related drugs appear to 
inactivate members of the Src tyrosine kinase family other than Src (Hanke, Gardner et 
al. 1996).  The additional benefit derived from the non-specific activity of PP1 can be 
recognized in the study of Src knockout mice (Paul, Zhang et al. 2001).  Src knockouts 
are protected from stroke damage, registering a 50% reduction in infarct volume relative 
to Src-positive mice.  In mice where Fyn (another member of the Src tyrosine kinase 
family) expression was knocked out, small improvements in infarction tolerance were 
observed and largely dismissed.  However, PP1 inhibition of Src was reported to impart a 
20% improvement in infarct volume beyond that observed in Src knockout mice.  This 
suggests that chemical inhibition by PP1 is not restricted to Src and may involve other 
kinases that are detrimental to stroke, such as Fyn.  Therefore, the strategic advantage of 
RNAi, highly selective downregulation of gene expression in a sequence-specific 
manner, is lost in this particular context.   Even complete siRNA knockdown would fail 
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to achieve the neuroprotection observed with non-specific chemical inhibition of Src, 
chemical inhibition that notably failed to result in significant neuroprotection in our 
studies.    
2.4.1. Alternative Therapeutic Targets 
 In moving forward, it is important to identify targets for stroke that may be more 
responsive to our MPAP-based imaging probe brain delivery system than Src.  Table 2.2 
presents a summary of protein targets that could serve as potential alternatives for future 
investigation.  Their selection was informed by the challenges we encountered while 
investigating Src silencing, as well as published guidelines that aim to improve the design 
of pre-clinical stroke studies (Fisher, Hanley et al. 2007; Liu, Zhen et al. 2009). Some of 
the criteria used for the selection of these targets include: validation of the efficacy of the 
target by multiple research groups; evidence that modest levels of target downregulation 
are therapeutically effective; effective therapies are target-specific (i.e., no off-target 
effects); and manipulation of the target leading to neuroprotection in more than one 
species or ischemic model.  Each potential target is considered briefly below. 
Calmodulin 
 One mechanism of ischemic injury involves pathological elevations in 
intracellular calcium levels consequent to excitatory neurotransmitter stimulation of 
neurons (Brouns and De Deyn 2009).  This is followed by the activation of a diverse 
collection of degradative calcium-dependent enzymes that first requires the complexation 
of calcium with one of its main binding proteins, calmodulin (Ghosh and Greenberg 
1995).   Downregulation of calmodulin using a variety of drugs with different inhibitory 
mechanisms has resulted in pronounced neuroprotection in several species.  For instance, 
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Table 2.2. Potential Targets for Neuroprotection in Stroke.  
Target Description Antagonist Animal Model 
Trifluoperazine Transient MCAo (2 hr), Wistar rat (Kuroda, Nakai et al. 1997) 
Tamoxifen Transient MCAo (2 hr), Sprague-Dawley rat (Kimelberg, Feustel et al. 2000; 
Osuka, Feustel et al. 2001) 
DY-9760e Transient MCAo (1 hr), Wistar rat (Sato, Morishima et al. 1999) 
 Permanent MCAo, spontaneously hypertensive rats (Takagi, Sato et al. 2001) 
 Transient forebrain ischemia, gerbil (Hashiguchi, Kawano et al. 2003) 
Calmodulin Intracellular calcium-
binding protein that 
participates in the 
activation of calcium-
dependent degradative 
enzymes (Ghosh and 
Greenberg 1995). 
 Permanent MCAo, cat (Sugimura, Takamori et al. 2005) 
NR2C subunit 
knockout 
Permanent MCAo, mouse (Kadotani, Namura et al. 1998) 
SM-31900 Permanent MCAo, spontaneously hypertensive rats (Ohtani, Tanaka et al. 2003) 
NMDA 
receptor 
Glutamate receptor 
involved in excitotoxic 
cell death (Brouns and De 
Deyn 2009). 
Antisense ODN to NR1 
subunit 
Permanent MCAo, spontaneously hypertensive rats (Wahlestedt, Golanov et al. 
1993) 
Aminoguanidine  Transient MCAo (2 hr), Sprague-Dawley rat (Iadecola, Zhang et al. 1996) 
iNOS gene knockout  Permanent MCAo, mouse (Iadecola, Zhang et al. 1997; Sugimoto and Iadecola 
2002) 
Antisense ODN to 
iNOS  
Transient MCAo (2 hr), Sprague-Dawley rat (Parmentier-Batteur, Bohme et al. 
2001) 
1400W Transient MCAo (2 hr), Sprague-Dawley rat (Parmentier, Bohme et al. 1999)    
iNOS Inducible isoform of nitric 
oxide synthase that 
promotes the production 
of NO after ischemia, 
involved in vasodilation, 
oxidative damage, and 
recruitment of 
inflammatory cells 
(Parmentier-Batteur, 
Bohme et al. 2001).  Transient MCAo (1.5 hr), Wistar rat (Perez-Asensio, Hurtado et al. 2005) 
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Table 2.2. (Continued). 
ICAM-1 knockout Permanent MCAo, mouse (Kitagawa, Matsumoto et al. 1998) 
Antisense ODN to 
ICAM-1 
Transient MCAo (1 hr), spontaneously hypertensive rats (Vemuganti, Dempsey 
et al. 2004) 
Polydatin Transient MCAo (2 hr), Sprague-Dawley rat (Cheng, Zhang et al. 2006) 
Rosuvastatin Transient MCAo (1 hr), insulin resistant mouse (Mayanagi, Katakam et al. 2008) 
ICAM-1 Adhesion molecule 
upregulated after stroke 
responsible for the 
recruitment of 
inflammatory cells 
(Soriano, Lipton et al. 
1996). 
Progesterone Permanent MCAo, Sprague-Dawley rat (Wang, Zhao et al. 2011) 
P-selectin gene 
knockout  
Transient MCAo (45 min), mouse (Connolly, Winfree et al. 1997) 
Anti-E-selectin 
antibody  
Transient MCAo (45 min), C57BL/6 mouse (Huang, Choudhri et al. 2000) 
CY-1503  Transient MCAo (2 hr), Wistar rat (Zhang, Chopp et al. 1996) 
E/P-
selectin 
Adhesion molecules 
expressed by activated 
endothelial cells after 
ischemia that mediate 
leukocyte trafficking 
(Mayadas, Johnson et al. 
1993). 
Anti-E/P-selectin 
antibody, HuEP5C7 
Hemispheric cerebral ischemia (1 hr), baboon (Mocco, Choudhri et al. 2002) 
COX2 gene knockout  Permanent MCAo, mouse (Iadecola, Niwa et al. 2001) 
Parecoxib  Transient MCAo (1.5 hr), spontaneously hypertensive rat (Kelsen, Kjaer et al. 
2006) 
Valdecoxib  Transient MCAo (1.5 hr), Sprague-Dawley rat  (Ahmad, Zhang et al. 2009) 
NS-398  Transient MCAo (2 hr), Sprague-Dawley rat (Hara, Kong et al. 1998) 
COX-2 Expressed in neurons and 
upregulated by ischemia 
and mitogens, COX2 may 
contribute to ischemic 
injury through production 
of reactive oxygen species 
or inflammatory 
mediators (del Zoppo, 
Ginis et al. 2000). 
 Permanent MCAo, C57BL/6 mouse (Sugimoto and Iadecola 2003) 
Abbreviations: DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1- (4-imidazolylethyl)-1H-indazole dihydrochloride 3.5 
hydrate); NMDA, N-methyl-d-aspartic acid; NS-398, N-[2-cyclohexyloxy-4-nitrophenyl]methanesulphonamide; SM-31900, (3S)-7-chloro-3-[2-((1R)-1-
carboxyethoxy)-4-aminomethylphenyl]aminocarbonylmethyl-1,3,4,5-tetrahydrobenz[c,d]indole-2-carboxylic acid hydrochloride; ICAM-1, Intercellular 
Adhesion Molecule 1;  COX-2, cyclooxygenase 2.
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in a rat model of transient ischemia, trifluoperazine treatment immediately after ischemia 
reduced infarct size by more than 67% (Kuroda, Nakai et al. 1997).   Trifluoperazine is 
believed to prevent the effects of calcium overload by inducing a conformational change 
in the calcium-calmodulin complex that blocks its enzyme recognition site 
(Vandonselaar, Hickie et al. 1994).  Treatment with a different calmodulin inhibitor, 
tamoxifen, has demonstrated remarkable reductions in stroke volume in rats as large as 
87% (Kimelberg, Feustel et al. 2000; Osuka, Feustel et al. 2001).  The drug DY-9760e 
inhibits calmodulin through direct interaction with one of its binding sites and has proven 
effective against stroke in both transient and permanent rat models (Sato, Morishima et 
al. 1999; Takagi, Sato et al. 2001).   DY-9760e has also been an effective stroke therapy 
in animals that are closer to humans phylogenetically, including gerbils and cats 
(Hashiguchi, Kawano et al. 2003; Sugimura, Takamori et al. 2005).  The unparalleled 
reductions in stroke severity observed after calmodulin targeting and its conserved role in 
the pathogenesis of stroke in multiple species are the main factors that make calmodulin a 
viable target for testing of MPAP-siRNA probes.  
NMDA receptor 
 Excitotoxic death after ischemia occurs in part when excessive glutamate 
stimulation of NMDA receptors sets off a cascade of pathological ion fluxes and enzyme 
activation (Brouns and De Deyn 2009).  Therapeutic targeting of NMDA receptor 
components to inhibit receptor activation has been performed in both mouse and rat 
ischemia models (Wahlestedt, Golanov et al. 1993; Kadotani, Namura et al. 1998; 
Ohtani, Tanaka et al. 2003).   In one study, transgenic mice lacking the NR2C subunit 
had infarct volumes that were less than 50% of wild-type controls in a permanent 
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ischemia model (Kadotani, Namura et al. 1998).  Another group investigated the 
inhibition of NMDA receptors at the binding site of glycine, the coagonist of glutamate, 
with the drug SM-31900 and achieved infarct reductions in rats ranging from 35-40% 
after treatment (Ohtani, Tanaka et al. 2003).  Another approach targeted the NR1 subunit 
of the NMDA receptor using antisense oligodeoxynucleotides injected into the cerebral 
ventricles of rats (Wahlestedt, Golanov et al. 1993).  Reduction in stroke lesion volume 
of 43.5% was achieved.  These studies indicate that very selective targeting of NMDA 
receptors at multiple sites, and most notably, at the mRNA level, can be therapeutically 
beneficial.    
Inducible nitric oxide synthase (NOS) 
 Inducible nitric oxide synthase (iNOS) is the one of three members of the NOS 
family that becomes robustly activated in response to pathological stimuli, including 
ischemia (Forster, Clark et al. 1999).  The pathogenic role of iNOS may be related to its 
production of excessive levels of nitric oxide (NO).  NO forms oxidating agent 
peroxynitrite, which is known to cause tissue injury directly and promote apoptosis 
(Leist, Fava et al. 1997).  As in the case of Src, iNOS knockout mice were protected 
against ischemic insult in stroke models (Iadecola, Zhang et al. 1997; Sugimoto and 
Iadecola 2002), though some of these results are in dispute (Pruss, Prass et al. 2008).  
Mice heterozygous for iNOS exhibit small reductions in ishemic injury, providing 
evidence of the direct relationship between iNOS gene expression levels and infarct 
volumes (Zhao, Haensel et al. 2000). Neuroprotection has also been elicited in rats using 
two partially-selective chemical inhibitors of iNOS, aminoguanidine and 1400W, even 
when these drugs were administered hours after the ischemic insult (Iadecola, Zhang et 
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al. 1996; Parmentier, Bohme et al. 1999; Perez-Asensio, Hurtado et al. 2005).  More 
selective reduction of iNOS has been achieved with the use of antisense 
oligodeoxynucleotide inhibition (Parmentier-Batteur, Bohme et al. 2001).  A 39% 
reduction in iNOS protein expression was associated with 30% smaller infarct volumes in 
rats and a reduction in sensorimotor deficits.  This and other studies provide strong 
evidence that modest reductions in iNOS may be therapeutically beneficial in stroke.   
ICAM-1 
 ICAM-1 is an adhesion molecule expressed in a variety of central nervous system 
cells and implicated in ischemic stroke damage through its recruitment of inflammatory 
leukocytes (Hery, Sebire et al. 1995; Soriano, Lipton et al. 1996).  Knockout of the 
ICAM-1 gene in mice diminishes both transient and permanent ischemic stroke damage 
(Connolly, Winfree et al. 1996; Kitagawa, Matsumoto et al. 1998).  Progesterone, 
polydatin, and rosuvastatin administation have all been effective in partially inhibiting 
ICAM-1 expression and infarct volume in rodents (Cheng, Zhang et al. 2006; Mayanagi, 
Katakam et al. 2008; Wang, Zhao et al. 2011).  Reduction in ICAM-1 mRNA expression 
by only 30% through treatment with ferulic acid led to notable decreases in macrophage 
activation, oxidative stress and apoptosis in the ischemic penumbra of rats (Cheng, Su et 
al. 2008).  In addition, ICAM-1 specific antisense oligodeoxynucleotide treatment 
resulted in more than a 50% reduction in infarct volume in rats and was accompanied by 
improvement in neurological function (Vemuganti, Dempsey et al. 2004).   These data 
indicate that even small decreases of ICAM-1 may be effective in alleviating stroke 
damage, making ICAM-1 an attractive target for MPAP-siRNA probe testing.   
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E-selectin and P selectin  
 E- and P- selectins are glycoproteins that become upregulated in brain endothelial 
cells upon activation by inflammatory mediators and promote neutrophil influx into 
ischemic tissues (Pober, Bevilacqua et al. 1986; Geng, Bevilacqua et al. 1990; Mayadas, 
Johnson et al. 1993).  General selectin blockage through chemical inhibition with the 
drug CY-1503 led to 42% reduction in infarct volume and neutrophil accumulations in a 
transient rat model (Zhang, Chopp et al. 1996).   Blockage of distinct selectin variants 
through gene knockout or selectin antibody has likewise been effective against stroke 
(Connolly, Winfree et al. 1997; Huang, Choudhri et al. 2000).  Notably, selectin targeting 
with antibodies has also been therapeutic in a baboon model of cerebral ischemia 
(Mocco, Choudhri et al. 2002).  These studies provide strong evidence that E- and P-
selectins are universal and potent targets for stroke treatment.   
COX-2 
  Like iNOS, COX-2 is involved in the inflammatory response after ischemia and 
contributes to tissue damage by promoting the production of prostaglandins and reactive 
oxygen species (del Zoppo, Ginis et al. 2000).  COX-2 knockout mice are protected from 
infarction (Iadecola, Niwa et al. 2001), as are rodents treated with a variety of COX-2 
chemical inhibitors (Hara, Kong et al. 1998; Sugimoto and Iadecola 2003; Kelsen, Kjaer 
et al. 2006; Ahmad, Zhang et al. 2009).  Most promising is evidence that COX-2 
targeting up to 18 hours after stroke is effective in reducing neurological deficits and 
infarct volume in treated mice (Sugimoto and Iadecola 2003).  This is an extensive time 
window of action, which is important in a clinical setting where current treatments are 
only effective when administered within 3 hours of stroke (1995).  
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 In testing our MPAP-siRNA against any of these identified targets, it is important 
to consider a couple of additional points.  First, the targets are involved in different 
aspects of stroke pathogenesis and are expressed in different types of cells in the central 
nervous system.  Our MPAP-siRNA probes do not possess any targeting moieties that 
would promote their uptake by one cell type over another.  In our previous studies with 
MPAP, the addition of targeting peptides to MPAP-based probes helped direct their 
internalization (Medarova, Pham et al. 2007).   It would be straightforward to extend this 
approach to MPAP-siRNA probes to promote targeting of neurons, astrocytes or 
endothelial cells, depending on the differential expression profiles of therapeutic targets.   
However, incorporation of targeting peptides changes the uptake dynamics of probes and 
their bioactivity, which would require recharacterization beginning at the in vitro level.   
 Additionally, in most of our experiments the true effect of probes on infarct 
volume and neurological function was obscured by the high variability in stroke severity 
inherent in the intraluminal occlusion model.  A good alternative surgical model involves 
a craniotomy and either permanent or transient occlusion of the MCA as it is directly 
visualized (Chen, Hsu et al. 1986; Majid, He et al. 2000).  This procedure results in 
smaller and more defined infarcts that would make it easier to recognize small 
improvements in stroke outcome due to our probes.     
 In summary, we have demonstrated the proof-of-principle that simple 
complexation techniques can be employed to produce a bioactive RNAi-based optical 
imaging probe.  We confirmed that MPAP-Src complexes become internalized by cells in 
the in vitro and in vivo settings where they lead to statistically-significant reductions in 
endogenous Src levels in central nervous system cells without adversely affecting cell 
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viability.  The delivery platform provides a flexible method of targeted gene silencing 
that may prove effective against a variety of targets in experimental stroke studies.     
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3. Theranostic imaging probes for the treatment of malignant brain 
tumors. 
3.1 Introduction 
 Glioblastoma multiforme (GBM) is grade IV glioma, the most common and 
malignant form of brain cancer (Kleihues, Burger et al. 1993).  The median survival of 
GBM patients is only 12-15 months, even with aggressive medical intervention 
(Sathornsumetee and Rich 2008).  Recent clinical trials have demonstrated improved 
survival when patients receive the chemotherapeutic temozolomide concomitantly with 
radiotherapy (Stupp, Dietrich et al. 2002; Stupp, Mason et al. 2005; Stupp, Hegi et al. 
2009).   Combined radiation and temozolomide treatment resulted in a patient survival 
benefit of 2.5 months relative to standard radiotherapy and an increase in 2-year survival 
(Stupp, Mason et al. 2005; Mirimanoff, Gorlia et al. 2006).  This treatment regimen has 
since become standard of care for patients with newly diagnosed glioblastoma.   
 The mechanism of action of temozolomide involves its ability to alkylate DNA in 
tumor cells.  Temozolomide transfers a methyl group to select nitrogen and oxygen atoms 
of the DNA bases guanine and alanine (Denny, Wheelhouse et al. 1994). Methylation 
primarily occurs at the N7 position of guanine, with additional adducts occurring at the N3 
position of alanine and O6 position of guanine.  It is mainly the latter methylation site that 
accounts for most of the cytotoxic effects of temozolomide, as it causes errors in the 
DNA mismatch repair system, accumulation of nicks in cellular DNA, interference with 
cancer cell cycle progression and, ultimately, cell death (Karran, Macpherson et al. 1993; 
Liu, Markowitz et al. 1996).   
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 The responsiveness of GBM to the effects of temozolomide has been linked to the 
activity of the protein MGMT (O6-methylguanine–DNA methyltransferase) in tumor 
tissue (Pegg 1990; Hegi, Diserens et al. 2004; Hegi, Diserens et al. 2005).  MGMT acts 
by removing methyl adducts from DNA, thereby reversing the cytotoxic actions of 
alkylating agents such as temozolomide (Kaina, Fritz et al. 1991; Dumenco, Allay et al. 
1993).  In glioblastoma cell lines in which the MGMT gene promoter is in the 
methylated, inactivated state, temozolomide has the most pronounced cytotoxic effects 
(Plowman, Waud et al. 1994).  Similarly, epigenetic silencing of the MGMT gene is 
positively correlated with improved clinical outcome after temozolomide treatment in 
patients with newly diagnosed GBM (Hegi, Diserens et al. 2004; Paz, Yaya-Tur et al. 
2004; Weller, Stupp et al. 2010).  Furthermore, CD133 positive glioblastoma cancer stem 
cells, known to be involved in tumor initiation and recurrence, have been shown to 
express high levels of MGMT that contribute to tumor chemoresistance (Liu, Yuan et al. 
2006; Beier, Rohrl et al. 2008).  In addition, MGMT expression in recurrent GBMs is 
higher on average than for primary tumors, which may account for the poor response of 
these patients to therapy (Christmann, Nagel et al. 2010).  
 One strategy for enhancing temozolomide toxicity in resistant, MGMT-positive 
GBMs involves chemical depletion of MGMT in tumors.  O6-benzylguanine derivatives 
have been actively investigated as MGMT inhibitors, but administration of these 
compounds is associated with hematologic toxicity (Fairbairn, Watson et al. 1995; 
Chinnasamy, Rafferty et al. 1997; Friedman, Pluda et al. 2000; Ranson, Middleton et al. 
2006).  An alternative approach is to use RNA interference directed against MGMT to 
transiently reduce MGMT levels prior to chemotherapy treatment.  In one study, human 
 96 
nasopharyngeal carcinoma cell lines treated with MGMT siRNA displayed enhanced 
sensitivity to chemotherapeutics (Kuo, Liu et al. 2006).  In another study, MGMT 
knockdown by siRNA in chemoresistant glioma-initiating cells led to improved 
chemotherapy response (Kato, Natsume et al. 2010).  We focused on extending this 
approach by modifying siRNA to form a nanoparticle-based dual therapeutic and 
multimodal imaging agent for glioblastoma treatment.  We hypothesized that MGMT-
directed siRNA would increase the potency of temozolomide treatment in a 
chemotherapy-resistant mouse model of glioblastoma.  Furthermore, incorporating the 
siRNA onto superparamagnetic iron oxide nanoparticles renders it detectable by magnetic 
resonance imaging, the technique routinely used to assess glioblastoma tumor response to 
treatment.  We have previously demonstrated that multi-modal superparamagnetic iron 
oxide nanoparticles can be used as vectors for the delivery siRNA molecules in a variety 
of cancers (Medarova, Pham et al. 2007; Kumar, Yigit et al. 2010).  Nanoparticles 
functionalized with optical dye, membrane translocation moieties and siRNA 
successfully accumulated in subcutaneous human colorectal adenocarcinoma tumors 
following systemic injection (Medarova, Pham et al. 2007).  The nanoparticle platform 
enabled direct noninvasive visualization of delivery by optical and magnetic resonance 
imaging and promoted reduction in siRNA target gene expression in a therapeutic tumor 
model.  Tumor-specific nanoparticle-based siRNA delivery has also been demonstrated 
in a breast cancer model using therapeutic nanoparticles modified to target genes 
implicated in tumor survival in vivo (Kumar, Yigit et al. 2010).  In addition, the 
feasibility of nanoparticle delivery to brain cancer has been shown using a functionalized 
membrane-permeant iron oxide MRI contrast agent that was internalized by tumor cells 
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in an orthotopic xenograft model of GBM (Kumar, Medarova et al. 2009; Kumar, 
Medarova et al. 2010).   The success of these studies prompted our investigation of 
nanoparticle siRNA carriers as contrast agents that can modify the MGMT status of 
human gliomas and enhance sensitivity to temozolomide treatment.  
 In this work, nanoparticles were synthesized and conjugated to a cocktail of 
siRNAs specific for human MGMT in order to knockdown the MGMT gene. Glioma 
targeting by nanoparticles was enabled through surface modification with fluorescein-
labeled chlorotoxin (Lyons, O'Neal et al. 2002). Chlorotoxin has been identified as a 
peptide with an affinity and selectivity for gliomas that is capable of carrying diverse 
cargoes to tumors and improving cellular uptake (Veiseh, Sun et al. 2005; Veiseh, 
Gabikian et al. 2007; Sun, Veiseh et al. 2008).  Chlorotoxin was also selected to impart 
additional therapeutic potential to the nanoparticles given recent evidence that the peptide 
inhibits tumor proliferation and invasiveness (Deshane, Garner et al. 2003; McFerrin and 
Sontheimer 2006; Fu, Yin et al. 2007).   For correlative microscopy, the chlorotoxin 
peptide was labeled with fluorescein and magnetic nanoparticles were conjugated to 
Cy5.5 near infrared optical dye.  The superparamagnetic iron oxide core of the 
nanoparticles served as an MR imaging reporter in these studies.  The cellular uptake, 
bioactivity, and the synergy between temozolomide and the theranostic probe were 
evaluated in vitro in cell lines with different MGMT expression levels.  Our results 
demonstrate robust uptake of nanoparticles in cells that is detectable by optical and 
magnetic resonance imaging.  Uptake of nanoparticles bearing MGMT-specific siRNA 
was associated with significant decreases in MGMT gene expression detected at the 
mRNA and protein levels and reduced MGMT activity.  Furthermore, pretreatment of 
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MGMT-expressing tumor cells with nanoparticles bearing siRNA to MGMT was shown 
to improve the cytotoxic effects of temozolomide.  Results also indicated that chlorotoxin 
alone is effective in improving the cytotoxicity of temozolomide.  In vitro studies were 
followed by the investigation of nanoparticles in an orthotopic brain tumor mouse model.  
Mice bearing TMZ-resistant glioblastomas were subjected to intravenous or intratumoral 
nanoparticle treatment.  As with in vitro studies, we found that MGMT siRNA 
nanoparticles effectively modulated MGMT expression and activity in tumor cells while 
reducing tumor volume.  We also found that the chlorotoxin moiety reduces tumor size 
by a mechanism that is independent of MGMT expression.  Our results demonstrate that 
siRNA delivery by nanoparticles, in combination with chlorotoxin targeting, is capable of 
modulating tumor response to chemotherapy in an animal model of glioblastoma.  
3.2 Experimental Procedures 
3.2.1 Theranostic Probe Synthesis  
 Dextran-coated superparamagnetic iron oxide nanoparticles were synthesized 
according to the procedure described previously (Moore, Medarova et al. 2004).  The 
complete synthesis is illustrated schematically in Figure 3.1.  The addition of functional 
groups was enabled by amine-derivatization of nanoparticles (1, NP-NH2) through 
modification with epichlorohydrin and ammonia.  Nanoparticles were labeled with Cy5.5 
optical dye by reacting NP-NH2 (120 mM, 14.4 mg Fe) with Cy5.5-NHS ester (1 mg, 
1.40 mmole, 11.7 eq, GE Healthcare) in DMSO overnight at 4°C.  The resulting Cy5.5-
conjugated nanoparticles (2, Cy5.5-NP) were purified by size exclusion (SE) column. 
The attachment of chlorotoxin to nanoparticles was achieved by first incubating 
nanoparticle 2 with an excess of succinimidyl 3-(2-pyridyldithio)propionate (SPDP, 250  
 99 
 
 
 
 
Figure 3.1. Scheme for the preparation of multifunctional nanoparticle probes.  
Dextran-coated superparamagnetic iron oxide nanoparticles (1) were labeled with Cy5.5 
dye (2) and then modified with SPDP crosslinker (3) for attachment of functional groups.  
Chlorotoxin (CLX) tumor-targeting peptide was labeled with fluorescein dye (4) and 
conjugated to nanoparticles (5).  The nanoparticles were then conjugated to MGMT-
specific siRNA for gene silencing (6).  Control nanoparticles bearing scrambled siRNA 
(7) served as a control. 
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eq) for 4 hours at 4°C to generate Cy5.5-NP-SPDP (3) followed by purification by size 
exclusion column.  Chlorotoxin (CLX, Alamone) was labeled with Fluorescein-NHS 
ester (Thermo Scientific) and conjugated with N-succinimidyl S-acetylthioacetate 
(SATA) to generate Fluorescein-CLX-NH (4).  The CLX conjugate was treated with 
hydroxylamine to deprotect the thiol group and enable conjugation with SPDP on 
nanoparticle 3 upon mixing to form Cy5.5-CLX-NP (5).      
 A cocktail of thiol-modified siRNA targeting sequences for MGMT (siMGMT) 
manufactured by Dharmacon (Thermo Fisher Scientific) were selected for conjugation to 
nanoparticles.   The siRNA was treated with tris(2-carboxyethyl)phosphine (TCEP) to 
reduce their disulfide bonds prior to conjugation. A total of 50 nmol of Cy5.5-CLX-NP 
(5) were conjugated with siMGMT (400 nmol) to generate siMGMT-CLX-NP (6).  
Control nanoparticles were synthesized by attaching scrambled non-targeting siRNAs 
using the same procedure to form siSCR-CLX-NP (7).   
3.2.2 Characterization of siMGMT-CLX-NP Probes 
The number of functional groups per nanoparticle was evaluated as follows.  The 
number of Cy5.5 molecules per nanoparticle was quantified by UV absorption at 683 nm 
(ε = 250,000). The number of CLX moieties was quantified by Pierce BCA assay kit 
(Thermo Scientific) and confirmed by quantification of the CLX fluorescein label at 518 
nm (ε = 70,000) by UV spectrometer. The amount of siRNA on nanoparticles was 
determined by semi-quantitative agarose gel electrophoresis. This entailed loading 
siMGMT-CLX-NPs or siSCR-CLX-NPs on magnetic activated cell sorting (MACS) 
columns and washing in a magnetic field with nuclease-free water to remove 
unconjugated free siRNA.  The column was removed from the magnet and the samples 
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were collected by eluting the column with nuclease-free water.  The probes were treated 
with TCEP for 30 minutes to promote the release of siRNA from the nanoparticles. The 
TCEP-treated probes, untreated probes and siRNA standard (50, 100, 150, 200 pmol) 
reference solutions were loaded onto a 2% agarose gel in Tris borate-EDTA buffer 
(Invitrogen, Carlsbad, CA) and separated by electrophoresis at 120 V for 90 minutes. 
After electrophoresis, the siRNA residing in the gel was stained with 0.5 mg/ml ethidium 
bromide for 30 minutes and visualized using a Molecular Imager FX scanner (BioRad 
Laboratories, Hercules, CA). The intensities of siRNA bands in the image were 
quantified using ImageJ, version 1.45i software (NIH). The amount of siRNA released 
from nanoparticles following TCEP treatment was determined relative to reference 
siRNA solutions.  
Iron content of nanoparticles was determined by measuring the absorbance at 540 
nm using the Total Iron Reagent Set (Pointe Scientific, Canton, MI). Each experiment 
was performed in triplicate.  The relaxivities of nanoparticles were measured using a 20 
MHz NMR spectrometer (miniSpec, Bruker).  Nanoparticle size was measured with a 
Malvern Zetasizer Nano Series ZS instrument. 
3.2.3 In vitro siMGMT-CLX-NP Probe Uptake 
 Internalization of siMGMT-CLX-NPs and control probes was assessed in human 
glioma cell lines. T98G and U87MG cell lines that express high and negligible quantities 
of MGMT, respectively, were purchased from ATCC and propagated according to the 
supplier’s recommendations.  Cells were seeded at a density of 1x105 cells per well in 12-
well plates. Twenty-four hours after plating, siMGMT-CLX-NPs, siSCR-CLX-NPs, or 
unmodified Cy5.5-labeled NPs (Cy5.5-NPs) were added to cells at concentrations 
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ranging from 10 to 150 µg Fe/ml.  Cells were incubated with nanoparticles for 48 hours 
at 37°C in a humidified 6% CO2 atmosphere.  Media was removed and after washing 
with Hanks’ Balanced Salt Solution (HBSS), cells were dissolved in 1 ml of 6-N HCl 
with 3% hydrogen peroxide.  Iron content of the solutions was determined by Total Iron 
Reagent Set (Pointe Scientific) iron assay.  A subset of treated cells were washed, 
collected by trypsinization, and counted for the purpose of normalization. Each 
experiment was performed in triplicate and the results were expressed as picograms of 
iron per cell.   Cellular distribution of the nanoparticles was evaluated by fluorescence 
microscopy.  T98G cells plated in 12-well plates on coverslips and treated for 48 hours 
with siMGMT-CLX-NPs or Cy5.5-NPs were fixed in 4% paraformaldehyde for five 
minutes and washed thoroughly with PBS.  Coverslips were mounted on slides with 
Vectashield Mounting Media containing DAPI for nuclear staining.  Intracellular Cy5.5, 
fluorescein and DAPI fluorescence were detected using a Nikon Eclipse 50i microscope. 
3.2.4 Optical/MR Imaging of Cellular Phantoms  
 T98G and U87MG cells were incubated with probes for 48 hours, harvested, and 
pelleted in 0.2 mL PCR tubes to form cell phantoms. Probe uptake by cells was evaluated 
by optical (IVIS Spectrum, Caliper Life Sciences) and magnetic resonance imaging (9.4T 
Bruker horizontal bore scanner equipped with ParaVision 5.1 software). The MRI 
protocol consisted of T2-weighted spin echo (SE) pulse sequences with SE repetition 
time/echo time = 3,000/[8, 16, 24, 32, 40, 48, 56, 64]; FOV = 32 x 32 mm; matrix size = 
128 x 128 pixels; slice thickness = 0.5 mm; and in-plane resolution = 250 x 250 μm2. 
Image reconstruction and analysis were performed with ImageJ software (NIH). Optical 
imaging was performed immediately after the MRI session. Imaging of phantoms was 
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performed using 675-nm excitation and 720-nm emission filters for detection of Cy5.5-
labeled probe. The fluorescence imaging settings (i.e., exposure time, 0.5 seconds; F-
stop, 2; binning, medium) were kept constant for comparative analysis. Grayscale white-
light photographs and epifluorescent images were acquired and superimposed. The 
images were reconstructed using the Living Image software version 3.1 (Caliper Life 
Sciences). 
3.2.5 Real Time Quantitative RT-PCR 
 The effect of siMGMT-CLX-NP treatment on MGMT expression in cells or brain 
tumor tissue was evaluated using real-time quantitative RT-PCR (TaqMan).  For in vitro 
studies, T98G cells were seeded at a density of 2x104 cells per well in 12-well plates and 
treated with siMGMT-CLX-NPs (25 or 50 μg Fe/ml, corresponding to 238 and 475 
pmol/ml siRNA, respectively), siSCR-CLX-NPs (50 μg Fe/ml, 475 pmol siRNA) or 
Cy5.5-NPs (50 μg Fe/ml).  After 24 hours of incubation, cells were harvested and total 
RNA was extracted with an RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
protocol.  For in vivo studies, treated brain tumors were removed and flash frozen.  RNA 
was extracted from tissues with an RNeasy Mini Kit according to the manufacturer’s 
protocol.   
 TaqMan analysis was performed using an ABI Prism 7700 sequence detection 
system (PE Applied Biosystems).  The sequences of primers and probe used for 
amplification are as listed: MGMT forward primer, 5'-CTGGCTGAATGCCTACTTCC-
3'; MGMT reverse primer, 5'-CAACCTTCAGCAGCTTCCAT-3'; and MGMT probe, 5'-
TGTCTGGTGAACGACTCTT-GCTGGA-3'. Eukaryotic 18S rRNA served as an 
internal control.  Statistical analysis was performed using one-way analysis of variance 
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followed by the Holm multiple comparisons posttest.   
3.2.6 Western Blot Analysis 
 Western blot analysis was performed on treated cells and brain tumor extracts.  
For cell studies, T98G cells were seeded in 12-well plates (1x105 cells/well) and cultured 
for 24 hrs. Cells were incubated with siMGMT-CLX-NPs (25 or 50 μg Fe/ml), siSCR-
CLX-NPs (50 μg Fe/ml) or Cy5.5-NPs (50 μg Fe/ml) for 48 hours and then washed thrice 
with HBSS.  Cells were harvested by trypsinization. For animal studies, treated tumors 
were resected and snap frozen.  Cells or tissues were treated with lysis buffer (RIPA 
buffer with 100 mM EDTA, 100 mM PMSF and protease inhibitor cocktail) and 
centrifuged (12,000 rpm for 10 min). The supernatant was collected and the amount of 
protein per sample was quantified by Pierce BCA assay (Thermo Scientific).  
Denaturated protein extracts (40 mg) were loaded onto a polyacrylamide gel and 
subjected to SDS-PAGE. After electrophoresis, the protein was transferred onto a 
polyvinylidene fluoride membrane. The membrane was blocked in 5% non-fat milk for 1 
hour followed by overnight incubation with the mouse monoclonal antibody to MGMT 
(MT3.1, 1:500 dilution; abcam) at 4°C.  After washing, 1-hour incubation with secondary 
antibody (HRP-conjugated goat anti-mouse IgG (H+L), 1:2,000 dilution; Invitrogen) was 
performed at room temperature.  MGMT protein was detected following membrane 
incubation with Amersham’s ECL Plus Western Blot Detection system. MGMT protein 
levels were normalized by reference β-actin protein levels that were detected using the 
same protocol. 
3.2.7 MGMT Activity Assay  
 MGMT activity in cells after nanoparticle treatment was assessed according to a 
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published O6-alkylguanine-DNA alkyltransferase assay procedure (Watson and Margison 
1999). Assay substrate DNA was prepared by purifying 40 mg of calf thymus DNA (CT-
DNA, Sigma-Aldrich) with proteinase K (100 mg, Sigma-Aldrich).  The DNA was 
methylated with the use of 5 mCi tritylmethyl nitrosourea ([3H]-MNU, Moravek 
Biochemicals and Radiochemicals, Inc.) in 0.02M Ammediol (Sigma-Aldrich), pH 10. 
After overnight stirring, [3H-methyl]-labeled calf thymus DNA (3[H]-CT-DNA) was 
precipitated by adding 3M sodium acetate and cold ethanol. Protein extracts were 
prepared from T98G and U87MG cells after 48-hour incubation with siMGMT-CLX-
NPs, siSCR-CLX-NPs or Cy5.5-NPs (50 μg Fe/ml each). The cells were harvested and 
homogenized by sonication in buffer (Tris-HCl, 20 mM, pH 8.5, EDTA, 1 mM; β-
mercaptoethanol, 1 mM; 5% glycerol and the protease inhibitor phenylmethylsulphonyl 
fluoride, 0.1 mM). The cell lysate was centrifuged at 10,000 rpm for 10 min at 4˚C, and 
the protein concentration of the supernatant was determined by Pierce BCA assay 
(Thermo Scientific). Substrate 3[H]-CT-DNA (200 counts per minute (cpm)/ml, 100 ml) 
was incubated with the extract (50 mg protein) and concentrated with bovine serum 
albumin (BSA, 150 ml) solution for 90 min at 37°C. The DNA substrate was then 
hydrolysed with the addition of BSA (100 μL), 4M perchloric acid (PCA, 100 μL), 1M 
PCA (2 mL) and 50 minutes of heating at 75°C.  After centrifugation, the protein pellet 
was washed with 4 ml PCA, dispersed in 300 mL of 10 mM NaOH and then in 3 ml of 
Ecoscint solution.  Radioactivity was determined with a liquid scintillation counter. Data 
are expressed as [fmol radioactivity transferred from 3H-labeled DNA to protein]/[mg of 
protein added]. Statistical analysis included one-way analysis of variance followed by the 
Holm multiple comparisons posttest. 
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3.2.8 Synergistic Effect of siRNA and Temozolomide Treatment. 
 The effect of MGMT knockdown by siMGMT-CLX-NPs on temozolomide 
resistance was evaluated through combination treatment of cells with nanoparticles and 
chemotherapeutic.  A total of 1x105 cells were seeded in 12-well plates and allowed to 
adhere for 24 hrs. Each probe (siMGMT-CLX-NPs, siSCR-CLX-NPs and Cy5.5-NPs) 
was applied to cells in concentrations of 50 μg Fe/ml for 48 hrs.  Chemotherapeutic 
temozolomide (TMZ, Sigma-Aldrich) was added to the cells in varying concentrations 
(100, 300 and 650 µM) and incubated for four hours. Cells were trypsinized and the 
number of surviving cells was counted.  Viability was calculated relative to the mean 
number of cells in control wells treated with PBS.  
3.2.9 Establishment of Flank Tumor Xenografts 
 Six-week-old athymic nude mice (nu/nu, COX-7) were selected for in vivo T98G 
xenograft studies.   Several investigators have reported poor tumorigenicity of T98G cells 
following subcutaneous and orthotopic inoculation in mice (Stein 1979; Potapova, 
Fakhrai et al. 1996; Rubenstein, Shaw et al. 1999).  The reduced tendency to form de 
novo tumors has been linked to low expression of peripheral-type benzodiazepine 
receptors (PBRs) by T98G cells and correlative decrease in anchorage independent 
growth (Veenman, Levin et al. 2004).   To overcome this limitation, we seeded T98G 
cells in the presence of Matrigel (BD Biosciences) supportive basement membrane 
matrix (Rubenstein, Shaw et al. 1999).  Mice were inoculated in the flank with 5x106 
T98G cells suspended in a 1:1 mixture of Minimum Essential Medium (Cellgro) and 
Matrigel.  Substantial tumor mass measuring approximately 8 mm in diameter was 
evident within three months.  The xenograft was surgically resected under aseptic 
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conditions and sectioned into 2x2x2-mm tumor fragments.  Each fragment was dipped in 
Matrigel and subcutaneously implanted into the flank of a recipient mouse for 
propagation.  Flank tumors were serially passaged in vivo from donor to recipient nude 
mouse using this procedure at the point that xenografts measured 1 cm in diameter, or 
approximately 4-5 weeks following implantation.  
3.2.10 Establishment of Orthotopic Tumor Xenografts 
 For intracranial tumor implantation, short-term explant cultures were derived 
from established T98G flank tumors using a modification of a published procedure 
(Carlson, Pokorny et al. 2011).   Tumors of approximately 1 cm in diameter were 
surgically removed from anesthetized donor mice using sterilized instruments and under 
aseptic conditions.  The excised tumor was placed in a petri dish containing DMEM 
supplemented with 2.5% FBS and 1% pen-strep and minced using a sterile scalpel.  The 
tumor was further disrupted by triturating through a small-bore pipet tip to form a single 
cell suspension.  The cell suspension was distributed among four 75-cm2 cell culture 
flasks that had been coated for 30 minutes with 10% Matrigel in supplemented DMEM.  
Cells were allowed to adhere to culture flasks for 1-7 days, at which point culture 
medium was replaced with DMEM supplemented with 10% FBS and 1% pen-strep.  
Cells were propagated and expanded to additional flasks through trypsinization with 
0.05% Trypsin/0.53 mM EDTA.  Large tumor aggregates were removed by filtering cell 
suspensions through a 70 µm nylon mesh strainer.  After 10-20 days in culture, tumor 
cells (~80-90% confluent) were prepared for intracranial implantation.  Cells were 
trypsinized, centrifuged (1000 rpm, 5 minutes), resuspended in sterile PBS at 100,000 
cells/µl and placed on ice to await injection.   
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 Five- to six-week-old athymic nude mice were anesthetized with 2.0-2.5% 
isoflurane in 30%/70% oxygen/nitrous oxide gas vehicle after which anesthesia was 
maintained at 1.0-1.5% isoflurane.  Mice were transferred and secured to a small animal 
stereotactic instrument (Kopf) with a Quintessential Stereotactic Injector (Stoelting 
Company) for controlled microinjection.  A 5-mm incision was made in the scalp and the 
skull surface wiped clean of loose tissues until the landmark bregma was clearly visible.  
A hole was drilled through the skull over the right hemisphere, 2.0-mm lateral and 1.0-
mm anterior to bregma, using a high speed micro drill with 0.7-mm steel burrs (Fine 
Science Tools).  A 701RN 10-µl syringe with a 26-gauge needle attachment (Hamilton 
Company) was loaded with 3 µl of tumor cell suspension.  The needle was advanced 
through the drill hole 3 mm into the brain, then retracted 0.5 mm to form a small pocket 
for cells.  Cells were injected at a rate of 1 µl/minute. After injection was complete, the 
needle was left undisturbed for 1 minute before being removed.  The drill hole was 
patched with bone wax (Fine Science Tools) and the skin incision closed with 5-0 silk 
suture thread (Ethilon).  Postoperative buprenorphine (0.05 mg/kg subcutaneous, Bedford 
Labs) was administered every 12 hours or as needed.  Tumor growth was monitored 
weekly by magnetic resonance imaging.  In a group of comparative experiments, 
orthotopic brain tumors were seeded in 6-week old NOD SCID mice (Charles River 
Laboratories) with T98G cells provided as a gift from Dr. Nava Almog of Tufts 
University (Naumov, Bender et al. 2006).      
3.2.11 In vivo Magnetic Resonance Imaging 
 MR imaging was performed using a Bruker 9.4T horizontal bore magnet (Magnex 
Scientific) with gradient insert and operated using ParaVision 5.1 software.  Mice were 
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placed in a birdcage radiofrequency coil.  Coronal T2-weighted spin echo (SE) pulse 
sequences were used to acquire images for the monitoring of brain tumor size.  T2 maps 
were acquired for quantitative analysis of iron oxide probe accumulations.  The following 
imaging parameters were used:  SE TR/TE = 2500/[10, 20, 30, 40, 50, 60, 70, 80, 90, 
100, 110, 120, 130, 140, 150]; FOV = 1.91 x 1.92 cm2, matrix size = 128 x 128; slice 
thickness 0.5 mm.  Tumor volumes were quantified using ImageJ software (NIH).   The 
tumor ROI was identified in each MR image and pixel area was calculated.  The pixel 
area of each slice was converted to slice tumor volume (mm3) by multiplying pixel area 
by the in-plane resolution of the T2-weighted images and slice thickness.  Total tumor 
volume was obtained by summing the slice tumor volumes from consecutive slices.   T2 
maps were calculated using Marevisi 3.5 software (Institute for Biodiagnostics, National 
Research Council, Canada).      
3.2.12 Nanoparticle/Chemotherapy Treatment 
Intravenous route of probe administration 
 As soon as tumors became viable on MRI (~ 2-4 weeks post-injection), mice were 
subjected to two rounds of nanoparticle and temozolomide treatment.  Injection of 
siMGMT-CLX-NPs (10 mg/kg Fe, 95 nmol/kg siRNA, n=3) or control CLX-NPs (10 
mg/kg Fe, n=3) was performed by tail vein injection while mice were anesthetized with 
1.5% isofluorane in oxygen gas.  One day later, temozolomide was administered 
intraperitoneally at a concentration of 50 mg/kg.  Temozolomide treatment was 
performed for four consecutive days to complete the first round of treatment.  This 
combination of nanoparticle treatment followed by 5-day TMZ administration was 
repeated the following week.  Periodic T2-weighted MRI was performed to evaluate the 
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uptake of nanoparticles by tumor cells and tumor growth.  After the completion of the 
second round of treatment, mice were sacrificed and their tissues collected for further 
analysis.   
Intratumoral route of probe administration 
 As soon as tumors became visible by MRI, intratumoral injection of siMGMT-
CLX-NPs (n=6), CLX-NPs (n=5) or PBS vehicle (n=3) was performed in combination 
with TMZ treatments as follows.  On day one of the first week, nanoparticle treatment 
was initiated.  Mice were anesthetized in 2.0-2.5% isoflurane in 30%/70% oxygen/nitrous 
oxide gas vehicle, and anesthesia was maintained at 1.0-1.5% isoflurane during surgery.  
An incision was made in the scalp and the drill hole through which tumor cells were 
originally injected into the brain was identified. Two microliters of siMGMT-CLX-NPs 
(10.5 µg Fe, 100 pmol siRNA), CLX-NPs (10.5 µg Fe), or PBS were injected into the 
center of the tumor (coordinates measured by MR imaging) using a 701RN 10-µl syringe 
with a 26-gauge needle attachment (Hamilton Company) at a rate of 0.125 µl/minute.  
After injection was complete, the hole was patched with bone wax (Fine Science Tools) 
and the skin incision closed with 5-0 silk suture thread (Ethilon).  Postoperative 
buprenorphine (0.05 mg/kg subcutaneous, Bedford Labs) was administered every 12 
hours or as needed.  Treatment with temozolomide (50 mg/kg/day) was performed by 
intraperitoneal injections during each of the next 5 consecutive days.  Two additional 
rounds of treatment with nanoparticles and temozolomide were performed using the same 
procedure, with nanoparticle injections occurring on day one of the second and third 
weeks of treatment.  During the fourth week of treatment, mice were injected with TMZ 
without any nanoparticle treatment. Periodic T2-weighted MRI was performed to 
 111 
evaluate the uptake of nanoparticles by tumors and tumor growth.  After the completion 
of the fourth round of treatment, mice were sacrificed and their tissues collected for 
further analysis.    
3.2.13 Histological Staining 
 Mouse brains containing orthotopic tumors were embedded in Tissue-tek Optical 
Cutting Temperature (O.C.T) compound (Sakura Finetek USA) and frozen in dry ice.  
Frozen tissue sections (10-µm thickness) were cut using a Leica CM-3050S cryostat and 
placed on glass slides.  Sequential slices of each brain were stained using Prussian blue 
(for iron), hematoxylin and eosin (for tumor morphology), and mounted with DAPI for 
fluorescence microscopy. 
Prussian Blue Iron Staining 
 For Prussian Blue staining, slides were equilibrated at room temperature and fixed 
in 4% paraformaldehyde for 5 minutes.  Following washing with PBS, the slides were 
immersed in Perl’s solution (5% potassium ferrocyanide (ACROS Organics) and 5% HCl 
(Aldrich)) for 30 minutes at room termperature.  The slides were rinsed with water and 
counterstained with Nuclear Fast Red stain (Sigma-Aldrich) for 2 minutes.  After a wash 
in water, the slides were incubated in consecutive 50%, 75%, 95%, and 100% ethanol 
solutions for 1 minute each followed by two 2-minute incubations in xylene.  After air-
drying the coverslips were mounted in Permount mounting medium (Fisher Scientific).   
Hematoxylin and Eosin (H&E) Staining 
 Flank and orthotopic tumor xenograft growth was confirmed histologically by 
hematoxylin and eosin staining.  Fresh mouse brain tissue or subcutaneous tumor was 
embedded in Tissue-tek Optical Cutting Temperature (O.C.T) compound (Sakura Finetek 
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USA) and frozen in dry ice.  Frozen tissue sections (10-µm thickness) were cut using a 
Leica CM-3050S cryostat and mounted on glass slides.  For staining, sections were fixed 
in acetone (-80°C) for 15 minutes.   Following washes in PBS, slides were incubated in 
hematoxylin for one minute, then washed in water before incubating in eosin (Fisher 
Scientific) for an additional minute.  This was followed by one-minute incubations in 
consecutive 50%, 75%, 95%, and 100% ethanol solutions to dehydrate the tissues.  Five 
minute incubation in xylene was performed to remove any additional O.C.T. compound.  
Slides were air-dried and mounted using Permount mounting medium (Fisher Scientific).   
Fluorescence microscopy 
 To enable the visualization of nanoparticle uptake by fluorescence microscopy, 
tissue slices were fixed in 4% paraformaldehyde for five minutes and washed thoroughly 
with PBS.  Coverslips were mounted on slides with Vectashield Mounting Media 
containing DAPI for nuclear staining.  Microscopy was performed using a Nikon Eclipse 
50i microscope. 
 To evaluate the vascularity of tumors, frozen tissue sections of brains bearing 
U87MG or T98G tumors were fixed in 4% paraformaldehyde, blocked with bovine 
serum albumin, and incubated with rat antibody to mouse CD34 primary antibody (1:100, 
Abcam).  This was followed by incubation with biotinylated anti-rat secondary antibody 
(1:100, Vector Labs) and streptavidin-FITC conjugate (1:1000, Invitrogen). Coverslips 
were mounted on slides with Vectashield Mounting Media containing DAPI for nuclear 
staining.  Microscopy was performed using a Nikon Eclipse 50i microscope. 
 113 
3.3 Results 
3.3.1 Characterization of siMGMT-CLX-NP Probes 
 For synthesis of our theranostic probes we used dextran-coated 
superparamagnetic iron oxide nanoparticles.  Iron oxide nanoparticles are contrast agents 
that reduce the T2 relaxation time of associated tissues and promote signal intensity loss 
in T2-weighted magnetic resonance images.   The nanoparticles were modified with 
Cy5.5 dye to enable correlative fluorescence microscopy.  Nanoparticles were further 
modified with fluorescein-labeled chlorotoxin peptide for glioma tumor targeting and 
growth inhibition, while MGMT-specific siRNAs were conjugated to the nanoparticles 
for gene silencing to increase tumor responsiveness to the chemotherapeutic 
temozolomide.  We found the following ratio of functional groups/nanoparticle: 
Cy5.5/CLX/siRNA = 2.7/2.9/1 (Figure 3.2a).  The relaxivities of the probe were 
measured as R1 = 18.85 mM-1sec-1 and R2 = 100.94 mM-1sec-1 (Figure 2b).  The particle 
size of Cy5.5-CLX-NPs was 30.7±3.2 nm and the size of siMGMT-CLX-NPs after the 
addition of siRNA was 37.3±.73 nm.  
3.3.2 In vitro siMGMT-CLX-NP Probe Uptake 
 Two human glioblastoma cell lines were selected to test probe cellular uptake and 
bioactivity in vitro. T98G cells were selected as an MGMT-expressing cell line with 
temozolomide resistance.   The MGMT negative, temozolomide-sensitive U87MG cell 
line was chosen for control studies.   Probe internalization was investigated through 
incubation of T98G and U87MG with tumor-targeted siMGMT-CLX-NPs or unmodified 
Cy5.5-NPs at several probe concentrations (10 ~ 150 µg Fe/ml) for 48 hours.  The CLX 
targeting peptide promoted significant nanoparticle internalization by both T98G and  
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Figure 3.2. The siRNA content and R2 relaxivity of siMGMT-CLX-NP probes.  a) 
The number of siRNA molecules per nanoparticle was determined by semi-quantitative 
agarose gel electrophoresis.  TCEP was used to cleave MGMT siRNA from nanoparticles 
and enable its migration into the agarose gel.  The amount of free siRNA in TCEP-treated 
samples (+) was determined relative to siRNA standards (25, 50, 75 and 100 pmol).  b) 
Probe relaxivity was determined by measuring T2 parameters as a function of iron 
concentration using a 20 MHz NMR spectrometer. 
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U87MG cell lines as shown by iron uptake assay (Figure 3.3).  There was a concentration 
dependent nanoparticle accumulation that plateaued to saturation levels at a concentration 
of approximately 50 µg Fe/ml. Since there was little improvement in cellular nanoparticle 
uptake above this concentration, all further experiments were performed at 50 µg Fe/ml. 
Iron levels per cell were generally higher in T98G than U87MG cells, which may be a 
function of differences in cell doubling rates or cell membrane distribution of CLX’s 
target, matrix metalloproteinase-2 (MMP-2), between the two cell lines.  In contrast, 
unmodified nanoparticle treatment resulted in negligible uptake at every probe 
concentration tested, demonstrating how crucial the presence of CLX is for nanoparticle 
internalization.  Cellular uptake of siMGMT-CLX-NPs was confirmed by fluorescence 
microscopy.  T98G cells incubated with siMGMT-CLX-NPs or control Cy5.5-NPs are 
shown in Figure 3.4.  Co-localization of Cy5.5 and FITC signal indicated the uptake of 
the probe by the cells.  In contrast, virtually no uptake was observed with control probe, 
confirming the necessity of CLX presence for probe uptake.  
 Additional verification of nanoparticle uptake was obtained from magnetic 
resonance imaging of NP-treated cell phantoms.  T98G cells treated with siMGMT-CLX-
NPs, siSCR-CLX-NPs, or Cy5.5-NPs were trypsinized and pelleted to make cell 
phantoms.  The phantoms were subjected to optical and T2-weighted MR imaging.  
Optical imaging shows significant uptake of siMGMT-CLX-NPs and siSCR-CLX-NPs 
by cells relative to Cy5.5-labeled nanoparticles that lack the CLX targeting peptide 
(Figure 3.5a).  Phantom studies also demonstrate that siMGMT-CLX is an effective MR 
T2 contrast agent. In pellets of the cells treated with siMGMT-CLX-NPs and siSCR-
CLX-NPs, the signal intensity in T2-weighted images decreased significantly compared  
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Figure 3.3. Iron uptake assay.  T98G and U87MG cells were treated with different 
concentrations of siMGMT-CLX-NPs or unmodified Cy5.5-NPs for 48 hours.  The 
internalized iron content was determined by iron assay and normalized by cell number.  
CLX promoted significant nanoparticle uptake in both cell lines.   
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Figure 3.4. Cellular distribution of siMGMT-CLX-NPs.  T98G cells treated with 
siMGMT-CLX-NPs or Cy5.5-NPs were evaluated by fluorescence microscopy. There 
was a co-localization of Cy5.5 and FITC signal indicating probe uptake by the cells. In 
contrast, Cy5.5-NP treatment was not accompanied by any significant probe 
accumulation, indicating that CLX is necessary for probe uptake. 
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Figure 3.5. Optical and MR imaging of cell pellets. T98G cells were incubated with 
siMGMT-CLX-NPs, siSCR-CLX-NPs or Cy5.5-NPs and harvested to form cell pellet 
phantoms. a) Uptake of nanoparticles was evident by optical imaging, with significant 
Cy5.5 signal present in cells treated with nanoparticles functionalized with tumor-
targeting peptide CLX.  b) Cellular uptake was also confirmed by T2-weighted magnetic 
resonance imaging.  Internalized nanoparticles were associated with signal loss in 
siMGMT-CLX-NP and siSCR-CLX-NP treated cell pellets in MRI images.  No 
corresponding effect was observed in cells treated with Cy5.5-NPs. 
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to the cells treated with Cy5.5-NPs, signifying T2 shortening in phantoms that denotes 
uptake of probes (Figure 3.5b). 
3.3.3  Bioactivity of siMGMT-CLX-NPs 
 After establishing that siMGMT-CLX-NPs and control siSCR-CLX-NPs are 
taken up by glioma cells after incubation, we focused on evaluating the molecular 
consequences of probe internalization. First, the baseline expression of MGMT in the 
T98G and U87MG GBM cell lines was determined by western blot analysis, which 
confirmed that T98G cells have high MGMT expression and U87MG cells have no 
MGMT expression (results not shown).  To evaluate the silencing effect of probes on 
MGMT expression, cultured T98G cells were treated with siMGMT-CLX-NPs, siSCR-
CLX-NPs or unmodified Cy5.5-NPs and then processed for real time quantitative RT-
PCR analysis. The siMGMT-CLX-NPs caused 38.3% reduction in MGMT mRNA 
expression relative to unmodified NPs and 26.2% relative to NP containing scrambled 
siRNA (Figure 3.6a).  A small silencing effect observed with scrambled siRNA 
nanoparticles is common and associated with off-target effects that may be caused by the 
siRNA transfection process.  The MGMT gene knockdown achieved by siMGMT-CLX-
NPs at the mRNA level was associated with a reduction in protein expression as assessed 
by western blot analysis (Figure 3.6b).  MGMT protein expression decreased by 52% in 
T98G cells treated with 50 µg/ml of Fe (475 pmol/ml siRNA) siMGMT-CLX-NPs.  No 
apparent changes in expression were observed in cells treated with low-dose siMGMT-
CLX-NPs (25 µg/ml of Fe) or with siSCR-CLX-NPs (50 µg/ml of Fe) relative to 
unmodified NP controls.  We evaluated whether this apparent decrease in protein 
expression had functional consequences by performing MGMT activity assays on lysates  
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Figure 3.6. Bioactivity of probes.  T98G cells were treated with siMGMT-CLX-NPs, 
siSCR-CLX-NPs, or unmodified nanoparticles (Cy5.5-NPs). Gene expression was 
evaluated at the mRNA and protein levels by real time quantitative RT-PCR and western 
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Figure 3.6. (Continued).  blotting, respectively. Treatment with siMGMT-CLX-NPs was 
associated with a reduction in MGMT (a) mRNA expression and (b) protein expression.  
The effect of this gene knockdown on cellular MGMT activity was determined by (c) 
MGMT activity assay. Treatment with targeted nanoparticles (siMGMT-CLX-NP, 50 
µg/ml of Fe) resulted in a significant reduction in MGMT activity. The * denotes 
statistical significance. 
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of treated cells. MGMT activity was quantified by the transfer of radioactive trityl methyl 
group from donor calf thymus DNA (CT-DNA) to MGMT from cells.  Consistent with 
the results of RT-PCR and western blotting, siMGMT-CLX-NP treatment (50 µg/ml of 
Fe) was effective in reducing MGMT activity.  In these cells, a pronounced 64.1% 
decrease in MGMT activity relative to unmodified NP treatment was achieved, a 
reduction that proved to be significant (Figure 3.6c).  MGMT expression was not 
significantly affected by treatment with nanoparticles containing non-targeting, 
scrambled control siRNA, though activity levels were reduced by 19.6% in these cells.  
This is consistent with off-target effects potentially caused by the CLX nanoparticle 
mode of delivery.  Low concentration siMGMT-CLX-NP treatment (25 µg/ml of Fe) was 
associated with MGMT activity reduction of 40.7% relative to unmodified NP treatment.  
However, this reduction also failed to achieve statistical significance.  
 After demonstrating that nanoparticles targeting MGMT expression were 
effective in reducing MGMT enzyme activity, we tested whether siMGMT-CLX-NP 
pretreatment enhances TMZ cytotoxicity.  T98G cells pre-incubated with siMGMT-CLX 
–NP or control probes were exposed to TMZ (100 µM) for four hours. Cell survival is 
shown in Figure 3.7 for the different treatment groups.  Cells treated with unmodified 
nanoparticles exhibited no significant response to TMZ, with nearly100% survival.  In 
contrast, cells treated with siMGMT-CLX-NPs had a dramatic reduction in survival by 
38.5% relative to PBS-treated cells.  It is notable that reduction in cell survival by 24.3% 
after siSCR-CLX-NPs treatment was also observed.  The reductions after siMGMT-
CLX-NP and siSCR-CLX-NP treatments are significant relative to both PBS-treated and 
Cy5.5-NP-treated cells.  These results suggest that suppression of MGMT by  
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Figure 3.7.  Synergic effects of siMGMT-CLX-NP and temozolomide (TMZ) 
treatment.  T98G cells pretreated with siMGMT-CLX-NP, control nanoparticles (Cy5.5-
NP and siSCR-CLX-NP) or PBS were exposed to TMZ (100 µM) and cell survival was 
assessed.  The viabilities of cells treated with siMGMT-CLX-NPs and siSCR-CLX-NPs 
were both reduced relative to PBS and Cy5.5-NP-treated cells, indicating that chlorotoxin 
contributes to cell death after TMZ treatment.  MGMT gene knockdown also contributed 
to cell death, and was observed as a reduction in cell viability in siMGMT-CLX-NP 
treated cells relative to siSCR-CLX-NP treated cells.  The * denotes statistical 
significance. 
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nanoparticles contributes to enhancement of TMZ chemotherapy, resulting in a 
significant decrease in cell viability of approximately 36% beyond that achieved by 
siSCR-CLX-NP treatment.  More importantly, they show that chlorotoxin is the main 
contributor to cell death after TMZ treatment.  After demonstrating that functionalized 
CLX nanoparticles are effective in improving the tumor cell responsiveness to 
temozolomide treatment, we proceeded to in vivo models.   
3.3.4 Intravenous Delivery of siMGMT-CLX-NP Probes in Glioblastoma Model 
 To test whether siMGMT-CLX-NPs can be effectively delivered to glioblastoma 
tumors in vivo and enhance temozolomide cytotoxicity, we first developed a T98G 
xenograft model.  MGMT-expressing cell lines like T98G are associated with low de 
novo tumorigenicity that has hampered in vivo studies (Stein 1979; Potapova, Fakhrai et 
al. 1996; Rubenstein, Shaw et al. 1999; Naumov, Bender et al. 2006).  Therefore, it was 
necessary for us to develop a procedure that would induce the formation of tumors from 
T98G cells.  For this, we employed a method that has been used to transform primary 
glioblastomas to xenografts (Carlson, Pokorny et al. 2011).  First, a subcutaneous tumor 
model was established by inoculating immunocompromised mice in the flank with T98G 
cells that have been incorporated into a basement membrane matrix for improved tumor 
nucleation (Figure 3.8a-c).  Next, the excised tumor was processed to form short-term 
explant cultures that were propagated in culture flasks prior to inoculation in the brains of 
recipient mice (Figure 3.8d).  We elected to use short-term explants rather than tumor 
pieces in the formation of orthotopic brain tumors because the former method is 
associated with more uniform tumor growth (Carlson, Pokorny et al. 2011).  Explant  
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Figure 3.8.  Establishment of T98G xenograft model.  (a) Subcutaneous T98G tumors 
were grown by inoculating T98G cells with Matrigel (BD Biosciences) in the flanks of 
nude mice.  (b) Flank tumors were excised and observed by (c) H&E staining to confirm 
the presence of cancer cells.  Excised flank tumor explants were disrupted to form cell 
suspensions that were propagated in cell culture.  (d) Explant cultures were 
stereotactically injected into the brain and evaluated by (e) MRI and (f) histology. 
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cultures were tested for iron uptake and MGMT expression, and each were similar to 
those observed in parental T98G cells (data not shown).   
 Following orthotopic injection of T98G cells, weekly MRI scanning was used to 
monitor brain tumor growth (Figure 3.8e).  Brain tumors appeared as hyperintense 
regions in MRI scans (Figure 3.9a, Pre-contrast). At the time of brain tumor appearance, 
we initiated two rounds of nanoparticle/TMZ treatment.  Each round of treatment entailed 
intravenous injection of mice with siMGMT-CLX-NPs (10 mg/kg Fe, 95 nmol/kg 
siRNA) or control CLX-NPs (10 mg/kg Fe), followed a day later by 5 days of TMZ 
administration (i.p. 50 mg/kg/day).   MRI was performed after the first nanoparticle 
injection to evaluate probe delivery.  Ideally, nanoparticle accumulations should lead to 
T2 shortening and image darkening of tumors in MRI scans.   However, no significant 
negative contrast enhancement was observed in treated mice (Figure 3.9a, Post-contrast), 
calling into question whether efficient tumor delivery had taken place.  To investigate this 
further we performed histology and quantitative RT-PCR analysis on nanoparticle-treated 
brain tumors after sacrifice.  The presence of a small number of nanoparticles in tumor 
tissue was confirmed by fluorescence microscopy of Cy5.5 (Figure 3.9b).  However, 
nanoparticles failed to induce any significant change in MGMT expression (Figure 3.9c).  
Furthermore, no difference in tumor volume between siMGMT-CLX-NP and control 
treated mice was observed (Figure 3.9d).  These results indicate that nanoparticle 
accumulation observed in the tumor after intravenous injection was insufficient to induce 
gene silencing or improve tumor responsiveness to TMZ chemotherapy.  Since elevated 
MGMT expression has been shown to cause poor vascularization of tumors (Chahal, Xu 
et al. 2010), we next investigated whether this was the case with T98G tumors.  We  
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Figure 3.9.  Intravenous delivery of siMGMT-CLX-NPs. T98G orthotopic tumors in 
mice were visualized by (a) magnetic resonance imaging before (Pre-contrast) and after 
(Post-contrast) the injection of siMGMT-CLX-NPs or control CLX-NPs.  Nanoparticle 
injection was not associated with tumor enhancement despite (b) traces of nanoparticle 
accumulations observed as Cy5.5 signal in fluorescence microscopy images.  (c) Real 
time quantitative RT-PCR also indicated no significant effect of nanoparticles on tumor 
MGMT expression.  (d)  Likewise, no difference in final tumor volume between TMZ-
treated mice injected with siMGMT-CLX-NPs and control NPs was observed.    
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compared vascularization of T98G and U87MG tumors and found that there were 
approximately two times fewer blood vessels in any given field of view in T98G tumors 
(60.8±27.3 vessels/mm2) compared to U87MG tumors (131.9±21.3 vessels/mm2) that 
lack MGMT expression (Figure 3.10). We next evaluated alternative methods of 
siMGMT-CLX-NP administration for glioblastoma treatment.  
3.3.5 Intratumoral Delivery of siMGMT-CLX-NP Probes in Glioblastoma Model 
 Improving siMGMT-CLX-NP delivery and effectiveness through direct 
intratumoral injection was investigated in the mouse orthotopic glioblastoma model that 
we developed in the previous study.  The nanoparticle and TMZ treatment schedule used 
for this series of experiments is illustrated in Figure 3.11a.  After orthotopic brain tumor 
growth was confirmed by MRI (Figure 3.11b-d, Pre-treatment), a first dose of siMGMT-
CLX-NPs (10.5 µg Fe, 100 pmol siRNA), CLX-NPs (10.5 µg Fe), or PBS was injected 
into the tumor using a stereotactic frame at injection coordinates derived from MR scans.  
This was followed one day later by five consecutive days of TMZ treatment (i.p. 50 
mg/kg/day).  Two additional rounds of nanoparticle and TMZ treatment were performed, 
followed by one round of TMZ treatment alone.   
 MR images of control PBS-treated mice (Figure 3.11b, Pre-sacrifice) show that 
brain tumors grew unabated despite TMZ treatment.  This confirmed the chemotherapy 
resistance of MGMT-expressing cells that had been observed clinically.  MR imaging of 
nanoparticle-treated tumors revealed abundant uptake of siMGMT-CLX-NPs and CLX-
NPs by tumors, which was evident as image-darkened regions in T2-weighted MR scans 
(Figure 3.11c-d, Pre-sacrifice).  Nanoparticle accumulations were generally restricted to 
within the boundaries of the tumor, though in select cases they were observed in the  
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Figure 3.10.  T98G and U87MG tumor vasculature.  Orthotopic T98G and U87MG 
tumors were stained for CD34 expression of endothelial cells to identify differences in 
vascularity.  MGMT-positive T98G tumors were associated with decreased vessel 
number relative to MGMT-null U87MG tumors.  Scale bar = 50 µm. 
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Figure 3.11. Intratumoral siMGMT-CLX-NP delivery and efficacy.  The 
administration of siMGMT-CLX-NPs, CLX-NP or PBS to tumors by direct stereotactic 
injection with periodic MRI imaging was performed as illustrated (a).  For each of three 
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Figure 3.11. (Continued). weeks, intratumoral injection of probes was followed by five 
days of TMZ treatment.  During the fourth week, probe injection was omitted and a final 
course of TMZ was administered.  MR imaging performed at the time of tumor 
appearance (Pre-treatment) and sacrifice (Pre-sacrifice) for PBS-treated (b), CLX-NP 
treated (c) and siMGMT-CLX-NP treated (d) mice demonstrated robust uptake of 
nanoparticles by tumors.  Tumor margins and nanoparticle uptake was also evident in ex 
vivo tissue scans.  (d) Both siMGMT-CLX and CLX nanoparticle treatments were 
associated with significant reductions in tumor volume relative to PBS-treated control 
mice. There was a small reduction in tumor size in siMGMT-CLX-NP-treated animals 
compared to CLX-NP-treated animals. The * denotes statistical significance. 
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lateral ventricles of the brain.  Following the full course of treatment, mice were 
sacrificed and their brains excised, sectioned and scanned with a Dell 810 flatbed scanner 
(Figure 3.11b-d, Ex vivo).  Initial tumor volumes, obtained from pre-treatment MR 
images, and final tumor volumes, obtained from ex vivo brain scans, are shown in Figure 
3.11e.  Interestingly, tumor sizes in siMGMT-CLX-NP and CLX-NP treated mice were 
both significantly reduced relative to PBS-treated mice.  This shows that tumor volume is 
impacted by the combination treatment of nanoparticles and chemotherapy.  The final 
tumor volumes of mice treated with each type of nanoparticles were not significantly 
different than their respective initial volumes, demonstrating that nanoparticle treatment 
was effective in almost eliminating tumor growth in these animals.  The final tumor 
volume of mice treated with siMGMT-CLX-NPs was smaller than for mice treated with 
CLX-NPs, which is consistent with our observations in the in vitro synergistic studies.  
However, this difference was not statistically significant.  The outcome of this study 
suggests that while MGMT-specific siRNA contributes to the reduction in tumor size by 
synergizing TMZ treatment, chlorotoxin contribution was also significant in the reduction 
in tumor volume that we observed.  To obtain greater insight into these results we 
analyzed the MGMT gene expression and activity in the tumor tissues of treated mice 
(Figure 3.12).  Western blot analysis showed that mice treated with siMGMT-CLX-NPs 
had a marked reduction in MGMT gene expression of nearly 68% relative to PBS-treated 
mice and more than 45% relative to CLX-NP treated mice (Figure 3.12a).  CLX-NP 
treatment was associated with a slight reduction in MGMT expression compared to PBS 
treatment, but this difference was not statistically significant.  Furthermore, siMGMT-
CLX-NP treatment led to a reduction in MGMT activity to below the limit of detection of  
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Figure 3.12.  Bioactivity of siMGMT probes in glioblastoma tumors.  (a) Western blot 
analysis revealed that tumors receiving siMGMT-CLX-NP treatment had significant 
reductions in MGMT protein expression relative to both PBS and CLX-NP treated 
tumors.  (b) MGMT activity assay showed that MGMT activity was suppressed in 
siMGMT-CLX-NP treated tumors.   The * denotes statistical significance.  
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the assay (Figure 3.12b, red dashed line), demonstrating a potent suppressive effect.  It is 
noteworthy that CLX-NP treatment led to reductions in tumor size without comparable 
suppressions in MGMT expression or activity.   
 Histological staining of tissues for the presence of iron with Prussian blue stain 
revealed abundant nanoparticle uptake in tumor cells treated with siMGMT-CLX-NPs 
and CLX-NPs (Figure 3.13a-c).  This was confirmed by fluorescence microscopy of the 
Cy5.5 nanoparticle label (Figure 3.13d-f).  PBS treated mice had intact tumors with large 
nuclei and irregular cell morphology characteristic of neoplastic tissues as seen by H&E 
staining (Figure 3.13g).  In both types of nanoparticle treated tumors there was evidence 
of degenerated tumor nuclei and tissue degradation associated with internalized 
nanoparticles (Figure 3.13h-i).  In these treated tissues several signs of cell death, 
including condensation of the chromatin in the nucleus and fragmentation of nuclear 
material, were apparent.  This was most pronounced for siMGMT-CLX-NP tumors, in 
which there were fewer instances of healthy intact tumor cells than were observed in 
tumors treated with CLX-NPs.    
 Together, these results suggest that the presence of nanoparticles influences the 
response of tumor cells to TMZ-induced cell death.  Although almost complete 
reductions in MGMT activity were achieved using siMGMT-CLX-NPs, the overall tumor 
responses we observed in mice cannot be attributed solely to MGMT-dependent 
mechanisms.  There is evidence that the progression to cell death was also due to the 
presence of the CLX targeting moiety.  Below we consider the implications of this 
finding and future directions of investigation.   
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Figure 3.13. Histological staining of T98G brain tumors.  Tumors treated with PBS, 
CLX-NP or siMGMT-CLX-NP (a-c) were stained with Prussian blue to visualize iron 
content.  DAPI stained tissues were evaluated by fluorescence microscopy (d-f) for the 
presence of Cy5.5-labeled nanoparticles.  (g-i) H&E (hematoxylin and eosin) staining 
revealed that nanoparticle uptake was associated with tumor degradation. 
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3.4 Discussion    
 In this work our focus was to use RNA interference to reduce the tumor 
expression of MGMT, a protein implicated in chemotherapy resistance, in order to 
improve the response of gliomas to temozolomide.  For this we investigated iron oxide 
nanoparticles as targeted vectors for the delivery of siRNA to tumor cells in culture and 
in an animal model of glioblastoma.  In cell studies we demonstrated that functionalizing 
nanoparticles with chlorotoxin peptide promoted their uptake by glioblastoma cell lines.  
The internalized nanoparticles were visible by magnetic resonance imaging due to the 
intrinsic MR contrast imparted by iron oxide nanoparticles, and by optical imaging 
through the dual fluorescent labels incorporated into the probes.  Internalized 
nanoparticles were bioactive, leading to reductions in MGMT mRNA expression, protein 
expression, and activity in a TMZ-resistant cell line, T98G.   Suppression of MGMT 
expression led to enhanced cytotoxicity of temozolomide in these cells.  We also 
investigated nanoparticles for intravenous treatment in an orthotopic glioblastoma mouse 
model of brain cancer.  It was evident from MRI and confirmed by RT-PCR analysis that 
intravenous injection of nanoparticles failed to traffic to tumor tissues.  In our previous 
experience with U87MG tumors, intravenous nanoparticle injection was associated with 
significant reduction in T2 relaxation that was grossly evident in T2-weighted images and 
T2 maps (Kumar, Medarova et al. 2010).  In that study, accumulation of nanoparticles in 
tumors was attributed to vascular changes occurring in late stage U87MG tumor 
development that led to their increased permeability to materials in the nanometer size 
range (Hobbs, Monsky et al. 1998).   Evidence of highly vascularized U87MG tumors 
was also suggested by the high T2 values of unenhanced tumor tissues that easily 
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distinguished them from surrounding normal brain.  In contrast, the T98G tumors in our 
studies generally had much lower (by > 5 ms) average T2 values than U87MG tumors, 
values that were only slightly elevated above the T2 values of normal tissue.  MRI 
analysis suggests that T98G brain lesions are less vascularized and permeable than their 
U87MG counterparts, which would account for the limited intravenous delivery to tissues 
we observed in these tumors.  This observation was confirmed histologically by staining 
of brain tumor vasculature of the two cell types.  The scientific literature also suggests 
that MGMT-expressing tumors are poorly vascularized (Chahal, Xu et al. 2010).     
 After confirming that systemic administration of nanoparticles was unable to 
modulate MGMT expression and sensitize cells to the effects of temozolomide, we 
investigated direct intratumoral administration of siMGMT-CLX-NPs.  Intratumoral 
administration techniques are feasible and have been used clinically to improve delivery 
to gliomas and to decrease systemic toxicity of drugs and imaging agents (Oshiro, Tsugu 
et al. 2006; Cordier, Forrer et al. 2010; Jenkinson, Smith et al. 2010).  Stereotactically-
injected nanoparticles were generally well-tolerated by the mice in our experiments.  
After injection, nanoparticles spread throughout the tumor parenchyma and remain 
therein through the full course of the experiment as observed by MRI.  Weekly 
nanoparticle injections were performed to overcome the siRNA dilution and blunted 
silencing response that occurs for cells with short doubling times such as T98G (i.e., 
26±2 hours) (Stein 1979; Bartlett and Davis 2006).  Our investigations of direct 
siMGMT-CLX-NP administration revealed several important findings.  First, siMGMT-
CLX-NPs differed significantly from CLX-NPs in its effects on MGMT protein 
expression and activity.  Our siMGMT-CLX-NPs performed as they were designed to, 
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resulting to reductions in MGMT protein expression so complete that enzyme activity 
was effectively eliminated in treated tumor samples.  One would expect that once MGMT 
activity ceased, tumors would be completely susceptible to the effects of TMZ.  In fact, 
we did observe large reductions in tumor volume in these mice relative to PBS controls.  
Moreover, within two weeks of siMGMT-CLX-NP injection, tumors generally appeared 
quiescent when monitored by MRI, with no large increases in apparent tumor volume 
over time.  However, these characteristics were not restricted to tumors treated with 
siMGMT-CLX-NPs.  Despite having little effect on MGMT expression or activity, CLX-
NPs were also associated with reductions in tumor volume, though less than those 
observed for siMGMT-CLX-NPs.  Given the important contribution of chlorotoxin to the 
efficacy of our nanoparticles, we would like to briefly consider the effects of this 
targeting peptide.   
 Chlorotoxin is a 36-amino acide peptide derived from scorpion venom 
(Soroceanu, Gillespie et al. 1998; Lyons, O'Neal et al. 2002).  Its selectivity for all grades 
of gliomas, and not normal astrocytes and neurons, has made chlorotoxin an attractive 
tumor-targeting moiety for nanoparticles (Veiseh, Sun et al. 2005).  When chlorotoxin 
nanoparticles were applied at diagnostic concentrations they were not found to be toxic 
(Veiseh, Sun et al. 2009).  Accordingly, chlorotoxin has generally been used in 
combination with potent cancer drugs or therapeutic siRNAs to trigger cell death in 
tumors (Sun, Fang et al. 2008; Veiseh, Kievit et al. 2010).  However, there is significant 
evidence that chlorotoxin has its own anti-angiogenic and anti-proliferative effects on 
cancers.  It is believed that chlorotoxin binds to glioma chloride channels and disrupts the 
generation of chloride gradients that are essential for the migration and invasiveness of 
 139 
glioma cells (McFerrin and Sontheimer 2006).  Chlorotoxin treatment of glioma cells in 
vitro at concentrations below those used in some of our experiments was associated with 
reductions in cell proliferation (Fu, Yin et al. 2007). Another study found that chlorotoxin 
binds specifically to matrix metalloproteinase 2 on the surface of gliomas, inhibiting its 
catalytic activity and ultimately reducing degradation and remodeling of the extracellular 
matrix that is essential for cell invasion (Deshane, Garner et al. 2003).  More recently, 
Annexin A2, expressed in a variety of tumor types, was identified as a binding partner for 
chlorotoxin (Kesavan, Ratliff et al. 2010).  Chlorotoxin binding to Annexin A2 inhibits 
VEGF-induced tissue plasminogen activator and angiogenesis.  These studies provide 
insight into the reason for the chlorotoxin-induced cytotoxicity we observed in cell and in 
vivo studies.  Histologically there is some evidence that siMGMT-CLX-NPs induce more 
complete tumor destruction than CLX-NPs.  In tissues with siMGMT-CLX-NP treatment 
and MGMT knockdown, more widespread nuclear fragmentation and condensation were 
observed than in CLX-NP treated tissues.  This observation provides evidence that 
MGMT knockdown is an important factor in the complete destruction of tumors after 
temozolomide treatment.  However, more work needs to be done to quantify the 
differential cytotoxic effects of the two types of nanoparticle treatments and to more 
precisely characterize their mechanisms of action in our model.   
 In summary, we have demonstrated that iron oxide nanoparticles functionalized 
with siRNA induce robust knockdown of endogenous MGMT levels and activity in 
glioma cells and in an orthotopic glioblastoma mouse model.  Suppression of MGMT 
enhanced cell sensitivity to temozolomide treatment and was associated with widespread 
tumor destruction.  Furthermore, we confirmed the therapeutic efficacy of the chlorotoxin 
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component of nanoparticles, which proved cytotoxic when administered independent of 
siRNA.  These results suggest that combination chlorotoxin and siRNA delivery by 
nanoparticles may be an effective treatment option for cells that are resistant to the effects 
of standard chemotherapies.  Future studies will focus on investigating the mechanism 
and extent of tumor destruction after nanoparticle treatment.   
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